{
    "paper_id": "xml_output_cochrane\\Al-Inany_et_al-2016-Cochrane_Database_of_Systematic_Reviews",
    "header": {
        "generated_with": "S2ORC 1.0.0",
        "date_generated": "2024-04-05T17:20:04.729399Z"
    },
    "title": "Gonadotrophin-releasing hormone antagonists for assisted reproductive technology",
    "authors": [
        {
            "first": "Hesham",
            "middle": [
                "G"
            ],
            "last": "Al-Inany",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "Cairo University",
                "location": {
                    "settlement": "Cairo",
                    "country": "Egypt"
                }
            },
            "email": ""
        },
        {
            "first": "Mohamed",
            "middle": [
                "A"
            ],
            "last": "Youssef",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "Cairo University",
                "location": {
                    "settlement": "Cairo",
                    "country": "Egypt"
                }
            },
            "email": ""
        },
        {
            "first": "Reuben",
            "middle": [
                "Olugbenga"
            ],
            "last": "Ayeleke",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "University of Auckland",
                "location": {
                    "settlement": "Auckland",
                    "country": "New Zealand"
                }
            },
            "email": ""
        },
        {
            "first": "Julie",
            "middle": [],
            "last": "Brown",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "The University of Auckland",
                "location": {
                    "settlement": "Auckland",
                    "country": "New Zealand"
                }
            },
            "email": ""
        },
        {
            "first": "Wai",
            "middle": [
                "Sun"
            ],
            "last": "Lam",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "University of Auckland",
                "location": {
                    "settlement": "Auckland",
                    "country": "New Zealand"
                }
            },
            "email": ""
        },
        {
            "first": "Frank",
            "middle": [
                "J"
            ],
            "last": "Broekmans",
            "suffix": "",
            "affiliation": {
                "laboratory": "",
                "institution": "University Medical Center",
                "location": {
                    "settlement": "Utrecht",
                    "country": "Netherlands"
                }
            },
            "email": ""
        }
    ],
    "year": "",
    "venue": null,
    "identifiers": {},
    "abstract": "Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-e ects, flare-up, or long down-regulation period associated with agonists.The antagonists directly and rapidly inhibit gonadotrophin release within several hours through competitive binding to pituitary GnRH receptors.This property allows their use at any time during the follicular phase.Several di erent regimens have been described including multiple-dose fixed (0.25 mg daily from day six to seven of stimulation), multiple-dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single-dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill.Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS).Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens.This is an update of a Cochrane review first published in 2001, and previously updated in 2006 and 2011.\nTo evaluate the e ectiveness and safety of gonadotrophin-releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles.\nSearch methods",
    "pdf_parse": {
        "paper_id": "xml_output_cochrane\\Al-Inany_et_al-2016-Cochrane_Database_of_Systematic_Reviews",
        "_pdf_hash": "",
        "doi": "10.1002/14651858.cd001750.pub4",
        "keywords": [
            "Informed decisions",
            "Better health",
            "Informed decisions",
            "Better health Trusted evidence",
            "Informed decisions",
            "Better health Better health"
        ],
        "abstract": [
            {
                "text": "Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-e ects, flare-up, or long down-regulation period associated with agonists.The antagonists directly and rapidly inhibit gonadotrophin release within several hours through competitive binding to pituitary GnRH receptors.This property allows their use at any time during the follicular phase.Several di erent regimens have been described including multiple-dose fixed (0.25 mg daily from day six to seven of stimulation), multiple-dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single-dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill.Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS).Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens.This is an update of a Cochrane review first published in 2001, and previously updated in 2006 and 2011.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Abstract",
                "sec_num": null
            },
            {
                "text": "To evaluate the e ectiveness and safety of gonadotrophin-releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Abstract",
                "sec_num": null
            },
            {
                "text": "Search methods",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Abstract",
                "sec_num": null
            }
        ],
        "body_text": [
            {
                "text": "ABSTRACT",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "T A B L E O F C O N T E N T S",
                "sec_num": null
            },
            {
                "text": "Controlled ovarian hyperstimulation (COH) coupled with in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) was one of the major advances in the treatment of subfertility in the second half of the 20th century.One aspect of COH-IVF or ICSI that requires attention is the occurrence of a luteinizing hormone (LH) surge which may occur prematurely, before the leading follicle reaches the optimum diameter for triggering ovulation.Such premature LH surges prevent e ective induction of multiple follicular maturation patterns for a significant number of women.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "Gonadotrophin-releasing hormone agonists (GnRH agonists) have played an important role in reducing the incidence of premature LH surges by reversibly blocking pituitary gonadotrophin secretion.As a result, the rates of cancellation of assisted conception cycles are decreased and pregnancy rates increased (Albano 1996; Hughes 1992).However, the use of GnRH agonists is not without disadvantages.Even though the standard long-course GnRH agonist protocol proved to be the most e icacious protocol (Daya 2000) for the use of GnRH agonists, it requires two to three weeks for desensitisation, with relatively high costs due to an increased requirement for gonadotrophin injections, and the need for hormonal and ultrasonographic measurements (Olivennes 1994).",
                "cite_spans": [
                    {
                        "start": 497,
                        "end": 508,
                        "text": "(Daya 2000)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "A common complication associated with ovarian stimulation with exogenous gonadotrophins is ovarian hyperstimulation syndrome (OHSS) (Mathur 2007).It usually occurs following a LH surge or a er exposure to human chorionic gonadotrophin (hCG) (Mozes 1965) .Most cases of OHSS are mild with few or no clinical consequences.However, severe cases occur occasionally with serious morbidity and mortalities (Delvigne 2002).Gonadotrophinreleasing hormone analogues (GnRH agonists and antagonists) stabilise the luteal phase thereby preventing premature LH surges and reducing the risk of OHSS.",
                "cite_spans": [
                    {
                        "start": 241,
                        "end": 253,
                        "text": "(Mozes 1965)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "B A C K G R O U N D Description of the condition",
                "sec_num": null
            },
            {
                "text": "In 1999, gonadotrophin-releasing hormone antagonists (GnRH antagonist) were introduced to the market to prevent LH surge, and it was assumed that GnRH antagonists might be a more patientfriendly protocol than the mid-luteal GnRH agonist protocol.GnRH antagonists cause immediate, reversible and dose-related inhibition of gonadotrophin release by competitive blockade of the GnRH receptors in the pituitary gland, and therefore treatment can be restricted to those days when a premature LH surge is likely to occur (Duijkers 1998; Felberbaum 1995; Huirne 2007) .",
                "cite_spans": [
                    {
                        "start": 515,
                        "end": 530,
                        "text": "(Duijkers 1998;",
                        "ref_id": null
                    },
                    {
                        "start": 531,
                        "end": 547,
                        "text": "Felberbaum 1995;",
                        "ref_id": null
                    },
                    {
                        "start": 548,
                        "end": 560,
                        "text": "Huirne 2007)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "The first generation of GnRH antagonists were associated with allergic side-e ects due to an induced histamine release, which hampered the clinical development of these compounds.Third generation GnRH antagonists such as ganirelix (NV Organon, Oss, the Netherlands) and cetrorelix (ASTA-Medica, Frankfurt am Main, Germany) have resolved these issues and are approved for clinical use (Olivennes 1998).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "Two approaches have emerged in GnRH antagonist administration; the single-dose protocol, in which one injection of GnRH antagonist (Cetrotide\u00ae 3 mg, Merck SeronoSA., Geneva, Switzerland ) is administered in the late phase of ovarian stimulation and the multiple-dose regimen, in which 0.25 \u00b5g of cetrorelix or ganirelix is administered daily from stimulation day 6 onwards (fixed regimen).A flexible regimen based on the follicular size, has since been introduced to minimise the number and duration of GnRH antagonist injections (Huirne 2007).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "In a natural ovulatory cycle, ovulation, the release of the dominant follicle from the ovary, usually occurs about 36 hours a er LH surge.In women undergoing controlled ovarian stimulation (COS) during assisted reproductive technology (ART), certain agents are usually administered to mimic the natural LH surge.Ultrasound scan and blood oestrogen levels are used to determine the day on which to administer the triggering agents.Ovulation triggering agents include hCG and GnRH agonist.These agents have di erent modes of action and their use might, therefore, di erentially influence the e ectiveness of GnRH antagonists.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Description of the intervention",
                "sec_num": null
            },
            {
                "text": "Applying GnRH antagonists for pituitary desensitisation during COH is expected to result in a dramatic reduction in the duration of GnRH analogue treatment and to reduce the amount of gonadotrophin needed for stimulation as compared with the long agonist protocol.Other potential benefits include a lower risk of developing severe ovarian hyperstimulation syndrome (OHSS) and avoidance of oestrogen deprivation symptoms (for example hot flushes, sleep disturbances, headaches) frequently observed in the pre-stimulation phase of a long agonist protocol.Whether the previously mentioned benefits justify a change in routine treatment from the standard long-course GnRH agonist protocol to the GnRH antagonist regimen depends on whether the clinical outcomes using these protocols are similar.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "How the intervention might work",
                "sec_num": null
            },
            {
                "text": "The first Cochrane review on this topic was published in 2001 and was updated in 2006 and 2011.As further RCTs have been published, this is a further update of the evidence on the comparative e ectiveness of GnRH antagonists versus GnRH agonists in women undergoing COH-IVF or ICSI, with respect to reducing the risk of OHSS and cycle cancellation while maintaining the live birth rate.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Why it is important to do this review",
                "sec_num": null
            },
            {
                "text": "To evaluate the e ectiveness and safety of gonadotrophinreleasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "O B J E C T I V E S",
                "sec_num": null
            },
            {
                "text": "Only randomised controlled trials (RCTs) with a parallel design were eligible for inclusion.Quasi-randomised trials were not included (e.g.studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias.If cross-over studies, with cross-over occurring between cycles, were available, we would have included only the first cycle, before the cross-over.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of studies",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Subfertile couples undergoing controlled ovarian hyperstimulation (COH) as part of an IVF or ICSI programme using GnRH antagonists or long-course GnRH agonist protocols for the prevention of premature LH surges.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of participants",
                "sec_num": null
            },
            {
                "text": "Pituitary suppression with GnRH antagonists (for example cetrorelix, ganirelix) or long-course GnRH agonists together with ovarian stimulation with recombinant or urinary human follicle stimulating hormone (hFSH) or human menopausal gonadotrophin (hMG), or both, or clomiphene citrate as part of an IVF or ICSI treatment cycles.Further, the use of oral contraceptive pill (OCP) pre-treatment did not constitute an inclusion or exclusion criterion but rather was a variation in the protocols used.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Types of interventions",
                "sec_num": null
            },
            {
                "text": "\u2022 Live birth rate (LBR) per woman randomised, defined as delivery of a live fetus a er 20 completed weeks of gestation.\u2022 Ovarian hyperstimulation syndrome (OHSS) rate per woman randomised, with grading as detected by clinical grading of OHSS, laboratory investigations (e.g.haematocrit, haemoglobin, renal function) or imaging techniques (ovarian and abdominal ultrasound, chest X-ray), or both: all women, moderate or severe OHSS.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Primary outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 Ongoing pregnancy rate (OPR) per woman randomised, defined as a pregnancy beyond 12 weeks' gestation.\u2022 Clinical pregnancy rate (CPR) per woman randomised, defined as the presence of a gestational sac \u00b1 fetal heart beat at transvaginal ultrasound.\u2022 Other adverse e ects.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 Miscarriage rate per woman randomised: miscarriage is defined as pregnancy loss before 20 weeks' gestation.Miscarriage rate per clinical pregnancy was analysed as a secondary analysis).\u2022 Cycle cancellation rate per woman randomised.Two types of cycle cancellation were assessed in separate analyses: cycle cancellation due to high risk of OHSS and cycle cancellation due to poor ovarian response.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "We searched for all published and unpublished RCTs of GnRH antagonist versus the long-course GnRH agonist protocol in women undergoing COH-IVF or ICSI using the following search strategy, without language restriction and in consultation with the Gynaecology and Fertility Group (CGF) (formerly known as Menstrual Disorders and Subfertility Group (MDSG)) Information Specialist.We performed the most recent searches on 28 April 2015.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Search methods for identification of studies",
                "sec_num": null
            },
            {
                "text": "The following electronic databases, trial registers and websites were searched (from their inception).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Electronic searches",
                "sec_num": null
            },
            {
                "text": "\u2022 Menstrual Disorders and Subfertility Group (MDSG) Specialised Register (updated search from 2010 to 28 April 2015) (Appendix 1).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Electronic searches",
                "sec_num": null
            },
            {
                "text": "We also searched the reference lists of all known primary studies, review articles, citation lists of relevant publications, abstracts of major scientific meetings (for example of the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM)).We contacted known experts and personal contacts regarding any unpublished materials.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "In addition, we handsearched appropriate journals.The list of journals is in the CGF Module, which can be found in The Cochrane Library under BROWSE -'By Review Group' -'Cochrane Gynaecology and Fertility Group' -then 'about this group' at the top of this page.We liaised with the CGF Information Specialist to avoid duplication of handsearching.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Searching other resources",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "A er an initial screen of titles and abstracts retrieved by the search, we retrieved the full texts of all potentially eligible studies.Two review authors (RA and JB) independently examined these full-text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review.We contacted study investigators as required, to clarify study eligibility.We resolved disagreements as to study eligibility by discussion or by involving a third review author (MAY).We documented the selection process with a \"PRISMA\" flow chart (Figure 1 ",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 570,
                        "end": 571,
                        "text": "1",
                        "ref_id": "FIGREF1"
                    }
                ],
                "eq_spans": [],
                "section": "Selection of studies",
                "sec_num": null
            },
            {
                "text": "Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).Where studies had multiple publications the review authors collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review, and such studies would have a single study ID with multiple references.We contacted trial authors to request additional information or data.We also received a response from the sponsoring pharmaceutical companies.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Three authors (RA, JB and WSL) independently assessed the risk of bias of the included trials using The Cochrane 'Risk of bias' (RoB) tool (Higgins 2011b).The domains assessed were: (1) sequence generation (for example; was the method used for allocation sequence adequately described?);(2) allocation concealment (for example, was allocation adequately concealed?);(3) blinding of participants, personnel and outcome assessors (for example; was knowledge of the allocated intervention adequately prevented during the study?);(4) incomplete outcome data (for example, were incomplete outcome data adequately addressed?);(5) selective outcome reporting (for example, were reports of the study free of suggestion of selective outcome reporting?);and (6) other sources of bias (for example, was the study apparently free of other problems that could put it at a high risk of bias?).Other potential sources of bias included baseline imbalances, source of funding, early stopping for benefit, and appropriateness of cross-over design.We resolved disagreements by discussion or by consulting a fourth review author.We described all judgements fully and presented the conclusions in the 'Risk of bias' table (see the Characteristics of included studies table), which was incorporated into the interpretation of review findings by means of sensitivity analyses (see below).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "With respect to selective reporting, we sought published protocols and compared the outcomes between the protocol and the final published study, but the searches did not yield published protocols of any of the included studies.We took care to search for within-trial selective reporting, such as non-reporting of obvious outcomes, or reporting them in insu icient detail to allow for inclusion.Where identified studies failed to report the primary outcomes of live birth and OHSS but did report interim outcomes such as pregnancy, we undertook informal assessment as to whether the interim values (e.g.pregnancy rates) were similar to those reported in studies that also reported live birth.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "We only reported dichotomous data (e.g.live birth rates) in this review and we used the numbers of events in the control and intervention groups of each study to calculate Mantel-Haenszel odds ratios (ORs).We reversed the direction of e ect of individual studies, if required, to ensure consistency across trials.We presented 95% confidence intervals (CIs) for all outcomes.Where data to calculate ORs were not available, we utilised the most detailed numerical data available that facilitated similar analyses of included studies (e.g.test statistics, P values).We compared the magnitude and direction of e ect reported by studies with how they were presented in the review, taking account of legitimate di erences (Deeks 2011).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Measures of treatment e ect",
                "sec_num": null
            },
            {
                "text": "The primary analysis was per woman randomised.We also included per clinical pregnancy data for miscarriage.we contacted authors of studies that did not allow valid analysis of data (e.g.'per cycle' data) and requested 'per woman' data.If no 'per woman' data was provided a er contact, we did not include such studies in metaanalyses.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unit of analysis issues",
                "sec_num": null
            },
            {
                "text": "We analysed the data on an intention-to-treat basis as far as possible and made attempts to obtain missing data from the original trialists.Initially, we planned to undertake imputation of individual values for the primary outcomes if we were unable to obtain missing data from the original trialists but no data imputation was undertaken in the end and we analysed only the available data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Dealing with missing data",
                "sec_num": null
            },
            {
                "text": "We considered whether the clinical and methodological characteristics of the included studies were su iciently similar for meta-analysis to provide a clinically meaningful summary.We assessed statistical heterogeneity by the measure of the I 2 statistic (Higgins 2003).We took an I 2 statistic measurement greater than 50% to indicate substantial heterogeneity (Deeks 2011).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of heterogeneity",
                "sec_num": null
            },
            {
                "text": "In view of the di iculty of detecting and correcting for publication bias and other reporting biases, the review authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data.We used a funnel plot to explore the possibility of small study e ects (a tendency for estimates of the intervention e ect to be more beneficial in smaller studies) (Egger 1997).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Assessment of reporting biases",
                "sec_num": null
            },
            {
                "text": "Where the studies were su iciently similar, we combined the data using a fixed-e ect analysis (on the assumption that the underlying e ect size was the same for all the trials in the analysis) comparing GnRH antagonist versus long course GnRH agonist.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "An increase in the odds of a particular outcome that were likely to be beneficial (e.g.live birth) or detrimental (e.g.adverse e ects), were displayed graphically in the meta-analyses to the right of the centre-line and a decrease in the odds of an outcome to the le of the centre-line.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "All analyses were performed using Review Manager so ware (RevMan) (RevMan 2014).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Data synthesis",
                "sec_num": null
            },
            {
                "text": "Where there were su icient data we performed subgroup analyses for the following variables, for live birth and pregnancy outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Subgroup analysis and investigation of heterogeneity",
                "sec_num": null
            },
            {
                "text": "\u2022 Triggering agent used for oocyte maturation (hCG, GnRH agonist, mixed (hCG/GnRH agonist) or unknown agent) \u2022 Minimal or standard level of stimulation Where we detected substantial heterogeneity, we explored possible explanations in sensitivity analyses.We took any",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Subgroup analysis and investigation of heterogeneity",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews statistical heterogeneity into account when interpreting the results, especially where there was any variation in the direction of e ect.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "We conducted sensitivity analyses for LBR and OPR to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis (Moher 1999).These analyses included consideration of whether the review conclusions would have di ered if:",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "\u2022 a random-e ects model had been adopted;",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "\u2022 the summary e ect measure was risk ratio rather than odds ratio.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Sensitivity analysis",
                "sec_num": null
            },
            {
                "text": "We prepared a 'Summary of findings' table using GRADEpro Guideline Development Tool (GRADEpro GDT 2015) .This table evaluated the overall quality of the body of evidence for all review outcomes (live birth, OHSS, ongoing pregnancy, clinical pregnancy, miscarriage and cycle cancellation), using GRADE criteria (study limitations (i.e.risk of bias), consistency of e ect, imprecision, indirectness and publication bias).Judgements about evidence quality (high, unclear (moderate) or low) were justified, documented, and incorporated into reporting of results for each outcome (Summary of findings for the main comparison).",
                "cite_spans": [
                    {
                        "start": 84,
                        "end": 103,
                        "text": "(GRADEpro GDT 2015)",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall quality of the body of evidence: 'Summary of findings' table",
                "sec_num": null
            },
            {
                "text": "See the table 'Characteristics of included studies'.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "R E S U L T S Description of studies",
                "sec_num": null
            },
            {
                "text": "We retrieved 479 records a er removal of duplicates, excluded 399 as ineligible, and assessed 80 full-text articles.Of these, we excluded 51 and included 28 studies (29 reports).Seventythree randomised controlled studies (84 reports), involving 12,212 randomised women, met the inclusion criteria and were fully reviewed (Characteristics of included studies) (See Figure 1 for details of this process).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 371,
                        "end": 372,
                        "text": "1",
                        "ref_id": "FIGREF1"
                    }
                ],
                "eq_spans": [],
                "section": "Results of the search",
                "sec_num": null
            },
            {
                "text": "\u2022 Twelve studies were multi-centre ( ",
                "cite_spans": [
                    {
                        "start": 35,
                        "end": 36,
                        "text": "(",
                        "ref_id": null
                    }
                ],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Study characteristics",
                "sec_num": null
            },
            {
                "text": "For the risk of bias (ROB) of the included trials, please see Figure 2 and Figure 3 .",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 69,
                        "end": 70,
                        "text": "2",
                        "ref_id": null
                    },
                    {
                        "start": 82,
                        "end": 83,
                        "text": "3",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Risk of bias in included studies",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "\u2022 We examined blinding with regard to who was blinded in the trials.We looked for all levels of blinding and categorised them as follows: (i) However, some of the outcome measures such as live birth were objectively assessed and non-blinding of study outcome assessors was not likely to have a ected their measurement.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Blinding",
                "sec_num": null
            },
            {
                "text": "We judged thirty-seven of the included studies as being at low risk of bias in this domain, because they reported that there were no losses to follow up, proportions of withdrawals and reasons for withdrawals were balanced in both treatment groups, or women were analysed on the basis of intention-to-treat, where all women randomised were included in the final analysis whether or not they completed treatment.We judged the remaining studies either as unclear (where studies reported insu icient information with regard to attrition) or high risk of bias (where proportions of and reasons for withdrawals were not balanced between the two treatment groups and not all participants were included in the final analysis).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data",
                "sec_num": null
            },
            {
                "text": "Although the protocols of the included studies were not available for assessment, we scrutinised the methods section for prespecified outcome measures.Most of the included studies were rated as low risk of bias in this domain as they pre-specified the outcomes on which data were reported in the methods section.The remaining studies were judged to be either at unclear risk, where there was insu icient information to make conclusive judgements, or low risk, where it was clear that they engaged in selective outcome reporting.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Selective reporting",
                "sec_num": null
            },
            {
                "text": "We found no potential sources of within-study bias in most of the included studies as the baseline characteristics were similar between the treatment groups and were, therefore, rated to be at low risk of bias.The remaining studies were rated either as unclear risk, where there was insu icient information to arrive at a judgement, or high risk where there was evidence of significant di erences in demographic characteristics between the treatment groups.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Other potential sources of bias",
                "sec_num": null
            },
            {
                "text": "See: Summary of findings for the main comparison GnRH antagonist compared to long-course GnRH agonist for assisted reproductive technology (ART)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "The included studies enrolled a total of 12,212 randomised participants, although the sample size varied across the trials.We performed the analyses on the number of women randomised and not on the number of participants treated.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "E ects of interventions",
                "sec_num": null
            },
            {
                "text": "1.1 Live birth rate per woman randomised (Analysis 1.1; Figure 4 )",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 63,
                        "end": 64,
                        "text": "4",
                        "ref_id": "FIGREF3"
                    }
                ],
                "eq_spans": [],
                "section": "Primary outcomes",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews Twelve trials reported live birth rates in 2303 women.There was no evidence of a di erence following GnRH antagonist compared with GnRH agonist (OR 1.02, 95% CI 0.85 to 1.23; I 2 = 27%, moderate quality evidence).The evidence suggested that if the chance of live birth following treatment with GnRH agonist is assumed to be 29%, the chance following treatment with GnRH antagonist would be between 25% and 33%.On sensitivity analysis, there was no change in the above conclusion using a random-e ects model (OR 1.01, 95% CI 0.80 to 1.27) or using risk ratio (RR) as a measure of e ect estimate (RR 1.02, 95% CI 0.89 to 1.15).A funnel plot to explore the possibility of small study e ect showed a tendency for estimates of the intervention e ect to be more beneficial in smaller studies in the GnRH antagonist group (see Figure 5 ).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 867,
                        "end": 868,
                        "text": "5",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews Two trials reported live birth rates in 524 women undergoing minimal stimulation IVF.There was no evidence of a di erence following GnRH antagonist treatment compared with GnRH agonist treatment (OR 0.89, 95% CI 0.62 to 1.26; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Grouped by trigger ( Analysis 1.3; Figure 7 )",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 42,
                        "end": 43,
                        "text": "7",
                        "ref_id": "FIGREF5"
                    }
                ],
                "eq_spans": [],
                "section": "Live birth rate per woman randomised -Subgroup analysis:",
                "sec_num": "1.3"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "In a subgroup analysis, 11 trials reported live birth rates in 1899 women receiving hCG for ovarian maturation.There was no evidence of a di erence following GnRH antagonist treatment compared with GnRH agonist treatment (OR 1.09, 95% CI 0.89 to 1.34; I 2 = 26%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "hCG trigger",
                "sec_num": "1.3.1"
            },
            {
                "text": "One trial did not report the triggering agent used for ovarian maturation in 404 women.There was no evidence of a di erence in live birth rate between GnRH antagonist and GnRH agonist treatment groups (OR 0.80, 95% CI 0.54 to 1.21).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unknown trigger",
                "sec_num": "1.3.2"
            },
            {
                "text": "( Analysis 1.4; Figure 8 ) Thirty-six trials reported ovarian hyperstimulation rates in 7944 women.There was evidence of a lower OHSS rate in women who received GnRH antagonist compared with those were treated with GnRH agonist: 290/4474 (6%) versus 396/3470 (11%) (OR 0.61, 95% CI 0.51 to 0.72; I 2 = 31%, moderate quality evidence).The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%.Twenty trials reported moderate or severe ovarian hyperstimulation rates in 5141 women.There was evidence of a lower rate of moderate or severe OHSS in GnRH antagonist compared with GnRH agonist groups: 97/2971 (3%) versus 155/2170 (7%) (OR 0.53, 95% CI 0.40 to 0.69; I 2 = 17%).",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 23,
                        "end": 24,
                        "text": "8",
                        "ref_id": "FIGREF6"
                    }
                ],
                "eq_spans": [],
                "section": "Ovarian hyperstimulation per woman randomised",
                "sec_num": "1.4"
            },
            {
                "text": "1.6 Ongoing pregnancy rate per woman randomised ( Analysis 1.6) Thirty-seven trials reported ongoing pregnancy rates in 8311 women.There was no evidence of a di erence in ongoing pregnancy rate following treatment with GnRH antagonist compared with GnRH agonist (OR 0.92, 95% CI 0.83 to 1.01; I 2 = 0%; moderate quality evidence).The evidence suggested that if the chance of ongoing pregnancy following GnRH agonist treatment is assumed to be 29%, the chance following GnRH antagonist treatment would be between 26% and 30%.There was no change in the conclusion on sensitivity analysis using either a random-e ects model (OR 0.91, 95% CI 0.83 to 1.01) or RR as a measure of treatment e ect (RR 0.94, 95% CI 0.88 to 1.01).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Secondary outcomes",
                "sec_num": null
            },
            {
                "text": "( Analysis 1.7)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing pregnancy rate per woman randomised -Subgroup analysis: Minimal stimulation",
                "sec_num": "1.7"
            },
            {
                "text": "Seven trials reported ongoing pregnancy rates in 1456 women undergoing minimal stimulation IVF.There was no evidence of a di erence following GnRH antagonist treatment compared with GnRH agonist treatment (OR 0.94, 95% CI 0.75 to 1.18; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing pregnancy rate per woman randomised -Subgroup analysis: Minimal stimulation",
                "sec_num": "1.7"
            },
            {
                "text": "( Analysis 1.8)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Ongoing pregnancy rate per woman randomised -Subgroup analysis: Grouped by trigger",
                "sec_num": "1.8"
            },
            {
                "text": "In a subgroup analysis, 29 studies reported ongoing pregnancy rate in 5170 women in whom hCG was used to trigger oocyte maturation.There was no evidence of a di erence in ongoing pregnancy rate between the two treatment groups (OR 0.95, 95% CI 0.84 to 1.08; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "hCG trigger",
                "sec_num": "1.8.1"
            },
            {
                "text": "One study used hCG and GnRH agonist in GnRH antagonist and GnRH agonist groups respectively to trigger oocyte maturation in 66 women.There was no evidence of a di erence in ongoing pregnancy rate between GnRH antagonist and GnRH agonist groups (OR 0.61, 95% CI 0.23 to 1.61).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Mixed trigger",
                "sec_num": "1.8.2"
            },
            {
                "text": "In a subgroup analysis, seven trials reported ongoing pregnancy rates in 3075 women in whom the agent used in triggering oocyte maturation was unknown.There was no evidence of a di erence following treatment with GnRH antagonist compared with GnRH agonist (OR 0.87, 95% CI 0.74 to 1.03; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unknown trigger",
                "sec_num": "1.8.3"
            },
            {
                "text": "1.9 Clinical pregnancy rate per woman randomised ( Analysis 1.9)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unknown trigger",
                "sec_num": "1.8.3"
            },
            {
                "text": "Trusted evidence.Informed decisions.Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Library",
                "sec_num": null
            },
            {
                "text": "Fi y-four trials reported clinical pregnancy rates in 9959 women .",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "There was evidence of a di erence following GnRH antagonist treatment compared with GnRH agonist treatment with a smaller proportion of women reporting clinical pregnancies in the GnRH antagonist group: 1510/5431 (28%) versus 1365/4528 (30%) (OR 0.91, 95% CI 0.83 to 1.00; I 2 = 1%, moderate quality evidence).The evidence suggested that if the chance of clinical pregnancy following GnRH agonist treatment is assumed to be 30%, the chance following GnRH antagonist treatment would be between 27% and 30%.Thirty-four trials reported miscarriage rates in 7082 women.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "There was no evidence of a di erence following GnRH antagonist treatment compared with GnRH agonist treatment (OR 1.03, 95% CI 0.82 to 1.29; I 2 = 0%; moderate quality evidence).The evidence suggested that if the risk of miscarriage following GnRH agonist treatment is assumed to be 5%, the risk following GnRH antagonist treatment would be between 4% and 6%.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "1.12 Miscarriage rate per clinical pregnancy rate ( Analysis 1.12)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Thirty-four trials reported miscarriage rates per clinical pregnancy rates in 2308 women.There was no evidence of a di erence following treatment with GnRH antagonist compared with GnRH agonist (OR 1.08, 95% CI 0.84 to 1.37; I 2 = 0%)..",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "(Analysis 1.13)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cycle cancellation rate per woman randomised",
                "sec_num": "1.13"
            },
            {
                "text": "Nineteen trials reported rates of cycle cancellation due to high risk of OHSS in 4256 women.There was evidence of a di erence in cancellation rates with fewer cycles cancelled in the GnRH antagonist groups compared with the GnRH agonist groups (OR 0.47, 95% CI 0.32 to 0.69; I 2 = 0%).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cancelled due to high risk of OHSS",
                "sec_num": "1.13.1"
            },
            {
                "text": "Twenty-five trials reported rates of cancellation due to poor ovarian response in 5230 women.There was evidence of a di erence in cycle cancellation rates with more cycles cancelled in GnRH antagonist groups compared with GnRH agonist groups (OR 1.32, 95% CI 1.06 to 1.65; I 2 = 68%, moderate quality evidence).The evidence suggested that if the risk of cycle cancellation following GnRH agonist treatment is assumed to be 6%, the risk following GnRH antagonist treatment would be between 7% and 10%.There was evidence of statistical heterogeneity among the trials that contributed data to the pooled e ect estimate, with variations in the direction of e ect estimates of individual trials.On sensitivity analysis using a random-e ects model, there was no evidence of a di erence in cancellation rate between the two treatment groups (OR 1.38, 95% CI 0.82 to 2.31).Thus there is some degree of uncertainty with respect to this outcome, as it is sensitive to the choice of statistical model.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cancellation due to poor ovarian response",
                "sec_num": "1.13.2"
            },
            {
                "text": "The previous version of this systematic review included 45 studies, while this updated version includes 73 RCTs and 12,212 randomised women.To our knowledge this systematic review and metaanalysis represents the most recent and largest amount of evidence comparing the use of GnRH antagonist with long-course GnRH agonist protocols in IVF or ICSI treatment cycles.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "In this updated version of the review we focused on the e ectiveness and safety of GnRH antagonist compared to GnRH agonist cycles in ART.Regarding e ectiveness, there was no evidence of di erences in live birth rate and ongoing pregnancy rate between GnRH agonist and GnRH antagonist LH peak suppression protocols.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "With regard to safety, GnRH antagonists substantially reduced the incidence of OHSS.For the overall population from assembled studies, the evidence suggested that, if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%.In addition, there was evidence of a lower rate of moderate or severe OHSS in women who received the GnRH antagonist protocol compared with those who were treated with the GnRH agonist long protocol.However there was no evidence of a di erence in miscarriage rates per woman randomised between the two treatment protocols.There was no clear picture with respect to cycle cancellation between the two treatment groups.While fewer cycles were cancelled in the GnRH antagonist group due to high risk of OHSS, there is some degree of uncertainty with cancellation due to poor ovarian response, as this outcome was sensitive to the choice of statistical model.In summary, there is moderate quality evidence that the use of GnRH antagonist compared with long-course GnRH agonist protocols is associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth or ongoing pregnancy.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "Previous versions of this systematic review showed substantially lower clinical and ongoing pregnancy rates for the GnRH antagonist protocol.Two earlier meta-analyses of studies, comparing fixed and flexible GnRH antagonist protocols directly, demonstrated a trend towards higher pregnancy rates when using the fixed protocol, possibly explained by better LH control (Al-Inany 2005; Kolibianakis 2006).The improved performance of antagonist cycles in the present update cannot be explained by the relative use of fixed protocols however, as relatively few new fixed protocols were included.Cochrane Database of Systematic Reviews in antagonist cycles, although the mechanism for such change is still unclear.Further studies are needed to investigate the possible role of LH-instability in the improvement of pregnancy outcomes of GnRH antagonist cycles.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "Increased favourable pregnancy outcomes with GnRH antagonist treatment may also be the result of an improved learning curve with the relatively new GnRH antagonist over the last 15 years.Extensive experience with GnRH antagonist protocols in large studies, leading to more favourable study outcomes, may have positively influenced pregnancy outcomes of GnRH antagonist cycles.Finally, changes in the use of OCP pretreatment (Griesinger 2008), scheduling of hCG for final oocyte maturation (Kolibianakis 2004; Tremellen 2010; Orvieto 2008) or patient selection (Sbracia 2009) may all have contributed to the optimisation of the use of antagonist cycles in ART.However, the improvement in pregnancy outcomes could also be due to the e ects of potential bias in the included studies.For example, the forest plot (Figure 5 ) suggests a tendency for publication of studies with more favourable outcomes with the possibility of existence of unpublished studies with less favourable outcomes.",
                "cite_spans": [],
                "ref_spans": [
                    {
                        "start": 817,
                        "end": 818,
                        "text": "5",
                        "ref_id": null
                    }
                ],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "Previous work on the role of OCP pretreatment in direct comparison studies has indicated that OCP pretreatment leads to a longer duration of stimulation, higher oocyte yield, but reduced ongoing pregnancy rate (Smulders 2010).Also a trend towards lower pregnancy rates when using OCP pretreatment has been observed in a separate meta-analysis (Griesinger 2008).As such, it has been recommended that OCP pretreatment does not seem to be the regimen of choice for GnRH antagonist cycles.In the previous versions of this review, however, a subgroup analysis of studies that used OCP pretreatment revealed no substantial di erence between the agonist and antagonist groups for ongoing or clinical pregnancy rates.The percentage of women receiving OCP pretreatment in the 2011 update was comparable with the preceding version in 2006.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Summary of main results",
                "sec_num": null
            },
            {
                "text": "Overall, the data demonstrate that GnRH antagonist is useful in women undergoing IVF or ICSI because it substantially reduces the occurrence of OHSS without reducing the chances of achieving live a live birth.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "A long-course GnRH agonist protocol with maximum ovarian stimulation has been the standard protocol for many decades.However, it is relatively complex and expensive, requires long treatment cycles and intensive monitoring, and leads to an abnormal hormonal environment in women.There is now an eager desire to shi to more patient-friendly, mild ovarian-stimulation regimens in which GnRH antagonist may be a suitable solution because there is evidence to suggest that its use is associated with comparable pregnancy outcomes.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "A good number of the included studies did not report live birth and OHSS: 12 of the included studies reported data on live birth while only 36 reported data on OHSS.One study used single embryo transfer in the antagonist arm and double embryo transfer in the agonist arm.Some of the outcomes of interest were reported by some of the included studies in such a way that they could not be included in meta-analyses.For example, some of the denominators were reported as 'per oocyte' or 'per embryo' transferred, where the numbers of oocytes or embryos transferred were not equal to the number of women randomised.In some of the included studies, some outcomes were not properly defined making it di icult to categorise such outcomes, for example, 'pregnancy rate' which could either be 'ongoing' or 'clinical' pregnancy.We included a small number of studies because they met the inclusion criteria, although they did not report data on any of the outcomes of interest.With respect to the triggering agent used for oocyte maturation, the majority of the studies either used hCG or did not report the triggering agent used.Thus no comparison could be made between the triggering agents such as hCG versus GnRH agonist.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Overall completeness and applicability of evidence",
                "sec_num": null
            },
            {
                "text": "The evidence was of moderate quality using GRADE ratings for live birth, OHSS, ongoing pregnancy, clinical pregnancy, miscarriage and cycle cancellation due to poor ovarian response.The main limitations in the evidence were poor reporting of study methods.For example, a majority of the included studies either did not report the processes involved in random sequence generation and allocation concealment or reported vague and insu icient information on the processes, thereby making it di icult to make conclusive judgements on these domains of risk of bias.Poor reporting also a ected the assessment of other domains of risk of bias with most of them being rated as 'unclear'.For live birth, there was evidence suggestive of the possibility of reporting (publication) bias with small studies more likely to report favourable outcomes for GnRH antagonist.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Quality of the evidence",
                "sec_num": null
            },
            {
                "text": "Although comprehensive searches were undertaken to ensure that all eligible studies were identified, it is not impossible that some potentially eligible studies could have been le out.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Potential biases in the review process",
                "sec_num": null
            },
            {
                "text": "The GnRH antagonist protocol is a short and simple protocol with evidence suggesting a comparable live birth rate and a substantial reduction in the incidence of ovarian hyperstimulation syndrome when compared to GnRH agonist long protocol in women undergoing ART.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for practice",
                "sec_num": null
            },
            {
                "text": "In view of the shortcomings noted in the included studies, especially with regard to the methods of reporting of trial procedures, more properly designed studies in accordance with the CONSORT statement are need to further evaluate the e ectiveness and safety of the GnRH antagonist protocol (Schulz 2010).For example, it would be desirable to have trials with low risk of bias with primary outcomes of live birth and OHSS.In addition, further studies are needed to assess this treatment regimen in poor and high responders.We attempted to subgroup treatment regimens by the ovulation triggering agent but no data were available for a proper analysis, as the majority of the included studies either used hCG or did not specify their triggering agents.This is a potential area to be explored by future research.It is also important to understand why pregnancy outcomes have become progressively more favourable with the use of GnRH antagonists.One possible explanation for this could be a decrease in LH instability.This area should be further investigated.Although not a focus of the current update, the potential e ects of OCP pretreatment should be further investigated.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "Patient satisfaction surveys should also be undertaken to evaluate their impression about GnRH antagonist treatment regimens.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Implications for research",
                "sec_num": null
            },
            {
                "text": "Embryo transfer: at 3 or 5 days",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Luteal phase support: progesterone, one centre treated women with P, 25 mg IM, on the day of retrieval, followed by P, 50 mg IM daily, with some women being supplemented with hCG 2,500 IU on days 3 and 6 after retrieval.The other centres prescribed luteal support with a daily dose of P (50 mg IM).",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "\u2022 Women who continued to have elevated E2 levels (> 60 pg/mL) and a cyst were removed from the study.If the E2 level was < 60 pg/mL and the cyst was still present, it could be aspirated and the participant would remain enrolled in the study and begin their recombinant FSH administration on Friday, along with a reduction of the GnRH agonist dose to 0.25 mg per day \u2022 Women who had a serum E2 level of > 60 pg/mL or a cyst > 20 mm were continued on the same leuprolide dose for another week \u2022 In women randomised to the GnRH-antagonist group who had an E2 level of < 60 pg/mL, they could begin recombinant FSH on that Friday (5th day after OC).If they had a cyst > 20 mm, they were withdrawn from the study",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "Luteal phase support: IM hCG (Profasi) 2000 IU given every 3 days for four doses starting on the day of oocyte retrieval",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "A clinical pregnancy was established when there was a gestational sac seen on ultrasonography",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "The main outcome measures were duration of stimulation, consumption of gonadotrophins, cycle cancellation rate, and the number of mature follicles recruited and total oocytes retrieved.The hormone levels throughout the cycle, laboratory outcomes and clinical pregnancy rates were also reviewed Notes Cochrane Database of Systematic Reviews USA) using the chemiluminescent method) were diagnosed with PCOS after all the other causes of hyperandrogenism were excluded.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Couples in their first IVF/ICSI cycles, women with PCOS whose body mass index was lower than 30 kg/ m and higher than 20 kg/m 2 Exclusion criteria: women with PCOS whose ovaries did not appear polycystic (where having polycystic ovaries identified by ultrasonography was defined as the presence of 12 or more follicles in each ovary measuring 2 -9 mm in diameter, and/or increased ovarian volume (> 10 ml))",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Patients treated with hormonal medications and other oral anti-diabetics within the previous three months",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "GnRH antagonist: Diane-35/day from day 5 of the cycle for 21 days + cetrorelix acetate was then initiated with a single dose of 0.25 mg administered SC + from day 4 to day 9, cetrorelix acetate was reduced to 0.125 mg/day + 150 IU of hMG (Pergonal) every day.The dose of cetrorelix acetate was increased to 0.25 mg/day from day 10 until the day before hCG (Pregnyl; NY Organon) injection, and the dose of HMG (Fixed) GnRH agonist: GnRH agonist long protocol.A GnRH agonist, buserelin acetate (Supremon), 500mg/ day was administered from day 3 of induced or spontaneous menstruation.After 14 days of buserelin injection, buserelin was continued until the day of hCG injection, while the dosage was decreased to 250 mg/day at the beginning of hMG administration + 150 IU/day hMG was prescribed for six days beginning from the day of ensuing pituitary down-regulation Oocyte maturation triggering: hCG, 10,000 IU, was administered IM when at least two follicles reached 18 mm in diameter with adequate E2 response",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Embryo transfer: was performed three days after oocyte recovery Luteal phase support: 600 mg of vaginally administered micronised progesterone (Utrogestan) daily starting from the day after oocyte retrieval Follow up: clinical pregnancy was defined as a visible fetal heart beat on ultrasonography at seven weeks of gestation",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oocyte retrieval: was performed 36 hrs later",
                "sec_num": null
            },
            {
                "text": "The primary outcome measures: fertilisation, pregnancy and implantation rates",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "The secondary outcome measures: serum LH and testosterone status upon starting and during HMG administration, and the total days of injection Exclusion criteria: women who has taken any hormonal therapy within the preceding three months Baseline characteristics: age (years) 32.5 \u00b1 4.5 vs. 32.2\u00b1 4.2, BMI (kg/m 2 ) 22.9 \u00b1 3.1 vs. 22.7 \u00b1 2.9, infertility duration (years) 3.3 \u00b1 1.6 vs. 3.1 \u00b1 1.3, number of nullipara 64 (60.4) vs. 66 (62.9),AFC 27.7 \u00b1 4.1 vs. 26.5 \u00b1 3.9, fasting glucose (mg/dL) 97.4 \u00b1 20.1 vs. 96.4\u00b1 18.4, two-hour glucose after 75 g glucose load (mg/dL) 132.5 \u00b1 27.8 vs. 128.5 \u00b1 24.6, basal FSH (IU/L) 4.2 \u00b1 1.3 vs. 4.3 \u00b1 1.0, basal LH (IU/L) 7.5 \u00b1 1.7 vs.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "GnRH agonist (n = 105): OCP + 50 to 150 IU of r-hFSH (Gonal-F) (adjusted) + 0.1 mg/day triptorelin (Decapeptyl) from day 18 of OCP pretreatment cycle.When pituitary desensitisation was achieved, ovarian stimulation was started and the dose of triptorelin was reduced to 0.05 mg daily and continued up to day of r-hCG administration.(Long protocol)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Oocyte maturation triggering: 250 \u03bcg r-hCG SC when one or more follicles reached a mean diameter of 17 mm Oocyte retrieval: 36 hours after r-hCG injection, followed by IVF or ICSI on the third day after oocyte retrieval",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "Luteal phase support: 90 mg vaginal progesterone gel (Crinone gel 8%) once daily from the day of oocyte retrieval Follow-up: Pregnancies were confirmed by rising serum \u03b2-hCG concentrations and transvaginal ultrasonographic evidence of a gestational sac.The serum level of \u03b2-hCG was measured 11 days after ET Outcomes Live birth rate, miscarriage rate, clinical pregnancy rate, incidence of severe OHSS, cycle cancellation rate, progesterone levels, estradiol levels and endometrial thickness on the day of hCG injection, total amount and days of r-hFSH administered, the numbers of retrieved, mature, fertilised oocytes and good quality embryos, numbers of embryos transferred and cryopreserved, embryo implantation rate, multiple pregnancy rate",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Maximum embryos transferred: 4",
                "sec_num": null
            },
            {
                "text": "Random sequence generation (selection bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Low risk \"The subjects, aged 25 to 39 years, were randomized into either the GnRH antagonist MDP-EL (antagonist group, n = 106) or the GnRH agonist LP (agonist group, n = 105) by the use of sealed envelopes and a computer-generated list.\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias Authors' judgement Support for judgement",
                "sec_num": null
            },
            {
                "text": "Unclear risk Study did not report whether envelope was sequentially-numbered, opaque and safe-guarded.\"\u2026by the use of sealed envelopes.The sequence of allocation to the two groups was provided to the investigating physicians and randomization was performed as planned according to the randomization list order.\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding (performance bias and detection bias) All outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Allocation concealment (selection bias)",
                "sec_num": null
            },
            {
                "text": "Blinding not reported but it is unlikely to influence measurement of outcomes",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Unclear risk",
                "sec_num": null
            },
            {
                "text": "Low risk Number randomised = 211, number analysed = 208 (missing data balanced across the groups, and reasons similar)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "\"One cycle (0.9%) in the antagonist group and 2 cycles (1.9%) in the agonist group were cancelled after oocyte retrieval due to a high risk of OHSS.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "There was no significant difference in cycle cancellation rate between the two groups\"",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "Selective reporting (reporting bias)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Incomplete outcome data (attrition bias) All outcomes",
                "sec_num": null
            },
            {
                "text": "\u2022 In cases of excessive ovarian response that could lead to life threatening OHSS (Navot 1992), elective cryopreservation was performed \u2022 Excessive ovarian response was defined by the following criteria: high E2 levels (.4000 pg ml 21) and more than 35 follicles on the day of hCG (Navot 1992), haematocrit > .45,white blood cell count > 15,000, ovarian size > 12 cm three days after oocyte retrieval (Navot 1992; Brinsden 1995).A modified system of OHSS classification previously described was adopted (Rizk 1999) (20.9 -29.3),FSH (IU/l) 6.0 (4.3 -6.9) vs 6.2 (4.8 -7.5), LH (IU/l) vs 5.9 (3.4 -7.6) 5.3 (4.0 -7.5)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Notes",
                "sec_num": null
            },
            {
                "text": "GnRH antagonist (n = 110): OCP + 150 IU FSH on 2nd day of the cycle (adjusted) + 0.25 mg SC of cetrorelix acetate (Cetrotide) administered when at least one of the following criteria were fulfilled, the presence of at least one follicle measuring > 14 mm, serum E2 levels > 600 pg/ml; and serum LH levels > 10 IU/l (flexible protocol)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "GnRH agonist (n = 110): OCP (Cilest) + 150 IU rFSH (adjusted) + long GnRH agonist, 0.1 mg triptorelin three days before discontinuation of the OCP, once down-regulation was achieved, the dose of GnRH agonist was decreased on that day to 0.05 mg/day (low-dose GnRH agonist protocol)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Oocyte maturation triggering: 3 follicles > 17 mm, 5000 IU of hCG was administered Oocyte retrieval: 35 -36 hours later, followed by IVF/ ICSI",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Interventions",
                "sec_num": null
            },
            {
                "text": "Luteal phase support: 600 mg of micronised progesterone was initiated two days after oocyte retrieval Follow up: OPR was confirmed by vaginal ultrasound scan at 12 weeks of gestation",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Maximum of embryo transferred: 3",
                "sec_num": null
            },
            {
                "text": "The primary outcome measure: ongoing pregnancy rate per participant randomised.Ongoing pregnancy and clinical pregnancy were defined as the presence of gestational sac with fetal heart beat detection at 12 weeks and at 6 -7 weeks of gestation, respectively Secondary outcome measures: OHSS incidence, duration of rFSH stimulation, total dose of rFSH, E2 and progesterone concentration on the day of hCG administration, cycle cancellation rate, number of cumulus-oocyte complexes (COCs) retrieved, number of metaphase II oocytes and fertilisation rates Notes OHSS classification: a modified classification system based on combined criteria previously reported (Golan 1989; Navot 1992; Rizk 1999) was used in the current study ): on the third day of the menstrual cycle, ovarian stimulation was started with a fixed dose of 150 -225 IU rFSH and 75 IU/day rLH for five days.On the eighth day of the menstrual cycle (sixth day of ovarian stimulation), follicular development was monitored by transvaginal ultrasound.The dose of rFSH was adapted according to the ovarian response, and supplementation with rLH was increased to 150 IU/day when one or more follicles measuring 10 mm in diameter were found.The GnRH antagonist, at a dose of 0.25 mg/day SC was started when at least one follicle greater or equal to 14 mm was observed on ultrasound",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "First, pituitary down-regulation was started during the luteal phase of the previous menstrual cycle with the GnRH agonist at a dose of 1 mg/day for 14 days.Then, ovarian stimulation was started with a fixed dose of 150-225 IU recombinant FSH (rFSH/Gonal F1; Serono, SP, Brazil) with 75 IU/day rLH (Lu-veris1; Serono, SP, Brazil) for seven days.On the eighth day of ovarian stimulation, follicular development was monitored by transvaginal ultrasound.The dose of rFSH was adapted according to the ovarian response, and rLH supplementation was increased to 150 IU/day when one or more follicles measuring greater than or equal to 10 mm in diameter were found Additional support: for both groups, 250 mg r-hCG (Ovidrel1; Serono, SP, Brazil) was administered SC when at least two follicles reached a diameter of 17 mm during final oocyte maturation.Oocyte retrieval was performed by transvaginal aspiration under ultrasound guidance 34 -36 h after r-hCG injection Outcomes None of the reported outcomes (DNA fragmentation, apoptosis) were relevant to the review In group B (n = 30), ovarian stimulation started at day 2 with rFSH at a dose of 375 IU (Gonal-F)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "GnRH agonist (n = 16)",
                "sec_num": null
            },
            {
                "text": "Oocyte maturation triggering: hCG (Profasi; Serono) 10,000 IU was administered IM 24 hrs after the last rFSH injection when at least two follicles had reached a diameter of 17 mm \u2022 When triggering of ovulation was not done within four days of administration of the 3 mg dose of cetrorelix, a daily injection of 0.25 mg was given to 11 women until hCG administration \u2022 Implantation rate was not mentioned as an outcome variable \u2022 Incidence of multiple pregnancies was not mentioned in the table of outcomes and was not clear in the text \u2022 Tolerability was not mentioned in the table of outcomes but stated in the text regarding the cetrorelix group only.No mention of itching or redness in the decapeptyl group \u2022 Although power calculation was not done, the authors were concerned with the response to cetrorelix so they assumed 107 would be a sufficient number to obtain 95% response rate with a CI width of 5% \u2022 Centre-adjusted analysis was done for all outcomes except miscarriage, ectopic and OHSS",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "Authors' judgement Support for judgement hCG, 10,000 IU in 1 ml saline (Pregnyl\u00ae, NV Organon, the Netherlands), was administered, either SC or IM, when at least three follicles 17 mm or at least one follicle 20 mm were observed on ultrasound.In case of risk of OHSS, the hCG dose was reduced to 5000 IU.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "Oocyte retrieval was performed 30 -36 hrs after hCG administration, followed by IVF or ICSI.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "No more than three embryos were transferred 2 -3 days after oocyte retrieval.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "Progesterone for luteal support was given daily (doses and administration form as per usual protocol of the participating centre), starting at the latest on the day of embryo transfer, for two weeks or up to menses",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "The study was approved by the Ethics Committee of each participating centre.All women gave written informed consent.The study was performed according to the principles of the Declaration of Helsinki, and the ICH/Good Clinical Practice guidelines.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "The study was monitored by uniformly trained Clinical Research Associates of Organon with assistance of a contract research organisation for the clinics in Perth and Adelaide",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Bias",
                "sec_num": null
            },
            {
                "text": "Prior to the start of treatment, a physical and gynaecological examination was performed to exclude any abnormality.Blood samples were taken for routine biochemistry, haematology, and hormonal parameters.A pregnancy test (urinary hCG) was performed.Blood samples for hormone assessments were taken just before the first rFSH injection (treatment day 1) and at least once every two days from day 5/6 of rFSH treatment (in the antagonist groups just before ganirelix injection) up to and including the day of hCG.Serum FSH, LH, estradiol, and progesterone values were determined by means of the automated Wallac AutoDelfia Fluoroimmunoassay system (PerkinElmer Inc., Wellesley MA, USA) at a central laboratory (ABL BV, Assen, The Netherlands).The maximum intra-assay and inter-assay coefficients of variation were 3.3% for FSH, 3.4% for LH, 4.9% for estradiol, and 4.3% for progesterone.To measure follicular development, ultrasonography was performed at least once every two days from day 5/6 of rFSH treatment up to and including the day of hCG.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Other parameters assessed were treatment failure (defined as the number of women who did not have an hCG injection or who received an hCG injection because of premature luteinisation), number of LH rises (LH = 10 IU/l), number of oocytes retrieved, number of good quality embryos (grade 1 (defined as",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Cochrane Library Trusted evidence. Informed decisions. Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Rombauts 2006 (Continued)",
                "sec_num": null
            },
            {
                "text": "Embryo transfer: no more than three embryos were to be replaced: two if transferred at blastocyst stage Luteal phase support: Micronised progesterone according to centres' practice",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Cochrane Database of Systematic Reviews",
                "sec_num": null
            },
            {
                "text": "The primary efficacy end-point: the number of metaphase II oocytes retrieved per patient Secondary efficacy: end-points were the duration and total dose of r-hFSH therapy, the total number of follicles > 14 mm on the day of r-hCG administration, oocyte and embryo quality and development, the number of participants with at least one embryo considered viable for cryopreservation, oestradiol concentration per follicle > 10 mm, total number of oocytes, implantation rates per-embryos transferred and pregnancy rates (biochemical and clinical)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Outcomes",
                "sec_num": null
            },
            {
                "text": "Cochrane Library Trusted evidence. Informed decisions. Better health.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk of bias",
                "sec_num": null
            },
            {
                "text": "Cochrane Database of Systematic Reviews cutaneously per day when the leading follicle reached 14 mm in diameter until the hCG injection.(Flexible)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk of bias",
                "sec_num": null
            },
            {
                "text": "GnRH agonist (n= 48): 1 mg/ day leuprolide acetate (Lucrin) started on the 21st day prior to menstruation for pituitary desensitization.When exogenous gonadotrophins were started on day 2 of menstruation, the dose of leuprolide acetate was decreased to 0.5 mg/day + 300 IU rFSH and hMG starting on the second day of menstruation for 6 days (adjusted)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk of bias",
                "sec_num": null
            },
            {
                "text": "Oocyte maturation triggering: When the leading follicle reached 18 mm in diameter or at least two follicles were >17 mm in diameter, a total of 10,000 units of hCG were administered intramuscularly.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Risk of bias",
                "sec_num": null
            },
            {
                "text": "For the 2016 update Reuben Olugbenga Ayeleke and Julie Brown screened the searches and selected studies for inclusion.Reuben Olugbenga Ayeleke, Julie Brown and Wai Sun Lam extracted and entered data; Reuben Olugbenga Ayeleke contributed to the modification and updating of the review text; Hesham Al-Inany, Frank J Broekmans and Mohamed Abdel Fattah Mahmoud Youssef contributed to the discussion and interpretation of results.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "C O N T R I B U T I O N S O F A U T H O R S",
                "sec_num": null
            },
            {
                "text": "Hesham Al-Inany: took the lead in writing the protocol, review, and update, performing initial searches of databases for trials, was involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, and was responsible for statistical analysis and interpretation of the data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Mohamed Abdel Fattah Mahmoud Youssef: performed updated searches of databases for new trials, was involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, and was responsible for statistical analysis and interpretation of the data.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Mohamed Aboulghar: commented on dra s of the protocol and review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Frank JM Broekmans: contributed to discussion and commented on review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Monique D Sterrenburg: contributed to discussion and commented on review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Janine G Smit: contributed to data analysis checks and discussion, and commented on review.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Ahmed Abou-Setta: was involved in selecting trials for inclusion, performed independent data extraction and quality assessment of the included trials, and contributed to discussion and interpretation of results.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "For the 2011 update",
                "sec_num": null
            },
            {
                "text": "Gonadotrophin-releasing hormone antagonists for assisted reproductive technology (Review)Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "",
                "sec_num": null
            }
        ],
        "back_matter": [
            {
                "text": "Mean age: Group 1: 36.7 \u00b1 3.1 years, Group 2: 35.9 \u00b1 2.8 years, Group 3: 36.4 \u00b1 3.3 years Setting: University-based infertility clinic, Seoul, South Korea Interventions Pretreatment was ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg for 21 days in the cycle preceding controlled ovarian stimulation Group 1: GnRH antagonist multiple dose protocol after OCP pretreatment (n = 40) ovarian stimulation commenced five days after OCP discontinued using rFSH 225 IU/day (dose-adjusted every three to four days).Cetrotide 0.25 mg started when lead follicle was 14 mm diameter and continued until day of hCG injection versus Group 2 GnRH antagonist multiple-dose protocol without OCP pretreatment (n = 40) ovarian stimulation commenced on cycle day three using rFSH 225 IU/day (dose adjusted every three to four days).Cerotide 0.25 mg started when lead follicle was 14 mm diameter and continued until day of hCG injection.versus Group 3 GnRH agonist luteal low-dose long protocol without OCP pretreatment (n = 40).Daily injection of decapeptyl 0.1 mg started from mid-luteal phase and continued until menses followed by a dose reduction to 0.05 mg daily and continued until day of hCG injection Methods RCT, open-label, multi-centre study.Phase III trial Participants 74 infertile women (aged 18 -39 years) undergoing ICSI Inclusion criteria: regular menstrual cycles, BMi < 35 kg/m 2 .Both ovaries present, no clinical signs of pelvic or uterine abnormalities, normal cervical cytology, wash-out period completed for any previous IVF drug protocols and FSH concentrations in the normal range.All women were also required to be willing and able to comply with the study protocol Baseline characteristics: mean age (\u00b1 SD) of the ITT population was 32.6 \u00b1 4.0 years.The age range was broad (22 -39 years) and there were no significant differences between the three treatment groups.Mean BMI was 24.2 \u00b1 4.5 g/m 2 .again with no significant differences between groups.Fi y-one of the 73 women in the ITT population (69.99%) were White and the proportion of White women did not differ between treatment groups Interventions GnRH antagonist: OCP pretreatment for 14 -18 days, followed by cetrorelix (3 mg), starting on day 7 + rFSH 225 IU, starting on day 5 after OCP/dose adjustments after day 6 GnRH agonist: leuprorelin (0.5 mg/ day reduced to 0.25 mg/day after down-regulation was achieved), long luteal, overlapping with OCP pretreatment for seven days + rFSH 225 IU, starting on day 5 after OCP/dose adjustments after day 6 Agonist -Pituitary down-regulation with nafarelin nasal spray 400 \u00b5g twice daily (Synarel; Pharmacia) commenced in the mid-luteal phase and continued for two weeks.After confirmation of down-regulation by ultrasound and recording of antral follicles, ovarian stimulation was commenced with gonadotrophin injections 450 IU/day and reduced dose of nafarelin 200 \u00b5g twice daily until hCG injection.hCG administered when three antral follicles reached \u2265 17 mm diameter (n = 37).Cochrane Library Trusted evidenceCochrane Library Trusted evidenceThere was a third group that received a short agonist protocol.This arm is not described further here as it is not a comparison for this review (n = 37)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "annex",
                "sec_num": null
            },
            {
                "text": "Luteal phase support with progesterone pessaries 400 mg once or twice daily commencing on the day of oocyte retrieval and continued to negative pregnancy test or 8 weeks' gestation Gonadotrophin dose: antagonist 4740.0 \u00b1 1131.9 versus antagonist 5540.32 \u00b1 1216.1Embryos transferred: antagonist 1.8 \u00b1 0.6 versus agonist 1.7 \u00b1 0. Cochrane Database of Systematic Reviews",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "Oocyte retrieval performed 34 to 38 hours after hCG",
                "sec_num": null
            },
            {
                "text": "Previous author Professor Dr Mohamed Aboulghar was an investigator in one of the included trials, the European Middle East Orgalutran trial Euro Middle East 2001.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D E C L A R A T I O N S O F I N T E R E S T",
                "sec_num": null
            },
            {
                "text": "\u2022 None, Other.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "S O U R C E S O F S U P P O R T Internal sources",
                "sec_num": null
            },
            {
                "text": "\u2022 None, Other.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "External sources",
                "sec_num": null
            },
            {
                "text": "In the 2016 update of this review, outcomes have been subgrouped with respect to the type of triggering agent and level of stimulation (minimal or standard).The protocol had the following subgroups.\u2022 GnRH antagonist regimen (fixed or flexible).\u2022 GnRH antagonist type (cetrorelix or ganirelix).\u2022 GnRH antagonist plus pre-treatment with oral contraceptive pill (OCP).\u2022 Patient characteristics (polycystic ovary syndrome (PCOS); poor responders).\u2022 Patients undergoing mild ovarian stimulation.Miscarriage rate per woman randomised has been introduced as one of the secondary outcomes, with miscarriage rate per clinical pregnancy (a secondary outcome in the protocol) retained as a secondary analysis.",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W",
                "sec_num": null
            },
            {
                "text": "Medical Subject Headings (MeSH)",
                "cite_spans": [],
                "ref_spans": [],
                "eq_spans": [],
                "section": "I N D E X T E R M S",
                "sec_num": null
            }
        ],
        "bib_entries": {
            "BIBREF0": {
                "ref_id": "b0",
                "title": "1 Hormone Antagonists/ (305) 2 gonadotropin releasing hormone antagonist$.tw. (87) 3 gonadotrophin releasing hormone antagonist$.tw. (29) 4 GnRH antagonist",
                "authors": [],
                "year": 2015,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF1": {
                "ref_id": "b1",
                "title": "tw. (0) 6 (Cetrorelix or Cetrotide$)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF2": {
                "ref_id": "b2",
                "title": "tw. (81) 8 (Abarelix or Plenaxis).tw. (11) 9 Antagon.tw. (10) 10",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ganirelix",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "Degarelix.tw",
                "volume": "",
                "issue": "29",
                "pages": "11--11",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF3": {
                "ref_id": "b3",
                "title": "/ or exp goserelin/ or exp leuprolide/ or exp nafarelin/ or exp triptorelin/ (1885) 13 gonadotropin releasing hormone agonist$.tw. (359) 14 gonadotrophin releasing hormone agonist$.tw. (146) 15 GnRH agonist",
                "authors": [],
                "year": null,
                "venue": "exp gonadotropin-releasing hormone/ or exp buserelin",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF4": {
                "ref_id": "b4",
                "title": "tw. (4) 17 (buserelin or goserelin).tw. (668) 18 (leuprolide or nafarelin)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF5": {
                "ref_id": "b5",
                "title": "triptorelin.tw. (196) 20 (Lupron or Eligard)",
                "authors": [],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF6": {
                "ref_id": "b6",
                "title": "(3) 23 Supprelin.tw. (0) 24 Zoladex.tw. (227) 25 deslorelin",
                "authors": [],
                "year": null,
                "venue": "Synarel.tw",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF7": {
                "ref_id": "b7",
                "title": "or Tryptorelin).tw. (1772) BUSERELIN/ (4084) Buserelin.tw. (1473) (Bigonist or Busereline or Receptal or Superfact or Suprefact).tw. (1135) (GNRH-a or GNRH a)",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Ovuplant",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "562",
                "issue": "",
                "pages": "14--27",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            },
            "BIBREF8": {
                "ref_id": "b8",
                "title": ") 28 and 52 (929) Cochrane Database of Systematic Reviews 13 deslorelin.tw. (5) (decapeptyl or trelstar).tw. (2) (GnRH-a or GNRH a)",
                "authors": [
                    {
                        "first": "",
                        "middle": [],
                        "last": "Rct",
                        "suffix": ""
                    }
                ],
                "year": null,
                "venue": "",
                "volume": "",
                "issue": "",
                "pages": "",
                "other_ids": {},
                "num": null,
                "urls": [],
                "raw_text": "",
                "links": null
            }
        },
        "ref_entries": {
            "FIGREF0": {
                "text": "..................................................................................................................................................................................................... PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... SUMMARY OF FINDINGS.............................................................................................................................................................................. BACKGROUND.............................................................................................................................................................................................. OBJECTIVES.................................................................................................................................................................................................. METHODS..................................................................................................................................................................................................... Figure 1.................................................................................................................................................................................................. RESULTS........................................................................................................................................................................................................ Figure 2.................................................................................................................................................................................................. Figure 3.................................................................................................................................................................................................. Figure 4.................................................................................................................................................................................................. Figure 5.................................................................................................................................................................................................. Figure 6.................................................................................................................................................................................................. Figure 7.................................................................................................................................................................................................. Figure 8.................................................................................................................................................................................................. Figure 9.................................................................................................................................................................................................. DISCUSSION.................................................................................................................................................................................................. AUTHORS' CONCLUSIONS........................................................................................................................................................................... ACKNOWLEDGEMENTS................................................................................................................................................................................ REFERENCES................................................................................................................................................................................................",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF1": {
                "text": "Figure 1.Study flow diagram.",
                "fig_num": "1",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF2": {
                "text": "Figure 3. (Continued)",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF3": {
                "text": "Figure 4. Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised.",
                "fig_num": "4",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF4": {
                "text": "Figure 5. Funnel plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised.",
                "fig_num": "56",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF5": {
                "text": "Figure 7. Forest plot of comparison: 1 GnRH antagonist versus long-course GnRH agonist, outcome: 1.3 Live birth rate per woman randomised -grouped by trigger.",
                "fig_num": "7",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF6": {
                "text": "Figure 8. Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.4 Ovarian hyperstimulation per woman randomised -all women.",
                "fig_num": "8",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF7": {
                "text": "Figure 9. Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.5 Ovarian hyperstimulation per woman randomised -moderate or severe.",
                "fig_num": "59",
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF8": {
                "text": "undergoing IVF Interventions GnRH antagonist (n = 62): 450 IU HP-FSH (Urofollitropin) + cetrorelix 0.25 mg daily added to the ovarian stimulation when the largest follicle measures \u2265 14 mm (flexible protocol) GnRH agonist (n = 62): 450 IU HP-FSH (Urofollitropin) + triptoreline 0.05 mg daily (half the standard dose) initiated in the mid-luteal phase prior to the treatment cycle (minidose long protocol)",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF9": {
                "text": "GnRH antagonist (n = 106): OCP + 50 to 150 IU of rhFSH (Gonal-F) five days after discontinuation of OCP (adjusted) + 0.125 mg/day cetrorelix (Cetrotide) in the morning of stimulation days 1 and 2. When the mean diameter of lead follicle reached 13 mm, cetrorelix at a dose of 0.25 mg/day was started again and continued daily up to the day of r-hCG injection.(Multiple dose protocol) Kim 2012 Gonadotrophin-releasing hormone antagonists for assisted reproductive technology (Review) Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF10": {
                "text": "Participants 60 infertile women (poor responders) undergoing IVF/ICSI Inclusion criteria: estradiol concentrations < 600 pg/ml concentration on the day of hCG administration and a poor response (number of oocytes retrieved < 3) after a previous standard long protocol using analogues for down-regulation and recombinant gonadotrophin at a dose of 225 IU for stimulation (rFSH, Gonal-F) Interventions GnRH antagonist (n = 30): 375 IU rFSH (Gonal-F) from cycle day 2 + GnRH antagonist cetrorelix 0.25 mg per day was then administered from when the two lead follicles had reached 14 mm diameter, irrespective of the day of the cycle until the day of hCG injection.(Flexible) GnRH agonist (n = 30): by analogues from day 23 of the cycle (Enantone 3.75 mg) + 375 IU daily , SC, rFSH, (Gonal-F) from day 3 of the next cycle at a dose of 375 IU.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "FIGREF11": {
                "text": "Methodsopen-label, RCT a web-based concealed randomization code Participants 1099 infertile women referred for their first IVF/ICSI at two public fertility clinics All less than 40 years of age and with no uterine malformation including women with poor ovarian reserve, polycystic ovary syndrome and irregular cycles.Interventions women allocated to either short GnRH antagonist or longGnRHagonist protocol in a 1:1 ratio and enrolled over a 5-year period Outcomes difference in severe OHSS, rates of mild and moderate OHSS, positive plasma (p)-hCG, on-going pregnancy and live birth Notes A total of 49 women withdrewtheir consent, thus 1050 subjects were allocated to the GnRH antagonist (n \u00bc 534) and agonist protocol (n \u00bc 516), respectively.",
                "fig_num": null,
                "num": null,
                "uris": null,
                "type_str": "figure"
            },
            "TABREF0": {
                "text": "\u2022 Ovid Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library; Issue 4 2015) (updated search from 2010 to 28 April 2015) (Appendix 2).The EMBASE search was combined with the trial filter developed by the Scottish Intercollegiate Guidelines Network (SIGN) (http://sign.ac.uk/methodology/filters.html).\u2022 Ovid PsycINFO (updated search from 2010 to 28 April 2015) (Appendix 5).The PsycINFO search was combined with the trial filter developed by the Scottish Intercollegiate Guidelines Network (SIGN) (http://sign.ac.uk/methodology/filters.html).\u2022 EBSCO CINAHL (Cumulative Index to Nursing and Allied Health Literature) (Appendix 6).PubMed (www.ncbi.nlm.nih.gov/pubmed/).The PubMed search was combined with the random control filter for PubMed.\u2022 OpenGrey -http://www.opengrey.eu/for unpublished literature from Europe.",
                "html": null,
                "num": null,
                "content": "<table><tr><td colspan=\"6\">\u2022 Ovid MEDLINE (updated search from 2010 to 28 April</td></tr><tr><td colspan=\"6\">2015) (Appendix 3). The MEDLINE search was based on the</td></tr><tr><td colspan=\"6\">Cochrane Highly Sensitive Search Strategy (HSSS) for identifying</td></tr><tr><td colspan=\"6\">randomised trials in MEDLINE: sensitivity-maximising version</td></tr><tr><td colspan=\"2\">(Lefebvre 2011).</td><td/><td/><td/></tr><tr><td colspan=\"6\">\u2022 Ovid EMBASE (updated search 2010 up to 28 April 2015)</td></tr><tr><td colspan=\"2\">(Appendix 4). \u2022 LILACS (Latin</td><td>American</td><td>and</td><td>Caribbean</td><td>Health</td></tr><tr><td>Sciences)</td><td colspan=\"5\">(http://bases.bireme.br/cgi-bin/wxislind.exe/iah/</td></tr><tr><td colspan=\"6\">online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F).</td></tr><tr><td>\u2022</td><td/><td/><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF1": {
                "text": "Seventy out of 73 studies reported that baseline characteristics were comparable between groups (Characteristics of included studies table) and three did not report information on this.In eighteen of the studies, age was the only reported characteristic compared.\u2022Of the 73 included studies, 49 trials involved an unspecified population of infertile couples, while the remaining trials were performed in specific infertile populations.These populations",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">2014; Hsieh 2008; Huirne 2006; Hwang 2004; Martinez 2008;</td><td>a sample size calculation; and it was not clear if sample size \u2022 Ovarian stimulation was started a er two weeks if pituitary</td></tr><tr><td colspan=\"2\">Moshin 2007; Sauer 2004); and (3) flexible daily administration</td><td>calculations had been performed in the remaining 36 studies. down-regulation was established (serum estradiol level &lt;</td></tr><tr><td colspan=\"2\">(Baart 2007; Badrawi 2005; Bahceci 2005; Barmat 2005; Brelik 2004; Check 2004; Choi 2012; Depalo 2009; El Sahwi 2005; Engmann 2008a; Franco 2003; Hershko Klement 2015; Hohmann 2003; Karimzadeh 2010; Kim 2004; Kim 2011; Kurzawa 2008; Lainas 2007; Lainas 2010; Lee 2005; Lin 2006; Loutradis 2004; Marci 2005; Moraloglu 2008; Rombauts 2006; Sbracia 2009; Serafini 2008; Tazegul 2008; Tehraninejad 2010; Xavier 2005; Ye 2009). In the fixed daily protocol, in most of the studies, GnRH antagonist was begun on day six of FSH treatment regardless of follicle size. In the flexible daily protocol, GnRH antagonist was administered according to the lead follicle size and not the cycle date, nor the day of FSH administration. In 25 of the included studies, the type of antagonist protocol used was not reported.</td><td>50 pg/ml). In both treatment groups, ovarian stimulation \u2022 Twenty-three studies said that they had performed intention-to-was started with a fixed daily dose of 150 IU or 225 IU treat analysis (Badrawi 2005; Choi 2012; Cota 2012; Depalo 2009; recombinant follicle stimulating hormone (rFSH) or human Engmann 2008a; Euro Middle East 2001; Euro Orgalutran 2000; menopausal gonadotrophin (hMG) for the first five stimulation Fluker 2001; Heijnen 2007; Hosseini 2010; Huirne 2006; Hwang days. Therea er, the dose of FSH was adapted depending on 2004; Khalaf 2010; Kim 2004; Kim 2011; Lin 2006; Loutradis 2004; the ovarian response, as monitored via ultrasonography (US). Marci 2005; Rombauts 2006; Sauer 2004; Serafini 2008; Sunkara Triggering of ovulation was induced with hCG (10,000 IU) if at 2014; Xavier 2005); 16 studies reported that the original analyses least three follicles that were more than 17 mm in diameter were did not use the intention-to-treat principle (Albano 2000; Baart observed by US. 2007; Bahceci 2005; Cheung 2005; El Sahwi 2005; Firouzabadi 2010; Hohmann 2003; Inza 2004; Kurzawa 2008; Kyono 2005; Lee 2005; Olivennes 2000; Sbracia 2009; Tazegul 2008; Tehraninejad 2010; Ye 2009); it was not reported clearly in the rest of the studies. \u2022 Trigger used: the majority of the included studies used hCG trigger or did not state which trigger was used; one of the included studies used a combination of both hCG and GnRH agonist as trigger agents (Engmann 2008a).</td></tr><tr><td colspan=\"2\">\u2022 In 44 included trials, the antagonist cetrorelix was administered (Albano 2000; Al-Karaki 2011; Bahceci 2005; Brelik 2004; Cheung</td><td>Participants</td></tr><tr><td colspan=\"2\">2005; Cota 2012; Depalo 2009; El Sahwi 2005; Ferrari 2006; Ferrero 2010; Hershko Klement 2015; Hohmann 2003; Hoseini 2014; Hosseini 2010; Hsieh 2008; Huirne 2006; Hwang 2004; Khalaf 2010; Kim 2004; Kim 2011; Kim 2012; Kurzawa 2008; Kyono 2005; Lainas 2010; Lavorato 2012; Lee 2005; Lin 2006; Loutradis 2004; Marci 2005; Mohamed 2006; Moraloglu 2008; Moshin 2007; Olivennes 2000; Rabati 2012; Revelli 2014; Rinaldi 2014; Sauer 2004; Sbracia 2009; Serafini 2008; Sunkara 2014;</td><td>\u2022 \u2022 The number of randomised women ranged from 20 (Franco</td></tr><tr><td/><td/><td>2003) to 1099 (Toltager 2015), including both the GnRH agonist</td></tr><tr><td/><td/><td>and antagonist groups.</td></tr><tr><td colspan=\"2\">Albano 2000; Baart 2007; Barmat 2005; Euro Middle East 2001; Euro Orgalutran 2000; Fluker 2001; Heijnen 2007; Huirne 2006; Olivennes 2000; Qiao 2012; Rombauts 2006; Sauer 2004), 43 studies were single-centre trials, while in the remaining studies it was unclear whether they were multi-centre or single centre. \u2022 Oral contraceptive pill pre-treatment was used in 18 studies (Barmat 2005; Cheung 2005; Engmann 2008a; Haydardedeoglu 2012; Hershko Klement 2015; Hosseini 2010; Huirne 2006; Kim 2004; Kim 2011; Kim 2012; Kurzawa 2008; Kyono 2005; Lainas 2007; Lainas 2010; Moraloglu 2008; Rombauts 2006; Sauer 2004; Tehraninejad 2010). Further single trials used Diane (Hwang 2004), estradiol in the luteal phase (Franco 2003), and vaginal Nuvaring (Martinez 2008). \u2022 Women randomised to treatment with GnRH antagonist started ovarian stimulation on day two to three of the menstrual cycle. The GnRH antagonist was started on stimulation day six, by daily subcutaneous administration up to and including the day of human chorionic gonadotrophin (hCG) administration in the fixed protocol or depending on the dominant follicle size in the flexible protocol.The GnRH long agonist reference treatment was \u2022 We considered sample size calculations to be appropriate when the authors of the studies pre-calculated the number needed Huirne 2006; Kim 2011; Kurzawa 2008; Lainas 2010; Sbracia 2004; Baart 2007; Cota 2012; Engmann 2008a; Heijnen 2007; they had performed a priori sample size calculations (Hwang the occurrence of type II errors. Fi een studies reported that in each arm prior to starting the trial. This helps to prevent started in the mid-luteal phase (cycle day 21 to 24) by either daily intranasal or subcutaneous administration.</td><td>\u2022 Fi een studies included 300 or more participants (Awata 2010; Euro Middle East 2001; Euro Orgalutran 2000; Tehraninejad 2011; Gizzo 2014; Haydardedeoglu 2012; Heijnen 2007; Martinez 2008; Prapas 2013; Revelli 2014; Rinaldi 2014; Rombauts 2006; Sbracia 2009; Toltager 2015). There were 30 studies with fewer than 100 participants (Anderson 2014; Barmat 2005; Celik 2011; Check 2004; Cheung 2005; Choi 2012; Cota 2012; Engmann 2008a; Ferrari 2006; Franco 2003; Friedler 2003; Hershko Klement 2015; Hoseini 2014; Hwang 2004; Inza 2004; Khalaf 2010; Kim 2004; Kurzawa 2008; Lainas 2007; Lavorato 2012; Lee 2005; Marci 2005; Mohamed 2006; Moraloglu 2008; Moshin 2007; Sauer 2004; Serafini 2008; Stenbaek 2015Tazegul 2008; Tehraninejad 2010). \u2022 Five studies were published before 2002. There were 28 studies published between 2002 and 2006, 18 studies published between 2007 and 2010 and 23 studies between 2011 and 2015 \u2022 We identified three types of antagonist protocols: (1) single, cycles. course GnRH agonist protocols in women undergoing IVF or ICSI \u2022 All included studies compared GnRH antagonist with long-Intervention</td></tr><tr><td colspan=\"2\">2009; Sunkara 2014; Tehraninejad 2010; Lin 2006; Depalo 2009;</td><td/></tr><tr><td colspan=\"2\">Tazegul 2008); 22 studies reported that they had not performed</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF2": {
                "text": "Since it was impossible to administer the di erent medications (that is long agonist and antagonist) according to one standard protocol without the use of a double dummy, almost all the studies were open-label (that is no blinding).",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">investigator and the participants knew the allocated treatment);</td><td/></tr><tr><td>(iv) unclear.</td><td/><td/></tr><tr><td colspan=\"2\">\u2022 One study</td><td/></tr><tr><td colspan=\"2\">(Cheung 2005) blinded the clinicians and embryologists from</td><td/></tr><tr><td colspan=\"2\">the treatment allocation by using a nurse practitioner to</td><td/></tr><tr><td colspan=\"2\">administer the medications. The embryologist scoring the</td><td/></tr><tr><td colspan=\"2\">embryos, or the researcher, was blinded to the study groups in</td><td/></tr><tr><td colspan=\"2\">five trials (Baart 2007; Depalo 2009; El Sahwi 2005; Hwang 2004;</td><td/></tr><tr><td>Martinez 2008).</td><td/><td/></tr><tr><td colspan=\"2\">\u2022 Twenty-seven trials reported no blinding and we assessed them</td><td/></tr><tr><td colspan=\"2\">as being at high risk of bias (Albano 2000; Badrawi 2005; Bahceci</td><td/></tr><tr><td colspan=\"2\">2005; Barmat 2005; Check 2004; Engmann 2008a; Euro Middle</td><td/></tr><tr><td colspan=\"2\">East 2001; Euro Orgalutran 2000; Firouzabadi 2010; Fluker</td><td/></tr><tr><td colspan=\"2\">2001; Franco 2003; Friedler 2003; Heijnen 2007; Hohmann 2003;</td><td/></tr><tr><td colspan=\"2\">Kurzawa 2008; Kyono 2005; Lainas 2007; Lainas 2010; Loutradis</td><td/></tr><tr><td colspan=\"2\">2004; Marci 2005; Olivennes 2000; Rombauts 2006; Sauer 2004;</td><td/></tr><tr><td colspan=\"2\">Tazegul 2008; Tehraninejad 2010; Xavier 2005; Ye 2009). The</td><td/></tr><tr><td colspan=\"2\">remaining trials did not clearly report if blinding was performed</td><td/></tr><tr><td colspan=\"2\">and we therefore assessed them as being at unclear risk of bias.</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF3": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>( Analysis 1.10)</td></tr><tr><td>Six studies reported clinical pregnancy rate in 1102 women</td></tr><tr><td>receiving minimal ovarian stimulation. There was evidence of</td></tr><tr><td>a higher clinical pregnancy rate in the GnRH antagonist group</td></tr><tr><td>compared to the GnRH agonist group: 179/552 (32%) versus</td></tr><tr><td>137/550 (25%) (OR 1.50, 95% CI 1.15 to 1.96; I 2 = 50%).</td></tr></table>",
                "type_str": "table"
            },
            "TABREF4": {
                "text": "Several studies have suggested that LH instability decreases the probability of pregnancy in antagonist cycles (Bosch 2003; Kolibianakis 2003; Seow 2010; Shoham 2002).LH instability is defined as any fluctuation in LH level, either a LH surge or rise in LH concentration, in the course of ovarian hyperstimulation.A decrease in the relative incidence of LH instability in the current review can possibly have improved pregnancy outcomes",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF5": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>short GnRH agonist. There was no di erence between GnRH</td></tr><tr><td>antagonist and GnRH agonist (long and flare-up protocols) with</td></tr><tr><td>respect to cycle cancellation rate, number of mature oocytes</td></tr><tr><td>and clinical pregnancy rate per cycle initiated, per oocyte</td></tr><tr><td>retrieval and per embryo transfer. When the meta-analysis was</td></tr><tr><td>applied to the two trials that had used GnRH antagonist versus</td></tr><tr><td>long protocols of GnRH agonist, a significantly higher number</td></tr><tr><td>of retrieved oocytes was observed in the GnRH antagonist</td></tr><tr><td>protocols (MD 1.12, 95% CI 0.18 to 2.05; P = 0.018).</td></tr><tr><td>\u2022 In another systematic review and meta-analysis of four RCTs</td></tr><tr><td>(n = 874) ongoing pregnancy rate was the main outcome</td></tr><tr><td>(Griesinger 2008). There was no evidence of a statistically</td></tr><tr><td>significant di erence between women with and without OCP</td></tr><tr><td>pre-treatment (OR 0.74, 95% CI 0.53 to 1.03). Duration of</td></tr><tr><td>gonadotrophin stimulation (1.41 days, 95% CI 1.13 to 1.68) and</td></tr><tr><td>gonadotrophin consumption (542 IU, 95% CI 127 to 956) were</td></tr><tr><td>significantly increased a er OCP pre-treatment. No significant</td></tr><tr><td>di erences were observed regarding the number of retrieved</td></tr><tr><td>oocytes.</td></tr><tr><td>\u2022 A systematic review and meta-analysis, Youssef 2012, compared</td></tr><tr><td>the e ectiveness and safety of various protocols including GnRH</td></tr><tr><td>antagonist versus long-course GnRH agonist protocol. There was</td></tr><tr><td>no evidence of a di erence between women who received GnRH</td></tr><tr><td>antagonist and those who were treated with long-course GnRH</td></tr><tr><td>agonist protocol in three RCTs, either in clinical pregnancy rate</td></tr><tr><td>(OR 0.72, 95% CI 0.49 to 1.05, five RCTs) or cycle cancellation rate</td></tr><tr><td>(OR 1.25, 95% CI 0.76 to 2.05).</td></tr><tr><td>\u2022 There is a systematic review and meta-analysis that included</td></tr><tr><td>22 RCTs (n = 3176) to compare GnRH antagonists and GnRH</td></tr><tr><td>agonists (Kolibianakis 2006). The reported outcome measure,</td></tr><tr><td>clinical pregnancy or ongoing pregnancy, was converted to live</td></tr><tr><td>births in 12 studies using the published data. No evidence of a</td></tr><tr><td>di erence was detected in the probability of a live birth between</td></tr><tr><td>the two GnRH analogues (OR 0.86, 95% CI 0.72 to 1.02). The</td></tr><tr><td>result remained stable in a subgroup analysis that ordered the</td></tr><tr><td>studies by type of population studied, gonadotrophin type used</td></tr><tr><td>for stimulation, type of agonist protocol used, type of agonist</td></tr><tr><td>used, type of antagonist protocol used, type of antagonist</td></tr><tr><td>used, presence of allocation concealment, presence of co-</td></tr><tr><td>intervention and the way the information on live births was</td></tr><tr><td>retrieved.</td></tr><tr><td>\u2022 A systematic review and meta-analysis, Franco 2006, evaluated</td></tr><tr><td>the e icacy of gonadotrophin antagonist versus GnRH agonist</td></tr><tr><td>in poor ovarian responders in IVF and ICSI cycles. The review</td></tr><tr><td>included six RCTs that compared GnRH antagonist to long or</td></tr></table>",
                "type_str": "table"
            },
            "TABREF6": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>Barmat 2005 {published data only}</td></tr><tr><td/><td>Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized</td></tr><tr><td>* Albano C, Felberbaum R, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserlin. Human</td><td>prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (r FSH) versus GnRH-agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility 2005;83(2):321-30. [MEDLINE: 15705369]</td></tr><tr><td>Reproduction 2000;15(3):526-31.</td><td>Brelik 2004 {published data only}</td></tr><tr><td>Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmuller-Winzen H, Schuler A, et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian</td><td>Brelik P, Kurzawa R, Baczkowski T, Sienkiewicz R, Glabowski W. Assessment of the predictive value of LH levels in IVF cycles stimulated with GnRH antagonists and agonists. Human Reproduction 2004;19:i62.</td></tr><tr><td>stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 2000;264(1):29-32.</td><td>Celik 2011 {published data only} Celik N, Celik O, Aktan E, Ozerol E, Celik E, Bozkurt K, et al.</td></tr><tr><td>Al-Karaki 2011 {published data only}</td><td>Plasma urocortin levels in women undergoing long agonist</td></tr><tr><td>Al-Karaki R, Irzouqi R, Khalifa F, Taher M, Sarraf M. E ectiveness of flexible GnRH antagonist protocol versus minidose long GnRH</td><td>and antagonist protocols for IVF. Human Reproduction 2011;26(1):i203.</td></tr><tr><td>agonist protocol in poor-responder patients undergoing IVF. Human Reproduction 2011;26(1):i47.</td><td>Check 2004 {published data only} Check ML, Check JH, Choel JK, Davies E, Kiefer D. E ect of</td></tr><tr><td>Anderson 2014 {published data only}</td><td>antagonists vs agonists on in vitro fertilization outcome. Clinical</td></tr><tr><td>Anderson S, Pereira NE, Brasile DR, Orris JJ, Davies EB, Glassner MJ. Comparison of antagonist to agonist in controlled</td><td>and Experimental Obstetrics &amp; Gynecology 2004;31(4):257-9. [MEDLINE: 15672958]</td></tr><tr><td>ovarian stimulation (COS) cycles using human-derived gonadotropin on in vitro fertilization (IVF) outcomes. A prospective randomized controlled study. Fertility and sterility. 2014; Vol. 102 (3; Suppl 1):e224.</td><td>Cheung 2005 {published data only} Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.</td></tr><tr><td>Awata 2010 {published data only}</td><td>Human Reproduction (Oxford, England) 2005;20(3):616-21.</td></tr><tr><td>Awata S, Tanaka A, Nagayoshi M. Selection of an optimal</td><td>[MEDLINE: 15608037]</td></tr><tr><td>controlled ovarian hyperstimulation method in relation to the number of antral follicles in patients less than 40 years old. Fertility and Sterility 2010;94 suppl 1(4):S164 Abstract no. P-244.</td><td>Choi 2012 {published data only} Choi MH, Kim HO, Cha SW, Koong MKK, Kim JY, Park CW. IVF comparison of ART outcomes in infertile PCOS women; in</td></tr><tr><td>Baart 2007 {published data only}</td><td>vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist</td></tr><tr><td>Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NGM, Verhoe A, et al. Milder ovarian stimulation for in-vitro</td><td>cycles. Clinical Experimental Reproductive Medicine December 2012;39(4):S210.</td></tr><tr><td>fertilization reduces aneuploidy in the human preimplantation</td><td/></tr><tr><td>embryo: a randomized controlled trial. Human Reproduction</td><td/></tr><tr><td>2007;22(4):980-8.</td><td/></tr><tr><td>Badrawi 2005 {published data only}</td><td/></tr><tr><td>Badrawi A, Al-Inany H, Hussein M, Zaki S, Ramzy AM. Agonist</td><td/></tr><tr><td>versus antagonist in ICSI cycles: a randomized trial and cost</td><td/></tr><tr><td>e ectiveness analysis. Middle East Fertility Society Journal</td><td/></tr><tr><td>2005;10(1):49-54.</td><td/></tr><tr><td>Bahceci 2005 {published data only}</td><td/></tr><tr><td>Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of</td><td/></tr><tr><td>a GnRH antagonist in controlled ovarian hyperstimulation for</td><td/></tr><tr><td>assisted conception in women with polycystic ovary disease: a</td><td/></tr><tr><td>randomized, prospective, pilot study. Journal of Reproductive</td><td/></tr><tr><td>Medicine 2005;50(2):84-90. [MEDLINE: 15755044]</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF7": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Depalo 2009 {published data only}</td></tr><tr><td>Depalo R, Lorusso F, Palmisano M, Bassi E, Totaro I, Vacca M, et</td></tr><tr><td>al. Follicular growth and oocyte maturation in GnRH agonist</td></tr><tr><td>and antagonist protocols for in vitro fertilisation and embryo</td></tr><tr><td>transfer. Gynecological Endocrinology 2009;25(5):328-34.</td></tr><tr><td>El Sahwi 2005 {published data only}</td></tr><tr><td>El Sahwi S. GnRH agonists versus GnRH antagonists in</td></tr><tr><td>controlled ovarian stimulation in ICSI trials. Book of Abstracts,</td></tr><tr><td>8th International Symposium on GnRH Analogues in Cancer and</td></tr><tr><td>Human Reproduction. Salzburg, Austria. 2005:A65.</td></tr><tr><td>Engmann 2008a {published data only}</td></tr><tr><td>Engmann L, DiLuigi A, Schmidt D, Nulsen D, Nulsen J,</td></tr><tr><td>Benadiva C. The use of gonadotropin-releasing hormone</td></tr><tr><td>(GnRH) agonist to induce oocyte maturation a er cotreatment</td></tr><tr><td>with GnRH antagonist in high-risk patients undergoing in vitro</td></tr><tr><td>fertilization prevents the risk of ovarian hyperstimulation</td></tr><tr><td>syndrome: a prospsective randomised controlled study. Fertility</td></tr><tr><td>and Sterility 2008;89(1):84-91.</td></tr><tr><td>Euro Middle East 2001 {published data only}</td></tr><tr><td>* European and Middle East Orgalutran Study Group.</td></tr><tr><td>Comparable clinical outcome using the GnRH antagonist</td></tr><tr><td>ganirelix or a long protocol of the GnRH agonist triptorelin for</td></tr><tr><td>the prevention of premature LH surges in women undergoing</td></tr><tr><td>ovarian stimulation. Human Reproduction (Oxford, England)</td></tr><tr><td>2001;16(4):644-51. [MEDLINE: 11278211]</td></tr><tr><td>Sonntag B, Kiesel L, Nieschlag E, Behre HM. Association of</td></tr><tr><td>inhibin B serum levels with parameters of follicular response in</td></tr><tr><td>a randomized controlled trial comparing GnRH agonist versus</td></tr><tr><td>antagonist protocols for ovarian hyperstimulation. Journal of</td></tr><tr><td>Assisted Reproduction and Genetics 2004;21(7):249-55.</td></tr><tr><td>Euro Orgalutran 2000 {published data only}</td></tr><tr><td>The European Orgalutran Study Group, Borm G, Mannaerts B.</td></tr><tr><td>Treatment with the gonadotrophin-releasing hormone</td></tr><tr><td>antagonist ganirelix in women undergoing ovarian stimulation</td></tr><tr><td>with recombinant follicle stimulating hormone is e ective,</td></tr><tr><td>safe and convenient: results of a controlled, randomized,</td></tr><tr><td>multicentre trial. Human Reproduction (Oxford, England)</td></tr><tr><td>15;7:1490-8.</td></tr></table>",
                "type_str": "table"
            },
            "TABREF8": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Hershko Klement A, Berkovitz A, Wiser A, Gonen O, Amichay K,</td><td>in ART outcome. Archives of Gynecology and Obstetrics</td></tr><tr><td>Shulman A. Follicular estrogen for GnRH-antagonist protocol</td><td>2010;281(4):741-6.</td></tr><tr><td>programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523.</td><td>Khalaf 2010 {published data only}</td></tr><tr><td>Hohmann 2003 {published data only}</td><td>Khalaf M, Mittre H, Levallet J, Hanoux V, Denoual C, Herlicoviez M, et al. GnRH agonist and GnRH antagonist</td></tr><tr><td>Hohmann FP, Macklon NS, Fauser BC. A randomized comparison</td><td>protocols in ovarian stimulation: di erential regulation pathway</td></tr><tr><td>of two ovarian stimulation protocols with gonadotropin-</td><td>of aromatase expression in human granulosa cells. Reproductive</td></tr><tr><td>releasing hormone (GnRH) antagonist cotreatment for in vitro</td><td>Biomedicine Online 2010;21(1):56-65.</td></tr><tr><td>fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH</td><td>Kim 2004 {published data only}</td></tr><tr><td>agonist protocol. The Journal of Clinical Endocrinology and</td><td>Kim C-H, Lee Y-J, Hong S-H, Nah H-Y, Kim S-H, Chae H-D, et al.</td></tr><tr><td>Metabolism 2003;88(1):166-73.</td><td>E icacy of a GnRH antagonist during early and late controlled</td></tr><tr><td>Hoseini 2014 {published data only}</td><td>ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF-ET. Human Reproduction</td></tr><tr><td>Hoseini FS, Mugahi SM, Akbari-Asbagh F, E ekhari-Yazdi P,</td><td>(Oxford, England) 2004;19:i104-5.</td></tr><tr><td>Aflatoonian B, Aghaee-Bakhtiari SH, et al. A randomized controlled trial of gonadotropin-releasing hormone antagonist</td><td>Kim 2011 {published data only}</td></tr><tr><td>in Iranian infertile couples: oocyte gene expression. Journal of</td><td>Kim C-H, Jeon G-H, Cheon Y-P, Jeon I, Kim S-H, Chae H-</td></tr><tr><td>Pharmaceutical Sciences 2014;22:67.</td><td>D, et al. Comparison of GnRH antagonist protocol with or</td></tr><tr><td>Hosseini 2010 {published data only}</td><td>without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing</td></tr><tr><td>Hosseini MA, Aleyasin A, Saeedi H, Mahdavi A. Comparison of</td><td>IVF/intracytoplasmic sperm injection. Fertility and Sterility</td></tr><tr><td>gonadotropin-releasing hormone agonists and antagonists in</td><td>2009;92(5):1758-60.</td></tr><tr><td>assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research 2010;36(3):605-10.</td><td>Kim C-H, You R-M, Kang H-K, Ahn J-W, Jeon I, Lee J-W, et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre-treatment in poor responders undergoing</td></tr><tr><td>Hsieh 2008 {published data only}</td><td>IVF/ICSI. Clinical and Experimental Reproductive Medicine</td></tr><tr><td>Hsieh YY, Chang CC, Tsai HD. Comparisons of di erent dosages</td><td>2011;38(4):228-33.</td></tr><tr><td>of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan Journal of Obstetrics and Gynecology 2008;47:66-74.</td><td>Kim CH, Lee HA, Lee JW, Lee YJ, Nah HY, Hong SH, et al. The e icacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol.</td></tr><tr><td>Huirne 2006 {published data only}</td><td>20 Suppl 1:i105-6.</td></tr><tr><td>Huirne JA, Van Loenen AC, Donnez J, Pirard C, Homburg R, Schats R, et al. E ect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online 2006;13(2):235-45.</td><td>Kim 2012 {published data only} Kim C-H, Moon J-W, Kang H-J, Ahn J-W, Kim S-H, Chae H-D, et al. E ectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients</td></tr><tr><td>Hwang 2004 {published data only} Hwang JL, Seow K, Lin Y, Huang L, Hsieh B, Tsai Y, et al. Ovarian</td><td>with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine 2012;39(1):22-7.</td></tr><tr><td>stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction 2004;19(9):1993-2000.</td><td>Kurzawa 2008 {published data only} Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization</td></tr><tr><td>Inza 2004 {published data only} Inza R, Van Thillo G, Lombardi E, Bisioli C, Diradourian M, Kenny A. Reproductive performance in second IVF cycles</td><td>in PCOS non-obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics 2008;25(8):365-74.</td></tr><tr><td>treated with the use of either GnRH antagonists (-antag) vs GnRH agonists (-ag) a er failure with long protocols with GnRH agonists: a prospective randomized trial. Fertility and Sterility 2004;82 Suppl:233-4.</td><td>Kyono 2005 {published data only} * Kyono K, Fuchinoue K, Nakajo Y, Yagi A, Sasaki K. A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and</td></tr><tr><td>Karimzadeh 2010 {published data only}</td><td>without low dose hCG. Fertility and Sterility 2004;82 Suppl:31.</td></tr><tr><td>Karimzadeh MA, Ahmadi S, Oskouian H, Rahmani E. Comparison of mild stimulation and conventional stimulation</td><td>Kyono K, Nakajo Y, Sasaki S, Kumagai S, Suzuki S. A prospective randomized study of three di erent controlled ovarian</td></tr></table>",
                "type_str": "table"
            },
            "TABREF9": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>hyperstimulation (COH) protocols. Fertility and Sterility 2005;84</td><td>cycles can achieve good pregnancy rates in poor responder</td></tr><tr><td>Suppl 1:299.</td><td>patients. Human Reproduction (Oxford, England) 2002;17:115-6.</td></tr><tr><td>Lainas 2007 {published data only}</td><td>Martinez 2008 {published data only}</td></tr><tr><td>Lainas TG, Petsas GK, Zorovilis IZ, Lliadis GS, Lainas GT,</td><td>Mart\u00ednez F, Clua E, Parera N, Rodr\u00edguez I, Boada M, Coroleu B.</td></tr><tr><td>Gazlaris HE, et al. Initiation of GnRH antagonist on day 1 of</td><td>Prospective, randomized, comparative study of leuprorelin</td></tr><tr><td>stimulation as compared to the long agonist protocol in PCOS</td><td>+ human menopausal gonadotropins versus ganirelix +</td></tr><tr><td>patients: a randomised controlled trial: e ect on hormonal</td><td>recombinant follicle-stimulating hormone in oocyte donors</td></tr><tr><td>levels and follicular development. Human Reproduction</td><td>and pregnancy rates among the corresponding recipients.</td></tr><tr><td>2007;22(6):1540-6.</td><td>Gynecological Endocrinology 2008;24(4):188-93.</td></tr><tr><td>Lainas 2010 {published data only}</td><td>Mohamed 2006 {published data only}</td></tr><tr><td>Basly M, Achour R, Ben Jemaa S, Chnitir M, Messaoudi L,</td><td>Mohamed KA, Davies WAR, Lashen H. E ect of gonadotropin-</td></tr><tr><td>Chibani M, et al. Flexible Gnrh antagonist protocol versus</td><td>releasing hormone agonist and antagonist on steroidogenesis</td></tr><tr><td>Gnrh agonist long protocol in patients with polycystic ovary</td><td>of low responders undergoing in vitro fertilization.</td></tr><tr><td>syndrome treated for IVF: a prospective randomised controlled</td><td>Gynecological Endocrinology 2006;22(2):57-62.</td></tr><tr><td>trial (RCT). Internet Journal of Gynecology &amp; Obstetrics 2012;16(3):1.</td><td>Moraloglu 2008 {published data only}</td></tr><tr><td>* Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled</td><td>Moraloglu O, Kilic S, Karayal\u00e7in R, Yuksel B, Tasdemir N, Ugur M. Comparison of GnRH agonists and antagonists in normo-responder IVF/ICSI in Turkish female patients. Advances in Therapy 2008;25(3):266-73.</td></tr><tr><td>trial (RCT). Human Reproduction 2010;25(3):683-9.</td><td>Moshin 2007 {published data only}</td></tr><tr><td>Lavorato 2012 {unpublished data only} Lavorato HL, Oliveira JB, Petersen CG, Vagnini L, Maur AL, Cavagna M, et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA</td><td>Moshin V, Croitor M, Hotineanu A. GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France 2007;22 Suppl 1:i121.</td></tr><tr><td>fragmentation and apoptosis in granulosa cells. European</td><td>Olivennes 2000 {published data only}</td></tr><tr><td>Journal of Obstetrics &amp; Gynecology and Reproductive Biology 2012;165(1):61-5.</td><td>Olivennes F, Belaisch-Allart, Emperare J, Dechaud H, S Alvarez S, Moreau L. Prospective randomized, controlled study of</td></tr><tr><td>Lee 2005 {published data only} Lee TH, Wu MH, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing</td><td>in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility 2000;73(2):314-20.</td></tr><tr><td>hormone antagonist administration. Fertility and Sterility</td><td>Papanikolaou 2012 {published data only}</td></tr><tr><td>2005;83(6):1700-7.</td><td>Papanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L,</td></tr><tr><td>Lin 2006 {published data only} Lin YH, Hwang JL, Seow KM, Huang LW, Hsieh BC, Tzeng CR. Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol -a randomized study. Gynecological</td><td>Polyzos NP, et al. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome a ected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction 2012;27(6):1822-8.</td></tr><tr><td>Endocrinology 2006;22(6):297-302.</td><td>Prapas 2013 {published data only}</td></tr><tr><td>Loutradis 2004 {published data only} Loutradis D, Stefanidis K, Drakakis P, Milingos S, Antsaklis A, Michalas S. A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility</td><td>Prapas Y, Petousis S, Dagklis T, Panagiotidis Y, Papatheodorou A, Assunta I, et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology 2013;166(1):43-6.</td></tr><tr><td>2004;82(5):1446-8. [MEDLINE: 15533377]</td><td>Qiao 2012 {published data only}</td></tr><tr><td>Marci 2005 {published data only} * Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reproductive Biomedicine Online</td><td>Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high e icacy and pregnancy rates. Gynecological Endocrinology 2012;28(10):800-4.</td></tr><tr><td>2005;11(2):189-93.</td><td>Rabati 2012 {published data only}</td></tr><tr><td>Marci R, Caserta D, Farina M, Dessole S, Germond M, Tatone C, et al. The use of GnRH antagonist in ovarian stimulation for IVF</td><td>Rabati BK, Zeidi SN. Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and</td></tr></table>",
                "type_str": "table"
            },
            "TABREF10": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">antagonist gonadotropin-releasing hormone protocol. Journal</td><td>Sunkara 2014 {published data only}</td></tr><tr><td colspan=\"2\">of Research in Medical Sciences 2012;17(11):1063-6.</td><td>Sunkara S, Coomarasamy A, Faris R, Braude P, Khalaf Y.</td></tr><tr><td colspan=\"2\">Revelli 2014 {published data only} Revelli A, Chiad\u00f2 A, Dalmasso P, Stabile V, Evangelista F, Basso G, et al. \"Mild\" vs. \"long\" protocol for controlled ovarian hyperstimulation in patients with expected poor</td><td>E ectiveness of the GnRH agonist long, GnRH agonist short and GnRH antagonist regimens in poor responders undergoing IVF treatment: a three arm randomised controlled trial. Human Reproduction. 2013; Vol. 28:i348.</td></tr><tr><td colspan=\"2\">ovarian responsiveness undergoing in vitro fertilization (IVF):</td><td>* Sunkara SK, Coomarasamy A, Faris R, Braude P, Khalaf Y. Long</td></tr><tr><td colspan=\"2\">a large prospective randomized trial. Journal of Assisted</td><td>gonadotropin-releasing hormone agonist versus short agonist</td></tr><tr><td colspan=\"2\">Reproduction and Genetics July 2014;31(7):809-15. [DOI:</td><td>versus antagonist regimens in poor responders undergoing in</td></tr><tr><td colspan=\"2\">10.1007/s10815-014-0227-y]</td><td>vitro fertilization: A randomized controlled trial. Fertility and</td></tr><tr><td colspan=\"2\">Rinaldi 2014 {published data only}</td><td>Sterility 2014;101(1):147-53.</td></tr><tr><td colspan=\"2\">Rinaldi L, Lisi F, Selman H. Mild/minimal stimulation protocol</td><td>Tazegul 2008 {published data only}</td></tr><tr><td colspan=\"2\">for ovarian stimulation of patients at high risk of developing</td><td>Tazeg\u00fcl A, G\u00f6rkemli H, Ozdemir S, Aktan TM. Comparison of</td></tr><tr><td colspan=\"2\">ovarian hyperstimulation syndrome. Journal of Endocrinological</td><td>multiple dose GnRH antagonist and minidose long agonist</td></tr><tr><td colspan=\"2\">Investigation 2014;37:65-70.</td><td>protocols in poor responders undergoing in vitro fertilization:</td></tr><tr><td colspan=\"2\">Rombauts 2006 {published data only}</td><td>a randomized controlled trial. Archives of Gynecology and Obstetrics 2008;278(5):467-72.</td></tr><tr><td colspan=\"2\">Rombauts L, Healy D, Norman RJ. A comparative randomized</td><td/></tr><tr><td colspan=\"2\">trial to assess the impact of oral contraceptive pretreatment</td><td/></tr><tr><td colspan=\"2\">on follicular growth and hormone profiles in GnRH antagonist-</td><td/></tr><tr><td colspan=\"2\">treated patients. Human Reproduction (Oxford, England)</td><td/></tr><tr><td>2006;21(1):95-103.</td><td/><td/></tr><tr><td colspan=\"2\">Sauer 2004 {published data only}</td><td/></tr><tr><td colspan=\"2\">Sauer MV, Thornton MH, Schoolcra W, Frishman GN.</td><td/></tr><tr><td colspan=\"2\">Comparative e icacy and safety of cetrorelix with or without</td><td/></tr><tr><td colspan=\"2\">mid-cycle recombinant LH and leuprolide acetate for inhibition</td><td/></tr><tr><td colspan=\"2\">of premature LH surges in assisted reproduction. Reproductive</td><td/></tr><tr><td colspan=\"2\">Biomedicine Online 2004;9(5):487-93.</td><td/></tr><tr><td colspan=\"2\">Sbracia 2009 {published data only}</td><td/></tr><tr><td colspan=\"2\">Sbracia M, Colabianchi J, Giallonardo A, Giannini P, Piscitelli C,</td><td/></tr><tr><td colspan=\"2\">Morgia F, et al. Cetrorelix protocol versus gonadotropin-</td><td/></tr><tr><td colspan=\"2\">releasing hormone analog suppression long protocol for</td><td/></tr><tr><td colspan=\"2\">superovulation in intracytoplasmic sperm injection patients</td><td/></tr><tr><td colspan=\"2\">older than 40. Fertility and Sterility 2009;91(5):1842-7.</td><td/></tr><tr><td colspan=\"2\">Serafini 2008 {published data only}</td><td/></tr><tr><td colspan=\"2\">Serafini P, Yadid I, Alegretti J, Panzan M, Cosloversusky M,</td><td/></tr><tr><td colspan=\"2\">Motta E. A prospective, randomized trial of three ovulation</td><td/></tr><tr><td colspan=\"2\">induction protocols for IVF including a novel approach with low-</td><td/></tr><tr><td colspan=\"2\">dose HCG and GnRH antagonist in the mid-late follicular phase.</td><td/></tr><tr><td colspan=\"2\">Human Reproduction (Oxford, England) 2003;18:1.</td><td/></tr><tr><td colspan=\"2\">* Serafini P, Yadid I, Motta ELA, Alegretti JR, Fioavanti J,</td><td/></tr><tr><td colspan=\"2\">Coslovsky M. Ovarian stimulation with daily late follicular phase</td><td/></tr><tr><td colspan=\"2\">administration of low dose human chorionic gonadotropin for</td><td/></tr><tr><td colspan=\"2\">in vitro fertilization: a prospective randomized trial. Fertility and</td><td/></tr><tr><td>Sterility 2006;86(4):830-8.</td><td/><td/></tr><tr><td colspan=\"2\">Stenbaek 2015 {published data only}</td><td/></tr><tr><td colspan=\"2\">Stenbaek DS, To ager M, Hjordt LV, Jensen PS, Holst KK,</td><td/></tr><tr><td colspan=\"2\">Bryndorf T, et al. Mental distress and personality in women</td><td/></tr><tr><td colspan=\"2\">undergoing GnRH agonist versus GnRH antagonist protocols</td><td/></tr><tr><td colspan=\"2\">for assisted reproductive technology. Human Reproduction</td><td/></tr><tr><td>2015;30(1):103-10.</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF11": {
                "text": "data only} Ashrafi M, Mohammadzadeh A, Ezabadi Z, Baghestani AR.A comparative study of GnRH-ant and GnRH-ag protocols on IVF-ICSI in PCOD patients.Book of Abstracts, 18th World Congress on Fertility and Sterility (IFFS 2004), Montreal Canada.2004.Eijkemans MJ, Heijnen EM, De Klerk C, Habbema JD, Fauser BC.Comparison of di erent treatment strategies in IVF with cumulative live birth over a given period of time as the primary end-point: methodological considerations on a randomized controlled non-inferiority trial.Evangelio PM, Buendicho IE, Yeste AMM, Gustem RB, Egea IB, Hernandez NC.Randomized prospective study on the e ect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response [Estudio prospectivo aleatorizado sobre el efecto de la adicion de actividad LH exogena en ciclos FIV/ICSI con antagonistas de GnRH en pacientes con factores predictivos de baja respuesta].Guivarc'h-Lev\u00eaque A, Arvis P, Bouchet JL, Broux PL, Moy L, Priou G, et al.E iciency of antagonist IVF cycle programming by estrogens [E icacit\u00e9 de la programmation des cycles FIV en antagonistes par les estrogenes].Gyn\u00e9cologie Obst\u00e9trique & Fertilit\u00e9 2010;38:18-22.Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles.Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001299] Higgins JPT, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses.BMJ 2003;327:557-60.Mathur R, Kailasam C, Jenkins J. Review of the evidence base strategies to prevent ovarian hyperstimulation syndrome.Human Fertility 2007;10:75-85.Schulz KF, Altman DG, Moher D, for the CONSORT Group.CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.Annals of Internal Medicine 2010;152:Epub 24 March.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Daya 2000 Mathur 2007</td><td/><td>Higgins 2003 term health risks related to polycystic ovary syndrome (PCOS).</td></tr><tr><td/><td/><td>Hum Reprod 2004;19(1):41-7.</td></tr><tr><td/><td/><td>Schulz 2010</td></tr><tr><td/><td/><td>Higgins 2011a</td></tr><tr><td colspan=\"2\">Bonduelle 2010 {published data only} Bonduelle M, Obery\u00e9 J, Mannaerts B, Devroey P. Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived a er treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation. Human Reproduction 2010;25(6):1433-40. Cattani 2000 {published data only} Cattani R, Cela V, Cristello F, Matteucci C, Valentino V, Artini P. E icacy and safety of gonadotrophin releasing hormone (GnRH) antagonist administration in infertile women during controlled ovarian hyperstimulation. Gynecological Endocrinology. 2000; Vol. 14, issue Suppl 2:212. Ibrahim 2011 {published data only} Ibrahim ZM, Mohamed Youssef HY, Elbialy MM, Farrag MM. Micro-dose flare-up gonadotrophin-releasing hormone (GnRH) agonist vs. flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol in patient with poor ovarian reserve. Middle East Fertility Society Journal 2011;16:272-277. [DOI: 10.1016/ j.mefs.2011.06.003] Jindal 2013 {published data only} Jindal A, Singh R. A prospective randomised controlled study comparing a low-cost antagonist protocol using oral ovulation inducing agents in IVF-ICSI cycles with a standard agonist long Moher 1999 Deeks 2011 Moher D, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, et 1007/ Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing al. Does quality of reports of randomised trials a ect estimates s00404-010-1429-x] Polinder 2008 {published data only} Polinder S, Heijnen EM, Macklon NS, Habbema JD, Fauser BJ, Eijkemans MJ. Cost-e ectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint. Human Reproduction 2008;23(2):316-23. data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of intervention e icacy reported in meta-analyses?. The Lancet 1999;352(9128):609-18. of Interventions Version 5.1.0 (updated March 2011). The Moher 2009 Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Delvigne 2002 Moher D, Liberati A, Tetzla J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 2002;8:559-77. 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] Mozes 1965 Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E,</td><td>Human Reproduction (Oxford, England) 2006;21(2):344-52. [MEDLINE: 16239317] Engmann 2008b {published data only} Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The e ect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility 2008;89(3):554-61. Evangelio 2011 {published data only} Maldonado 2013 {published data only} Maldonado LGL, Franco JG, Setti AS, Iaconelli A, Borges E. Cost-e ectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments. Fertility and Sterility May 2013;99(6):1615-1622. [DOI: 10.1016/j.fertnstert.2013.01.095] Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 Willman 2005 {published data only} Willman SP, Kliman HJ. Comparison of the luteal phase a er pituitary suppression with GnRH-agonist versus GnRH antagonist in controlled ovarian stimulation. Fertility and Sterility 2005;84 Suppl:308. (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Seow 2010 Seow KM, Lin YH, Hsieh BC, Huang LW, Huang SC, Chen CY, et Higgins 2011b al. Characteristics of progesterone changes in women with Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle. Gynecologic and Obstetric Investigation 2010;70:64-8. Zikopoulos 2005 {published data only} Zikopoulos K, Kaponis A, Adonakis G, Sotiriadis A, Kalantaridou S, Georgiou I, et al. A prospective randomized study comparing gonadotropin-releasing hormone agonists or of Interventions Version 5.1.0 (updated March 2011). The Shoham 2002 Cochrane Collaboration, 2011. Available from www.cochrane-Shoham Z. The clinical therapeutic window for luteinizing handbook.org. hormone in controlled ovarian stimulation. Fertility and Sterility 2002;77:1170-7.</td></tr><tr><td colspan=\"2\">Lin 1999 {published data only}</td><td/></tr><tr><td colspan=\"2\">Lin Y, Kahn JA, Hillensjo T. Is there a di erence in the function Rotterdam 2004</td><td/></tr><tr><td colspan=\"2\">of granulosa-luteal cells in patients undergoing in-vitro Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop</td><td/></tr><tr><td colspan=\"2\">fertilization either with gonadotrophin-releasing hormone group. Revised 2003 consensus on diagnostic criteria and long-</td><td/></tr><tr><td colspan=\"2\">agonist or gonadotrophin-releasing hormone antagonist?.</td><td/></tr><tr><td colspan=\"2\">Human Reproduction (Oxford, England) 1999;14(4):885-8.</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF13": {
                "text": "Moderate or severe OHSS.Clinical pregnancy was defined as fetal heart beat on ultrasonography.Ongoing pregnancy was defined as pregnancy ongoing after 12 weeks of amenorrhoeaNotes\u2022 Number of ICSI cases was not stated in the cetrorelix group or in the buserelin group.Implantation rate was not mentioned as an outcome variable also, no of embryos obtained and no of embryos transferred was not stated.Incidence of multiple pregnancies was not mentioned in the table of outcomes and was not clear in the text.Tolerability was not mentioned \u2022 Centre-adjusted analysis was done for all outcomes except miscarriage, ectopic and ovarian hyperstimulation syndrome reported as the number of antral follicles and not by the allocated treatment.The denominator for the pregnancy rate does not match either the total number of women or the number of cycles.Data could not be included in a meta-analysis Follow up: OPR was confirmed by vaginal ultrasound scan at 12 weeks of gestationOutcomesPrimary outcome measures: ovarian response, as assessed by the number of oocytes obtained and the proportion of chromosomally abnormal embryos per participant.This was expressed as the ratio of abnormal embryos on the number of embryos diagnosed per participant.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Albano 2000 (Continued) Anderson 2014 (Continued) Awata 2010 (Continued) Baart 2007 (Continued) Badrawi 2005 Badrawi 2005 (Continued) Bahceci 2005 (Continued)</td><td/><td/></tr><tr><td>Al-Karaki 2011 Interventions Interventions Methods Participants Notes Notes</td><td/><td colspan=\"2\">Baseline characteristics: age 31.9 \u00b1 3.7 versus 31.6 \u00b1 3.8. Duration of infertility: not stated. FSH: not stated. BMI not stated Group I (n = 198): hMG (menogon, humegon, pergonal) was started at 2 or 3 ampoules for four days and the dose was adjusted according to response + multiple-dose regimen of 0.25 mg of GnRH antag-onist (cetrorelix) was administered SC starting from day 6 of hMG treatment to 115 participants up to and including day of hCG administration (Fixed) Inclusion criteria: 21 to 40 years, anti-Mullerian hormone &gt; 1 ng/ml Exclusion criteria: no details Setting and timing: no details of setting. USA. No details of timing Baseline characteristics: no details Inclusion criteria: women &lt; 40 years undergoing COH but no other details Exclusion criteria: not stated Baseline characteristics: not stated Setting and timing: no details Group I (n = 67):150 IU FSH on 2nd day of the cycles (fixed) + 0.25 mg SC of GnRH antagonist co-treat-ment (ganirelix (Orgalutran)) administered when at least one follicle measuring &gt; 14 mm (flexible pro-Abortion rate Number of embryo transfers RCT, single-centre, open-label, parallel design Number of clinical pregnancies OHSS tocol) GnRH agonist (n = 44): 225 IU rFSH (fixed) + long GnRH agonist, 0.1 mg triptorelin(Long GnRH agonist protocol) 100 infertile women undergoing ICSI Inclusion criteria: primary infertility patients, 18 to 39 years old, with regular menstrual cycle and FSH levels &lt; 10 IU/L done at cycle day 3 and ultrasound examination showed normal uterus Number of participants at randomisation: 148 (cetrorelix: 75/leuprolide acetate: 73) Number of participants at randomisation: 100 (ganirelix 50/Superfact 50) Number of participants at stimulation: 129 (cetrorelix: 59/leuprolide acetate: 70) Number of participants at stimulation: 100 (ganirelix 50/Superfact 50) Number of participants at OPU: 95 (ganirelix 47/Superfact 50) Number of participants at OPU: 129 (cetrorelix: 59/leuprolide acetate: 70)</td></tr><tr><td colspan=\"4\">Mean number of embryos transferred: antagonist: 2.1 \u00b1 1.2 versus agonist: 2.3 \u00b1 1.3 Follow-up: Up to clinical pregnancy Clinical pregnancy rate, cycle cancellation rate, duration of stimulation, total gonadotrophins require-ment, estradiol level on day of hCG, mean numbers of mature oocytes retrieved, mean numbers of em-bryos formed, mean numbers of embryos transferred Authors' judgement Support for judgement Group II, GnRH agonist (n = 95): mid-luteal GnRH analogue (Buserlin 150 \u00b5g four times daily in-tranasally) + hMG (menogon, humegon,pergonal) was started at 2 or 3 ampoules for four days and the dose was adjusted according to response Luteal phase support: daily vaginal progesterone or hCG injections Premature LH surge defined as (LH &gt; 10 IU/L) and progesterone level &gt; 1 ng/L. Stimulation length, no. of hMG ampoules. E2 on hCG, no of oocytes retrieved, clinical pregnancy/OPU, clinical pregnancy/ET. Mis-carriage Ectopic. Risk of bias Outcomes Notes Risk of bias Bias Outcomes Interventions GnRH antagonist (no details) (n = 21) when follicle size reached 12 mm during the COS cycle Agonist (Leuprolide acetate) (n = 20) starting on day 18 of the oral contraceptive pill cycle Fixed protocol of human derived gonadotrophins at a 3:1 ratio (225/75 IU) for the first four days of stimulation followed by a flexible protocol to improve response Interventions Agonist long protocol -no details Agonist short protocol -no details Antagonist protocol -no details Outcomes Pregnancy rate, miscarriage rate Oocyte maturation triggering: 10,000 IU SC hCG (Pregnyl) when one follicle &gt; 18 mm plus 2 follicles &gt; 15 mm Exclusion criteria:women with severe endometriosis (American Fertility Society stage III and IV), and Risk of bias Risk of bias azoospermic males were excluded from the study Oocyte retrieval: 35 hours later, followed by IVF/ICSI. Baseline characteristics: age 30.8 \u00b1 4.8 vs 30.28 \u00b1 5.9 years Bias Bias Authors' judgement Support for judgement Authors' judgement Support for judgement Maximum embryos transferred: 2 Interventions GnRH antagonist (n = 50): 225 IU Menogon hMG (menogon, humegon, pergonal) was started at 2 or 3 ampoules for four days (adjusted) + 0.25 mg of GnRH antagonist SC ganirelix started from day 6 of hMG Random sequence genera-tion (selection bias) Unclear risk Random sequence genera-Low risk Random-number table Method of randomisation stated to be using sealed envelopes without any fur-tion (selection bias) ther details hCG given when at least three follicles reached 17 mm diameter All women underwent a cycle using an oral contraceptive pill before starting the controlled ovarian stimulation cycle for IVF Outcomes E2, LH, oocytes retrieved, mature oocytes, fertilisation rate, implantation rate, pregnancy rate Notes Notes Data are only Risk of bias treatment/lead follicle measures 14 mm (Flexible multiple-dose GnRH antagonist) GnRH agonist (n = 50): mid-luteal GnRH analogue, buserelin 150 ug four times daily intranasally (Suprefact) + 225 IU hMG (menogon, humegon, pergonal) was started at 2 or 3 ampoules for four days Allocation concealment Low risk Allocation concealment Unclear risk Unclear Sealed envelopes (selection bias) (selection bias) and the dose was adjusted according to response (Long GnRH agonist) Blinding (performance High risk Blinding (performance High risk Not blind No blinding bias and detection bias) bias and detection bias) All outcomes All outcomes The table included in the abstract does not match the abstract. No data could be included in the meta-analyses Sample size calculation -unclear Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Unclear risk 'randomly received' no other details Incomplete outcome data Low risk Incomplete outcome data Low risk No missing outcomes data, LBR not reported No missing outcomes data, LBR was not reported (attrition bias) (attrition bias) All outcomes All outcomes ITT analysis -unclear Funding -Ferring Pharmaceuticals Allocation concealment (selection bias) Unclear risk No details Risk of bias Selective reporting (re-porting bias) Low risk Selective reporting (re-Low risk The study protocol was not available, but it is clear that the published reports The study protocol was not available, but it is clear that the published reports included most expected outcomes porting bias) included most expected outcomes</td></tr><tr><td colspan=\"2\">Random sequence genera-Allocation concealment (selection bias) Blinding (performance bias and detection bias) Incomplete outcome data (attrition bias) All outcomes Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) (selection bias) Blinding (performance bias and detection bias) Incomplete outcome data All outcomes Selective reporting (re-porting bias) Other bias All outcomes bias and detection bias) Blinding (performance All outcomes Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Bias Random sequence genera-tion (selection bias) Allocation concealment Incomplete outcome data (attrition bias) All outcomes Allocation concealment (selection bias) Bahceci 2005 tion (selection bias) All outcomes Random sequence genera-bias and detection bias) tion (selection bias) Bias Risk of bias Blinding (performance Bias Outcomes Other bias Other bias</td><td colspan=\"2\">Unclear risk Unclear risk High risk Low risk Low risk Stimulation duration Unclear risk High risk Unclear risk hMG ampoule Low risk E2 pg/ml on day of hCG Unclear risk Unclear risk Low risk Authors' judgement Support for judgement Method of allocation not reported Insufficient data provided regarding withdrawals Open No missing outcome data No missing outcome data, LBR not addressed by the study No details, unlikely to be blinded but this should not influence fertility out-comes Conference abstract only Pregnancy and miscarriage rates reported only Embryologist Conference abstract only. No details as to number allocated to each group. Blinding not reported but unlikely to influence measurement of outcomes Only reported as a randomised trial with no further details of how randomisa-tion was performed Concealed; central telephone, 2:1 randomisation ratio Unclear risk 'randomised' no other details Unclear risk No details treating physician during the preparatory IVF consultation Day 14 E2 pg/ml Unclear risk Low risk Numbered sealed envelopes. After the participant agreed to participate, the next available numbered envelope on entry into the study was opened by the Day 3 LH mIU/ml No details Baseline FSH mIU/ml group: mild group) Low risk Computer-generated randomisation schedule in a ratio of 4:6 (conventional Infertility duration years Unclear risk Method of random sequence generation not reported Authors' judgement Support for judgement Unclear risk No details Authors' judgement Support for judgement Female partner age Low risk The study appears to be free from other sources of bias. Low risk The study appears to be free from other sources of bias</td></tr><tr><td>Selective reporting (re-All outcomes Incomplete outcome data (attrition bias)</td><td/><td>Unclear risk Unclear risk Number of follicles</td><td>Study protocol not available to identify outcomes of interest. Live birth rate Conference abstract, unclear if this is the full sample size or reporting prelimi-</td></tr><tr><td>porting bias) Selective reporting (re-(attrition bias) All outcomes All outcomes</td><td/><td>Low risk Size of follicles (mm)</td><td>not reported The study protocol was not available, but it is clear that the published reports nary data</td></tr><tr><td>Other bias porting bias) Selective reporting (re-Methods Selective reporting (re-porting bias)</td><td/><td colspan=\"2\">Low risk High risk RCT, two-centre trial Low risk Endometrial thickness Oocyte maturation triggering: hCG 10,000 IU administered when at least two follicles reached 18 mm None identified include most expected outcomes No raw data reported. The table does not match the abstract. No full paper The study protocol was not available, but it is clear that the published reports included most expected outcomes</td></tr><tr><td>Methods Participants Other bias Methods Participants Participants Methods Anderson 2014 porting bias) Other bias Awata 2010 Participants Other bias Outcomes Interventions</td><td/><td colspan=\"2\">RCT, open-label parallel design, multi-centre (7 centres), multi-national 293 Infertile couples undergoing ovarian stimulation for IVF-ET with or without ICSI Unclear risk Supported by pharmaceutical company, the study appears to be free from oth-er sources of bias 413 women (564 cycles) Pregnancy rate/ET Number of 2 pronuclear oocytes 41 women No of transferred embryos Number of COC RCT Number of women with one or more fertilised oocytes RCT identified Unclear risk Conference abstract only. No details of demographics 111 infertile women undergoing IVF/ICSI Inclusion criteria: were not at an a priori increased risk for chromosomally abnormal embryos. &lt; 38 years of age, regular indication for IVF and with a partner with a sperm count &gt; 5 million progressively motile sperm per millilitre, regular menstrual cycles (ranging from 25 to 35 days), BMI 19 -29 kg m 2 , no known chromosomal abnormalities, no relevant systemic disease or uterine and ovarian abnormali-ties, no history of recurrent miscarriage, and no previous IVF cycles not resulting in an embryo transfer High risk Number of oocytes retrieved Funding was provided by university and non-governmental organisation Early stopping due to benefit occurred. \"The proportion of chromosomally ab-normal embryos per patient was found to be significantly reduced after mild Number of MII oocytes Number of oocytes fertilised Days of analogue treatment GnRH antagonist (n = 40): OC (Desogen; Organon USA) on cycle days 2 to 4 for 14 to 28 days + 300 IU/ Number of women who reached the day of hCG (%) day rFSH SC (adjusted) + 250 \u00b5g ganirelix was initiated when a lead follicle obtained a mean diameter Number of hMG ampoules of 12 to 14 mm (flexible) Days of hMG treatment ovarian stimulation (P \u00bc 0.02, which is below the Pocock critical bound of 0.0354 for a single interim analysis after 61% (111 of 181) of women had been Number of follicles on the day of hCG injection GnRH agonist (n= 40): leuprolide (GnRH-agonist group), 0.5 mg per day during the mid-luteal phase Fertilisation rate Number of women with oocyte retrieval with approximately a 5-day overlap with the OCs. Once adequate pituitary desensitisation was included (Pocock, 1977)) and the study was terminated.\" Embryos Number of women with ovum retrieval achieved the dose of GnRH agonist was reduced to 0.25 mg per day + 300 IU/day rFSH SC (adjusted)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF15": {
                "text": "Number of participants at randomisation: 80 (ganirelix: 40/leuprolide acetate: 40) \u2022 Number of participants at stimulation: 79 (ganirelix: 38/leuprolide acetate: 41) \u2022 Number of participants at OPU: 77 (ganirelix: 36/leuprolide acetate: 41)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Barmat 2005 (Continued) Barmat 2005 (Continued) Brelik 2004 (Continued) Check 2004 (Continued)</td><td/><td/></tr><tr><td>All outcomes All outcomes Outcomes</td><td/><td colspan=\"2\">Clinical pregnancy, viable pregnancy, implantation rate</td></tr><tr><td>Incomplete outcome data (attrition bias) Selective reporting (re-porting bias) Notes All outcomes Other bias</td><td/><td colspan=\"2\">Low risk Low risk Number of participants at randomisation: 60 (ganirelix: 30/leuprolide: 30) No missing outcomes data The study protocol was not available, but it is clear that the published reports included most expected outcomes Number of participants at stimulation: 54 (ganirelix: 24/leuprolide: 30) Low risk The study appears to be free from other sources of bias Number of participants at OPU: 54 (ganirelix: 24/leuprolide: 30)</td></tr><tr><td>Selective reporting (re-porting bias) Risk of bias</td><td/><td>Low risk</td><td>The study protocol was not available, but it is clear that the published reports included most expected outcomes</td></tr><tr><td>Other bias Celik 2011 Bias</td><td/><td colspan=\"2\">Low risk Authors' judgement Support for judgement The study appears to be free from other sources of bias</td></tr><tr><td colspan=\"2\">Methods tion (selection bias) Random sequence genera-</td><td>Two-arm parallel RCT Unclear risk</td><td>Reported as a randomised trial without any further details</td></tr><tr><td>Brelik 2004 Participants Allocation concealment</td><td/><td colspan=\"2\">60 infertile women undergoing IVF at IVF centre; no further details were reported about participants Unclear risk Not reported</td></tr><tr><td>Methods Interventions (selection bias)</td><td/><td colspan=\"2\">GnRH antagonist: no details were reported RCT, single-centre, parallel design, randomisation: 1:1 (cetrorelix: triptorelin) ratio</td></tr><tr><td>Participants bias and detection bias) Blinding (performance</td><td/><td colspan=\"2\">120 infertile women undergoing IVF/ICSI GnRH agonist: no details were given High risk Not blind</td></tr><tr><td>Outcomes All outcomes</td><td/><td colspan=\"2\">Only pregnancy rate was reported but type of pregnancy was not defined</td></tr><tr><td>Notes Incomplete outcome data (attrition bias)</td><td/><td colspan=\"2\">High risk Unclear definition of pregnancy Intention-to-treat analysis was not used and drop-out rate was above 10% with reasons provided</td></tr><tr><td>Risk of bias All outcomes</td><td/><td/></tr><tr><td>Bias porting bias) Selective reporting (re-</td><td/><td colspan=\"2\">Authors' judgement Support for judgement Low risk Protocol not available but materials match results</td></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) Other bias</td><td>Unclear risk Unclear risk</td><td>No information was reported on random sequence generation Insufficient information to make a conclusive judgement</td></tr><tr><td>Outcomes (selection bias) Allocation concealment</td><td/><td colspan=\"2\">Number of FSH ampoules used Fertilisation rate (%) of all retrieved oocytes Number of oocytes retrieved Unclear risk No information was reported on allocation concealment</td></tr><tr><td/><td/><td>Early cleavage rate (%)</td></tr><tr><td>Blinding (performance bias and detection bias) Methods</td><td/><td colspan=\"2\">Grade A embryos rate (%) Number of embryos transferred Unclear risk No information was reported on blinding of participants and/or personnel; however, non blinding of outcome assessment may not affect some outcomes RCT, single-centre, parallel design</td></tr><tr><td>All outcomes Participants</td><td/><td colspan=\"2\">Clinical pregnancy rate (%) LH levels of interest as they are objectively assessed 66 infertile women undergoing IVF/ICSI</td></tr><tr><td>Incomplete outcome data</td><td/><td>Unclear risk</td><td>No information was reported on incomplete outcome data/attrition</td></tr><tr><td>Notes (attrition bias)</td><td/><td colspan=\"2\">Number of participants at randomisation: 120 (cetrorelix: 57/ triptorelin: 63)</td></tr><tr><td>All outcomes</td><td/><td colspan=\"2\">Number of participants at stimulation: 120 (cetrorelix: 57/ triptorelin: 63)</td></tr><tr><td/><td/><td colspan=\"2\">Number of participants at OPU: 120 (cetrorelix: 57/ triptorelin: 63)</td></tr><tr><td>Selective reporting (re-</td><td/><td>Unclear risk</td><td>Methods section not detailed enough to make conclusive judgement</td></tr><tr><td>Risk of bias porting bias)</td><td/><td/></tr><tr><td>Bias Other bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement Low risk None identified</td></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Unclear risk</td><td>Reported as a randomised trial without any further details</td></tr><tr><td>Bias tion (selection bias)</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Random sequence genera-Allocation concealment</td><td>Low risk Unclear risk</td><td>Dark sealed envelopes (true), randomisation: 1:1 (ganirelix acetate: leuprolide Not reported clearly</td></tr><tr><td>tion (selection bias) (selection bias) Methods</td><td/><td colspan=\"2\">acetate) ratio RCT, single-centre, open-label, parallel design, randomisation: 1:1 (ganirelix: leuprolide) ratio</td></tr><tr><td>Allocation concealment bias and detection bias) (selection bias) Blinding (performance Participants</td><td/><td colspan=\"2\">Low risk Unclear risk Couples requiring IVF or intracytoplasmic sperm injection (ICSI) Dark sealed envelopes (true) Not reported clearly</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Blinding (performance</td><td/><td>High risk</td><td>Not reported clearly</td></tr><tr><td>bias and detection bias) Incomplete outcome data</td><td/><td>Unclear risk</td><td>No missing outcomes data, LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF16": {
                "text": "classified as patients who had exhibited a poor ovarian response with < 3 mature follicles on a long GnRH agonist protocol in their previous IVF cycles, or those with repeated high basal levels of FSH > 10 IU/l",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td></tr><tr><td>Cheung 2005</td><td/></tr><tr><td/><td>Women with polycystic ovaries were excluded from the study</td></tr><tr><td>Interventions</td><td>GnRH antagonist (n = 33): OCP (Nordette) 30 \u00b5g of ethinyl estradiol and 150 \u00b5g of levonorgestrel for 21</td></tr><tr><td/><td>days + 300 IU daily rFSH (Gonal-F) + 0.25 mg SC cetrorelix (Cetrotide) (fixed), multi-dose GnRH antago-</td></tr><tr><td/><td>nist protocol starting on day 6 of the stimulation (fixed)</td></tr><tr><td/><td>GnRH agonist (n = 33): long GnRH agonist protocol, buserelin acetate nasal spray (Suprecur) dai-</td></tr><tr><td/><td>ly dose of 600 \u00b5g starting at the mid-luteal phase of the preceding cycle + 300 IU daily rFSH (Gonal-F)</td></tr><tr><td/><td>(long GnRH agonist)</td></tr><tr><td/><td>Oocyte maturation triggering: 10,000 IU of IM hCG (Profasi) when the leading follicles reached 18 -20</td></tr><tr><td/><td>mm together with at least three mature follicles &gt; 16 mm</td></tr><tr><td/><td>Oocyte retrieval: 36 hrs later. ICSI was performed only in cases with severe male factor or previous fer-</td></tr><tr><td/><td>tilisation failure</td></tr></table>",
                "type_str": "table"
            },
            "TABREF17": {
                "text": "\u2022 Number of participants at randomisation: 66 (cetrorelix: 33/buserelin acetate: 33) \u2022 Number of participants at stimulation: 63 (cetrorelix: 31/buserelin acetate: 32) \u2022 Number of participants at OPU: 40 (cetrorelix: 19/buserelin acetate: 21) \u2022 Cycles in which < 3 mature follicles developed, or if the ovaries failed to respond after 10 days of stimulation, were either cancelled or converted to intra-uterine insemination in patients with patent tube(s).Cochrane Database of Systematic Reviews Antagonist multidose flexible protocol (n = 36 women; 39 cycles).Stimulation started on day 2 or 3 and 0.25 mg cetrorelix acetate or 0.25 mg ganirelix acetate administered when follicles > 12 mm or serum E2 > 200 pg/ml Agonist long protocol (n = 14 women; 14 cycles) 0.5 mg buserelin acetate or 0.1 mg leuprolide acetate given from mid-luteal phase of previous cycle to day of hCG administration 250 micrograms hCG given when lead follicle > 18 mm diameter Center for Human Reproduction, Brazil Interventions GnRH antagonist (n = 32) cetrorelix.Ovarian stimulation using 150 to 225 IU recombinant FSH and 75 IU/day recombinant LH for five days starting on day 3. Follicular development monitored on Day 8. rFSH adapted according to ovarian response and rLH increased to 150 IU/day when one or more follicles reached 10 mm or more in diameter.Cetrorelix 0.25 mg/day SC started when at least one follicle was 14 mm or greater in diameter.Administered until day of hCG injectionGnRH agonist (n = 32) leuprolide acetate 1 mg/day starting in luteal phase of previous cycle for 14 days.Ovarian stimulation using 150 to 225 IU rFSH and 75 IU/day rLH for 7 days.rFSH adapted according to ovarian response and rLH increased to 150 IU/day when one or more follicles reached 10 mm or more in diameter.Administered until day of hCG injection age 24 -42 years, baseline FSH level < 10 IU/ml, absence of uterine or ovarian abnormalities or severe endometriosis or polycystic ovary syndrome, no more than three previous IVF attempts and, no oral contraceptive pills taken before the stimulation cycle.Male factor infertility cases, such as number of spermatozoa < 5.0 million/ml and < 30% motility were included.Criteria for cycle cancellation were as follows: 53 follicles with diameter 14 mm after 8-10 days of stimulation",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Cheung 2005 (Continued) Choi 2012 (Continued) Cota 2012 (Continued)</td><td/><td/></tr><tr><td>Methods</td><td/><td>RCT, single-centre study</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">136 consecutive patients undergoing ICSI</td></tr><tr><td/><td/><td colspan=\"2\">Oocyte retrieval 36 hours after hCG Dose of gonadotrophin antagonist 1656.7 \u00b1 669.77 versus agonist 2700.0 \u00b1 824.3 Inclusion criteria: Baseline characteristics: age 34.4 \u00b1 4 vs 34 \u00b1 3.9 yrs. Basal FSH (mIU/ml) 6.4 \u00b1 2.4 vs 5.7 \u00b1 2. Basal E2</td></tr><tr><td>Outcomes Interventions</td><td/><td colspan=\"2\">OHSS, clinical pregnancy, miscarriage, live birth rate: all reported as 'per cycle' and thus could not be (pg/ml) 21.71 \u00b1 3 vs 16.7 \u00b1 9.4. BMI (kg/m 2 ) 23.7 \u00b1 4.1 vs 22.7 \u00b1 3.4 Oocyte maturation: 250 micrograms recombinant hCG given SC when at least two follicles were 17 pooled mm or greater in diameter GnRH antagonist (n = 67): a daily dose of cetrorelix 0.25 mg (Cetrotide) was administered when a lead-</td></tr><tr><td>Notes</td><td/><td colspan=\"2\">Sample size calculation -no Oocyte retrieval: 34 -36 hours after hCG injection ing follicle reached a diameter of 12 -14 mm + rFSH (Gonal F) starting on cycle day 2 -3 at a dose of 225</td></tr><tr><td>Risk of bias</td><td/><td colspan=\"2\">ITT analysis -yes Total dose gonadotrophins: antagonist group 1877.3 \u00b1 817 IU versus agonist group 2185.5 IU UI/daily, for the first five days (adjusted) (Flexible protocol)</td></tr><tr><td>Bias Outcomes</td><td/><td colspan=\"2\">Authors' judgement Support for judgement Funding -not stated Oocyte morphology. Implantation rate, pregnancy rate (not defined)</td></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) Risk of bias Notes</td><td colspan=\"2\">Low risk Sample size calculation: yes Random-number table (true), randomisation: 1:1 (cetrorelix: buserelin ac-etate) ratio</td></tr><tr><td>Allocation concealment Bias</td><td/><td colspan=\"2\">Low risk Authors' judgement Support for judgement Performed ITT analysis -yes</td></tr><tr><td colspan=\"2\">(selection bias) Random sequence genera-</td><td>Unclear risk Funding: no details</td><td>'randomized' no other details</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Blinding (performance</td><td/><td>Low risk</td><td>Blind</td></tr><tr><td>bias and detection bias) (selection bias) All outcomes Allocation concealment</td><td/><td>Unclear risk</td><td>No details</td></tr><tr><td>Incomplete outcome data Blinding (performance (attrition bias) bias and detection bias) All outcomes All outcomes Risk of bias</td><td/><td>Unclear risk Unclear risk</td><td>No missing outcomes data, LBR not addressed by the study No details. Unlikely that participants and researchers were blinded but unlike-ly to affect fertility outcome. Blinding of outcome assessors is unclear</td></tr><tr><td>Selective reporting (re-porting bias) Incomplete outcome data (attrition bias) Bias</td><td/><td colspan=\"2\">Low risk Low risk Authors' judgement Support for judgement The study protocol was not available, but it is clear that the published reports included most expected outcomes Data reported on all women analysed</td></tr><tr><td colspan=\"2\">Other bias Selective reporting (re-tion (selection bias) All outcomes Random sequence genera-</td><td>Low risk Low risk Low risk</td><td>Outcomes reported including live birth rate The study appears to be free from other sources of bias Double randomisation using computer-generated number table then lots</td></tr><tr><td>porting bias) Allocation concealment</td><td/><td>Low risk</td><td>One nurse, blinded to subject identities, performed all the lot draws</td></tr><tr><td>Other bias (selection bias)</td><td/><td>Unclear risk</td><td>Groups appeared balanced at baseline. Data is per cycle and not per woman</td></tr><tr><td>Methods bias and detection bias) Blinding (performance</td><td/><td colspan=\"2\">Three-arm randomised controlled trial. Single centre randomised and could not be included in the meta-analysis Unclear risk No evidence of blinding of participants. Blinding of outcome assessors unclear</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Participants</td><td/><td colspan=\"2\">61 infertile women (67 cycles)</td></tr><tr><td>(attrition bias) Incomplete outcome data</td><td/><td colspan=\"2\">Inclusion criteria: PCOS (ESHRE/ASRM criteria). No other details Low risk All women randomised appear to be analysed</td></tr><tr><td>Methods All outcomes</td><td/><td colspan=\"2\">Exclusion criteria: no details Randomised controlled trial</td></tr><tr><td>Participants Selective reporting (re-</td><td/><td colspan=\"2\">Setting and timing -Seoul, Korea. April 2009 to November 2010 64 women undergoing ICSI (first cycle) Unclear risk Authors report pregnancy rate but it is not defined, therefore unclear if it is</td></tr><tr><td>porting bias)</td><td/><td/><td>biochemical, clinical or ongoing and cannot be included in a meta-analysis.</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics: age -antagonist 32.9 \u00b1 2.9 years versus agonist 34.4 \u00b1 3.8 years Inclusion criteria: 37 years or less, first IVF/ICSI cycle, BMI &lt; 30 kg/m2, regular menses, both ovaries Other data is reported per oocyte of which there were 300 per group</td></tr><tr><td/><td/><td>present</td></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>Groups appeared balanced at baseline</td></tr></table>",
                "type_str": "table"
            },
            "TABREF18": {
                "text": "OCPs for 21 days + 112 -225 IU/day rFSH + ganirelix acetate when the dominant follicle \u2265 14 mm (",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Depalo 2009</td><td/><td colspan=\"2\">Baseline characteristics: age (yrs) 32.0 \u00b1 3.7 vs 33.1 \u00b1 3.6, BMI (kg/m2) 28.3 \u00b1 7.1 vs 30.7 \u00b1 6.4. Baseline</td></tr><tr><td>El Sahwi 2005</td><td/><td colspan=\"2\">serum FSH (IU/L) 5.4 \u00b1 1.8 vs 5.3 \u00b1 1.2</td></tr><tr><td>Methods Interventions</td><td/><td colspan=\"2\">RCT, single-centre, parallel design, randomisation: 1:1 Study group:</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">160 patients scheduled for ICSI</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">Agonist group were treated with buserelin/hMG stimulation (long luteal protocol) while the antagonist</td></tr><tr><td/><td/><td colspan=\"2\">group were treated with cetrorelix/hMG stimulation (flexible protocol).</td></tr><tr><td>Outcomes</td><td/><td>The treatment period</td></tr><tr><td/><td/><td colspan=\"2\">Number of hMG ampoules used</td></tr><tr><td/><td/><td colspan=\"2\">Number of abandoned cycles</td></tr><tr><td/><td/><td colspan=\"2\">Number of oocytes retrieved</td></tr><tr><td/><td/><td>Fertilization rate</td></tr><tr><td/><td/><td>Implantation rate</td></tr><tr><td/><td/><td>Clinical pregnancy rate</td></tr><tr><td/><td/><td colspan=\"2\">The occurrence of hyperstimulation syndrome (OHSS)</td></tr><tr><td/><td/><td colspan=\"2\">The convenience and compliance of participants</td></tr><tr><td>Notes</td><td/><td colspan=\"2\">Number of participants at randomisation: 160 (cetrorelix: 80/buserelin: 80)</td></tr><tr><td/><td/><td colspan=\"2\">Number of participants at stimulation: 160 (cetrorelix: 80/buserelin: 80)</td></tr><tr><td/><td/><td colspan=\"2\">Number of participants at OPU: 142 (cetrorelix: 74/buserelin: 68)</td></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td>Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Low risk</td><td>Reported as randomisation using opaque envelopes without any further de-</td></tr><tr><td>tion (selection bias)</td><td/><td/><td>tails</td></tr><tr><td>Allocation concealment</td><td/><td>Low risk</td><td>Opaque envelopes</td></tr><tr><td>(selection bias)</td><td/><td/></tr><tr><td>Blinding (performance</td><td/><td>Low risk</td><td>Blind</td></tr><tr><td>bias and detection bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) All outcomes (attrition bias) Incomplete outcome data</td><td>Low risk Unclear risk</td><td>Software QuickCalcs) nist or agonist, by using a free internet software for randomisation (Graphpad Computer-generated list at initiation of stimulation, to receive GnRH antago-No missing outcomes data, LBR/OPR not addressed by the study</td></tr><tr><td>Allocation concealment (selection bias) Selective reporting (re-porting bias)</td><td/><td>Unclear risk Low risk</td><td>The study protocol was not available, but it is clear that the published reports Not reported included most expected outcomes</td></tr><tr><td>Blinding (performance Other bias</td><td/><td>Low risk Low risk</td><td>The embryologist scoring the embryos was blinded to the study groups The study appears to be free from other sources of bias</td></tr><tr><td>bias and detection bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Incomplete outcome data</td><td/><td>Low risk</td><td>No missing outcome data, LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes Methods</td><td/><td>RCT, single-centre</td></tr><tr><td>Selective reporting (re-Participants</td><td/><td colspan=\"2\">Low risk 60 women (high responders), aged 20 -39 years , normal basal FSH concentration \u2264 10.0 IU/L), and un-Outcomes were reported in a pre-specified manner</td></tr><tr><td>porting bias)</td><td/><td colspan=\"2\">dergoing their first cycle of IVF with either PCOS or PCOM (defined according to the Rotterdam consen-</td></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>Baseline characteristics balanced in both groups</td></tr></table>",
                "type_str": "table"
            },
            "TABREF19": {
                "text": "Luteal phase support: study group: 50 mg IM P in oil daily + 0.1 mg transdermal E2 patches every other day; control group: 50 mg IM P in oil daily Follow up: an ultrasound scan was carried out five to six weeks after oocyte retrieval to determine the viability of the pregnancy.A second ultrasound was performed at 12 weeks' gestation to confirm any ongoing pregnancy (positive heart beat) Cochrane Database of Systematic Reviews Methods RCT, multi-centre (12 centres, 9 countries), Europe and Middle East, multi-national, open-label, parallel Participants 321 infertile couples undergoing ovarian stimulation for IVF-ET with or without ICSI with all causes of infertility Number of participants at randomisation: 355 (ganirelix 236/triptorelin 119) \u2022 Number of participants at stimulation: 334 (ganirelix 226/triptorelin 108) \u2022 Number of participants at OPU: 319 (ganirelix 214/triptorelin 105) \u2022 Incidence of multiple pregnancies was not mentioned in the table of outcomes and was not clear in the text \u2022 The study authors used the estimated difference of ganirelix and buserelin in ongoing pregnancy rate compared with the margin of 5%.And for cumulus-oocyte complexes, the estimated treatment difference was compared with the equivalence margin of 3 oocytes \u2022 Centre-adjusted analysis was done for all outcomes except miscarriage, ectopic and ovarian hyperstimulation syndrome Number of participants at stimulation: 701 (ganirelix 463/buserelin 238 ) \u2022 Number of participants at OPU: 661 (ganirelix 440/buserelin 221) \u2022 Incidence of multiple pregnancies was not mentioned in the table of outcomes and was not clear in the text \u2022 Tolerability was not mentioned in the table of outcomes but stated in the text \u2022 The study authors used the estimated difference of ganirelix and buserelin in ongoing pregnancy rate was compared with the margin of -5%.And for cumulus-oocyte complexes, the estimated treatment difference compared with the equivalence margin of -3 oocytes \u2022 Centre-adjusted analysis was done for all outcomes except miscarriage, ectopic and ovarian hyperstimulation syndrome Inclusion criteria: healthy female partners of infertile couples, regular menstrual cycles of 26 -34 days, BMI between 20 and 25 kg/m 2 , age between 20 and 39 years at the time of screening, baseline serum FSH level < 10 IU/l, and baseline serum E 2 level \u2264 45 pg/ml on cycle day 3",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">Engmann 2008a (Continued) Euro Middle East 2001 Euro Middle East 2001 (Continued) Euro Orgalutran 2000 (Continued)</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">Local reaction: ganirelix group 11.9 versus triptorelin group 24.1 Luteal phase support: was done according to the centre's routine practice 60 women undergoing IVF treatment</td></tr><tr><td colspan=\"4\">Control group: OCP for 25 days overlapping with 1 mg leuprolide acetate (Lupron), then reduced to 0.5 mg once down-regulation was achieved (Low-dose long GnRH agonist protocol) + 112 -225 IU/day rFSH Oocyte maturation triggering: when 2 -3 leading follicles were &gt; 18 mm in diameter Study group: GnRH agonist, 1 mg approximately 12 hours after the last dose of ganirelix Control group: 3300 to 10,000 IU hCG (Profasi) Oocyte retrieval: 35 hours later, followed by IVF/ ICSI Inclusion criteria: healthy female partners of infertile couples, age at time of screening \u2265 18 but &lt; 39 years, a body mass index (BMI) between 18 and 29 kg/m , a regular menstrual cycle, and willing to give written informed consent Age: not stated Duration of infertility: ganirelix 4.3 years, triptorelin 4.1 years FSH: ganirelix 5.8 IU/ml, triptorelin 2.8 IU/ml BMI: not stated Premature LH surge defined as (LH &gt; 10 IU/L) and progesterone level &gt; 1 ng/L Stimulation length Number of hMG ampoules E2 on hCG No of oocytes retrieved No of embryos obtained No of embryos transferred Implantation rate Clinical pregnancy/OPU Clinical pregnancy/ET Miscarriage Baseline characteristics: Age (years) 34.0 \u00b1 4.3 vs. 34.6 \u00b1 4.3, BMI (kg/m 2 ) 22.9 \u00b1 0.8 vs. 23.4 \u00b1 0.7, base-line serum FSH (IU/l) 6.63 \u00b1 3.25 vs. 6.73 \u00b1 2.09, baseline serum LH (IU/l) 4.60 \u00b1 2.21 vs. 4.53 \u00b1 1.92 GnRH antagonist (n = 30): 225 IU daily SC rFSH (Gonal F) from cycle day 3 (adjusted) + 0.25 mg SC daily cetrorelix acetate (Cetrotide) when there was a 14 mm dominant follicle until and including the day of hCG administration \u2022 Risk of bias Notes Outcomes Interventions Ectopic GnRH agonist (n = 30): 0.5 mg/day SC leuprorelin acetate (Enantone die) beginning at the mid-luteal OHSS phase + 225 IU SC rFSH (Gonal-F) starting 14 days after pituitary down-regulation (adjusted). (long pro-Moderate or severe OHSS tocol)</td></tr><tr><td colspan=\"4\">Maximum number of embryos transferred: 3 GnRH antagonist (n = 215): 150 IU rFSH (Puregon) (adjusted) + multiple-dose regimen of 0.25 mg of Low risk Interactive response voice system, stratified randomisation, 2:1 randomisation ratio Low risk Adequate High risk Not blind Low risk No missing outcomes data, LBR not addressed by the study \u2022 Risk of bias Risk of bias Interventions Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes GnRH antagonist (ganirelix) was administered SC starting from day 6 of stimulation (fixed) Bias Authors' judgement Support for judgement Notes \u2022 Number of participants at randomisation: 730 (ganirelix 486/buserelin 244) Oocyte maturation triggering: 10,000 IU of hCG (Gonasi HP)</td></tr><tr><td colspan=\"2\">Bias Random sequence genera-tion (selection bias) Outcomes Selective reporting (re-Bias Other bias tion (selection bias) porting bias) Random sequence genera-</td><td colspan=\"2\">Authors' judgement Support for judgement Low risk Computer-generated random numbers. To ensure similar distribution of previ-ous high response in the two groups, separate randomisation schedules were Premature LH surge: (defined as (LH &gt; 10 IU/L) and progesterone level &gt; 1 ng/L) ganirelix group 1 versus Low risk Authors' judgement Support for judgement The study protocol was not available, but it is clear that the published reports triptorelin group 0 rFSH: ganirelix group 1350 IU versus triptorelin group 1800 IU Unclear risk Insufficient information to make a conclusive judgement Stimulation length: ganirelix group 9 versus triptorelin group 26 included most expected outcomes Low risk Interactive response voice system (true), 2:1 randomisation ratio</td></tr><tr><td>(selection bias) Allocation concealment</td><td/><td colspan=\"2\">drawn up for women undergoing their first cycle and for women with a previ-ous high response by the use of stratified randomised blocks E2 on hCG: ganirelix group 1090 pg/ml versus triptorelin group 1370 pg/ml Low risk Adequate</td></tr><tr><td>Allocation concealment (selection bias) Blinding (performance Methods All outcomes bias and detection bias) Blinding (performance</td><td/><td colspan=\"2\">Low risk Number of oocytes retrieved: ganirelix group 7.9 \u00b1 5.1 versus triptorelin group 9.6 \u00b1 6.8 Research nurse used a series of consecutively numbered sealed opaque en-velopes High risk Not blind Number of embryos transferred: not mentioned RCT, multi-centre (20 centres), open-label, parallel design Number of embryos obtained: ganirelix group 4.0 \u00b1 3.0 versus triptorelin group 4.7 \u00b1 3.0 High risk Not blind</td></tr><tr><td>bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Participants Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-Interventions porting bias)</td><td/><td colspan=\"2\">Low risk Implantation rate: ganirelix group 22.9 versus triptorelin group 22.9 No missing outcome data, LBR not addressed by the study 730 Infertile couples undergoing ovarian stimulation for IVF-ET with or without ICSI with all causes of Low risk No missing outcomes data, LBR not addressed by the study infertility Clinical preg/cycle: ganirelix group 32.3 versus triptorelin group 37.8 Baseline characteristics: age ganirelix 31.9 \u00b1 3.6, buserelin 31.9 \u00b1 3.8, duration of infertility: ganirelix Clinical preg/ET: ganirelix group 35.8 versus triptorelin group 41.7 4.5 \u00b1 2.7, buserelin 4.4 \u00b1 2.7, FSH: ganirelix 7.7, buserelin 8.4, BMI ganirelix 23 \u00b1 2.9, buserelin 23 \u00b1 2.7 Unclear risk The study protocol was not available, but it is clear that the published reports Ongoing pregnancy rate: ganirelix group 31.4 versus triptorelin group 33.9 GnRH antagonist (n= 486): rFSH (Puregon) was started at fixed daily dose of 150 IU for five days and included most expected outcomes</td></tr><tr><td>Selective reporting (re-porting bias) Other bias</td><td/><td colspan=\"2\">Low risk Miscarriage: ganirelix group 10.3 versus triptorelin group 11.4 The study protocol was not available, but it is clear that the published reports included most expected outcomes Cancellation: ganirelix group 22 versus triptorelin group 15 the dose was adjusted according to response + multiple-dose regimen of 0.25 mg of GnRH antagonist (ganirelix) was administered SC starting from day 6 of hMG treatment (fixed) Low risk The study appears to be free from other sources of bias</td></tr><tr><td>Other bias</td><td/><td colspan=\"2\">Low risk GnRH agonist (n= 244): mid-luteal GnRH analogue (buserelin 0.6 or 1.2 mg four times daily intranasal-The study appears to be free from other sources of bias Ectopic: ganirelix group 2 versus triptorelin group 0 ly) + rFSH (Puregon) was started at fixed daily dose of 150 IU for 5 days and the dose was adjusted ac-</td></tr><tr><td>Ferrari 2006</td><td/><td>cording to response OHSS: ganirelix group 4 versus triptorelin group 1</td></tr><tr><td>Methods</td><td/><td>Severe OHSS: only one case ganirelix group RCT, parallel design</td></tr></table>",
                "type_str": "table"
            },
            "TABREF20": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Ferrari 2006 (Continued)</td><td/><td/></tr><tr><td/><td/><td colspan=\"2\">Inclusion criteria: first cycle of the ART, age &lt; 35 years, and basal FSH &lt; 10 IU/L</td></tr><tr><td>Ferrero 2010</td><td/><td colspan=\"2\">Exclusion criteria: previous IVF or ICSI, hyperprolactinaemia, hyperthyroidism, hypothyroidism, uter-</td></tr><tr><td>Methods</td><td/><td colspan=\"2\">Randomised controlled trial, single centre ine abnormality, severe endometriosis, or solitary ovary</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics:age (years) 28.71 \u00b1 2.8 vs 28.36 \u00b1 3.1, BMI (kg/m 2 ) 28.1 \u00b1 3.4 vs 27.54 \u00b1 4.3,</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">144 women basal FSH (IU/L) 5.77 \u00b11.2 vs 5.54 \u00b1 1.1</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">Inclusion criteria: no specific details but included women who had had moderate or severe OHSS or GnRH antagonist (n =118): 225 IU rFSH on 2nd day of the cycles (adjusted) + HMG + 0.25 mg SC of who had been at risk of OHSS during their first IVF/ICSI cycle with a mid-luteal long agonist protocol ganirelix took place on the 6 th day of the stimulation (fixed protocol)</td></tr><tr><td/><td/><td colspan=\"2\">Exclusion criteria: no details GnRH agonist (n = 117): 150-225 IU rFSH (adjusted) + long GnRH agonist, 500 \u03bcg buserelin per day</td></tr><tr><td/><td/><td colspan=\"2\">(Suprefact) (SC), during menstrual cycle 21 and onwards, once down-regulation was achieved, the dose Setting and timing: Italy; no details of timing of buserelin was reduced to 250 \u00b5g (low-dose GnRH agonist protocol)</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics: not stated Oocyte maturation triggering: hCG 10,000 IU (Profasi) was administered intramuscularly (IM) when at</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">least two follicles were 18 mm Antagonist -cetrorelix 0.25 mg/day starting on day 3 of the menstrual cycle Oocyte retrieval: 36 hours later, followed by IVF/ICSI</td></tr><tr><td/><td/><td colspan=\"2\">Agonist -triptorelin 0.1 mg/day starting on day 21 of the menstrual cycle Maximum of embryo transferred: 3</td></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td>Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Unclear risk</td><td>No details</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Allocation concealment</td><td/><td>Unclear risk</td><td>No details</td></tr><tr><td>(selection bias)</td><td/><td/></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) Blinding (performance All outcomes bias and detection bias)</td><td>Low risk Unclear risk</td><td>Open label but blinding unlikely to effect fertility outcome. No details of blind-\"The patients were assigned randomly (computer-generated randomization GnRH-a (Group A, 30 patients) and Gn-RH-ant (Group B, 30 patients)\" list; SPSS Inc., Chicago, IL, USA) to two different GnRH analogue regimens ing of outcome assessors</td></tr><tr><td>Allocation concealment Incomplete outcome data (attrition bias) (selection bias) All outcomes</td><td/><td>Unclear risk Unclear risk</td><td>Although the abstract states that there were 144 women randomised, there are Method of allocation not reported no other denominators to indicate how many women were allocated to each group. No details on withdrawals or losses to follow-up</td></tr><tr><td>Blinding (performance All outcomes porting bias) bias and detection bias) Selective reporting (re-</td><td/><td>Unclear risk Unclear risk</td><td>Not reported but unlikely to affect measurement of outcome Conference abstract only. Outcomes are not pre-specified. OHSS not reported</td></tr><tr><td>Incomplete outcome data Other bias</td><td/><td>Low risk Unclear risk</td><td>Number randomised = 60, number analysed = 60 Conference abstract only. Groups were reported as being similar at baseline</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-porting bias) Firouzabadi 2010</td><td/><td>Unclear risk</td><td>All expected outcomes reported as pre-specified however live birth rate not re-ported</td></tr><tr><td>Methods</td><td/><td>RCT, single-centre</td></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>None identified</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">235 infertile women undergoing IVF/ICSI</td></tr></table>",
                "type_str": "table"
            },
            "TABREF21": {
                "text": "In the 21st day of the menstrual cycle, a dose of 200 \u00b5g of nafarelin acetate was taken through nasal twice a day.After 14 days of administration of the agonist, with the blockage established (menstruation), the administration of recombinant FSH was started in a fixed dose of 150 -300 IU for a period of five days.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Firouzabadi 2010 (Continued) Fluker 2001 (Continued) Franco 2003 (Continued) Friedler 2003 (Continued) Gizzo 2014 (Continued)</td><td/><td/></tr><tr><td>Fluker 2001 Allocation concealment Outcomes (selection bias)</td><td/><td colspan=\"2\">\u2022 Number of participants at randomisation: 313 (ganirelix 208/leuprolide 105) \u2022 Number of participants at stimulation: (ganirelix 198/leuprolide 99) Number of participants at stimulation: N/A Unclear risk Not reported Ongoing pregnancy, clinical pregnancy, mean value of E max at ovulation induction, mean value of en-Number of participants at OPU: N/A dometrial thickness at pick-up day, quality of embryos</td></tr><tr><td>Methods Risk of bias Blinding (performance Notes</td><td/><td colspan=\"2\">RCT, multi-centre (11 centres, United States and Canada), open-label, parallel design \u2022 Number of participants at OPU: (ganirelix 186/leuprolide 95) \u2022 Centre-adjusted analysis: not mentioned High risk Participants not blinded Three-arm study, excluded short GnRH agonist protocol (n = 90)</td></tr><tr><td>Participants Risk of bias Bias bias and detection bias) All outcomes</td><td/><td colspan=\"2\">313 infertile couples undergoing ovarian stimulation for IVF-ET with or without ICSI with all causes of infertility Authors' judgement Support for judgement \"After oocyte fertilization, according to the casual envelopes produced by software randomization, in each Group (A, B and C) patients were randomly assigned (with a randomization of 1:1) to one of three</td></tr><tr><td colspan=\"2\">Bias Random sequence genera-tion (selection bias) Incomplete outcome data (attrition bias) Interventions Random sequence genera-tion (selection bias) Allocation concealment Allocation concealment (selection bias) All outcomes Blinding (performance Selective reporting (re-porting bias) (selection bias) Blinding (performance bias and detection bias) All outcomes Other bias bias and detection bias) Incomplete outcome data All outcomes (attrition bias) Risk of bias</td><td colspan=\"2\">Baseline characteristics: age: ganirelix 33.0 \u00b1 3.4 vs leuprolide 32.8 \u00b1 4.0 Duration of infertility: ganirelix 4.1 \u00b1 3.0 vs leuprolide 3.8 \u00b1 2.6. FSH: ganirelix 7.9 IU/ml vs leuprolide 3.3 IU/ml. BMI: ganirelix 23.0 \u00b1 3.0 Authors' judgement Support for judgement Low risk Randomisation list, randomisation: 2:1 (ganirelix:nafarelin) ratio Low risk different subgroups (A1, A2 and A3; B1, B2 and B3 and C1, C2 and C3) in relation to the different phar-Protocol is not available but the methods and results match macological LPS starting from the first day after pick-up vs leuprolide 23.0 \u00b1 3.0 GnRH antagonist (n = 205): A multiple-dose regimen of 0.25 mg of GnRH antagonist (ganirelix) was administered SC starting from day 6 of rFSH treatment up to and including day of hCG administration (Fixed) + rFSH (Follistim) was started at fixed daily dose of 150 IU for five days and the dose was adjust-ed according to response GnRH agonist (n= 108): mid-luteal GnRH analogue (leuprolide 1.0 mg SC) to 99 participants of the con-trol group + rFSH (Follistim) was started at fixed daily dose of 150 IU for five days and the dose was ad-justed according to response Low risk Interactive response voice system (true), 2:1 randomisation ratio, stratified randomisation Low risk Adequate Unclear risk \u2022 subgroups A1 (60 patients), B1 (30 patients) and C1 (30 patients) received low-dose PG (200 mg vaginal Unclear High risk Not blind Low risk capsule twice daily) Intention-to-treat analysis was not used but the drop-out rate was less than \u2022 subgroups A2 (60 patients), B2 (30 patients) and C2 (30 patients) received high-dose PG (200 mg vagi-10% nal capsule three times daily plus 100 mg intramuscular daily). High risk Low risk \u2022 Subgroups A3 (60 patients), B3 (30 patients) and C3 (30 patients) received high-dose PG (200 mg vagi-Baseline characteristics are similar nal capsule three times daily plus 100 mg intramuscular daily) in association with valerate E2 (2 mg Not blind vaginal tablet twice daily).\" Low risk No missing outcomes data, LBR not addressed by the study</td></tr><tr><td colspan=\"2\">Outcomes Incomplete outcome data (attrition bias) All outcomes Gizzo 2014 Selective reporting (re-Methods Bias All outcomes Selective reporting (re-porting bias) porting bias) Participants Random sequence genera-tion (selection bias) Other bias</td><td colspan=\"2\">Luteal phase support was done according to the centre's routine practice Premature LH surge defined as (LH &gt; 10 IU/L) and progesterone level &gt; 1 ng/L ganirelix group versus leuprolide group Stimulation length ganirelix group versus leuprolide group Low risk No missing outcomes data, LBR not addressed by the study Low risk The study protocol was not available, but it is clear that the published reports Authors' judgement Support for judgement Superiority, randomised open-label, single centre RCT Low risk included most expected outcomes Unclear risk Study randomised participants into subgroups using appropriate random se-360 idiopathic subfertile participants quence generation but randomisation into large groups A, B, C not clearly stat-The study protocol was not available, but it is clear that the published reports included most expected outcomes Low risk The study appears to be free from other sources of bias ed</td></tr><tr><td>Other bias Allocation concealment (selection bias)</td><td/><td colspan=\"2\">rFSH: ganirelix group IU versus leuprolide group IU E2 on hCG ganirelix group pg/ml versus leuprolide group pg/ml Low risk Unclear risk Method of allocation not reported for the randomisation of participants into The study appears to be free from other sources of bias large groups A, B, C</td></tr><tr><td>Friedler 2003 Blinding (performance Methods Franco 2003 Methods bias and detection bias) Participants All outcomes</td><td/><td colspan=\"2\">Unclear risk Number of oocytes retrieved ganirelix group \u00b1 versus leuprolide group \u00b1 Study is an open label trial. \"As limitations we report:\u2026 the impossibility to Number of embryos obtained ganirelix group \u00b1 versus leuprolide group \u00b1 Number of embryos transferred RCT, open-label, parallel design, single-centre blind patients and clinicians to the treatment\u2026\" RCT, open-label, parallel design, single-centre \"All serum sample were analysed by a single laboratory as well all the endome-&lt; 40 years old undergoing IVF due to male or tubal infertility trial thickness measurements were performed by two skilled sonographers</td></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) Participants Interventions Incomplete outcome data (attrition bias) All outcomes Outcomes Selective reporting (re-porting bias)</td><td colspan=\"2\">Low risk Implantation rate ganirelix group versus leuprolide group Computer-generated randomisation schedules Clinical pregnancy/cycle ganirelix group versus leuprolide group blinded to patients' treatment\" All participants received vaginal micronised progesterone (300 mg/day) as luteal supplementation. LP 20 participants without specific ovulatory dysfunction aged \u2264 37 who would be submitted to ovarian stimulation characteristics were compared between the two groups and between the conception and non concep-Unclear risk Number randomised = 360, number analysed = unclear tion cycles. Estradiol (E2), progesterone and LH levels were measured on the day of hCG administration (day 0), days +5, +8, +11 and +16. (Unclear) Clinical pregnancy/ET ganirelix group versus leuprolide group Ongoing pregnancy rate ganirelix group versus leuprolide group Cancellation ganirelix group versus leuprolide group of E2 and progesterone levels 100, 225 and 300 UI per day in estimated high, normo and poor responders, respectively, administered Unclear risk All outcomes reported in a pre-specified manner. However, live birth rate not Clinical pregnancy rate of Implantation rates in third day after spontaneous menstruation (pending the basal E2 &lt; 0.3 nmol/l) (adjusted) + daily dose reported</td></tr><tr><td>Allocation concealment Notes Other bias (selection bias) Blinding (performance bias and detection bias) All outcomes Methods</td><td/><td colspan=\"2\">Low risk Miscarriage ganirelix group versus leuprolide group Sealed in envelopes and handed to participants Power calculation: no power calculation 0.25 mg/0.5 ml ganirelix starting from the TVS detection of at least one follicle &gt; 14 mm in diameter Low risk None identified and continued until hCG administration (short protocol) High risk Number of participants at randomisation: unclear Ectopic ganirelix group versus leuprolide group Number of participants at stimulation: unclear GnRH agonist (n =180): rFSH (Gonal-F) with a starting dose (maintained for the first five days) of 100, Not blind Number of participants at OPU: unclear 225 and 300 UI per day in estimated high, normo and poor responders, respectively, administered at OHSS ganirelix group 4 versus leuprolide group 1 Oocyte maturation triggering: 5 -10.000 IU uhCG at least two follicles \u2265 17 mm achievement of hypothalamic suppression + daily dose (0.1 mg) of triptorelin acetate (long protocol) Type of antagonist protocol: unclear Severe OHSS: ganirelix 3 cases, leuprolide 2 Maximum number of embryos transferred: 2 -3 Oocyte maturation triggering: 250 mg rhCG SC Single centre RCT</td></tr><tr><td colspan=\"2\">Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias Notes Notes Outcomes tion (selection bias) Risk of bias Bias Participants Random sequence genera-</td><td colspan=\"2\">Low risk Low risk Low risk equivalence margin of 3 oocytes No missing outcome data, LBR not addressed by the study The study protocol was not available, but it is clear that the published reports included most expected outcomes Number of participants at randomisation: 20 (ganirelix: 14/ nafarelin: 6) The study appears to be free from other sources of bias Local reaction ganirelix group 11.9 versus leuprolide group 24.1 \u2022 Incidence of multiple pregnancies was not mentioned in the table of outcomes and was not clear in the text \u2022 The study authors used the estimated difference of ganirelix and leuprolide in ongoing pregnancy rate compared with the margin of 5% \u2022 And for cumulus-oocyte complexes, the estimated treatment difference was compared with the Luteal phase support: not reported No of oocytes retrieved Fertilisation rate Pregnancy rate Follow-up: Up to ongoing pregnancy Implantation rate Luteal phase support: low-dose PG (200 mg vaginal capsule twice daily) or high-dose PG (200 mg vagi-300 women with PCOS nal capsule three times daily plus 100 mg intramuscular daily) or high-dose PG (200 mg vaginal capsule Authors' judgement Support for judgement Unclear risk Reported as a randomised trial without any further details. three times daily plus 100 mg intramuscular daily) in association with valerate E2 (2 mg vaginal tablet Inclusion criteria: women with PCOS younger than 35 years old and older than 23 years old: where di-twice daily) agnosis of PCOS was based on the Rotterdam 2004 Criteria, so patients with oligomenorrhoea (an irreg-</td></tr></table>",
                "type_str": "table"
            },
            "TABREF22": {
                "text": "Agonist long protocol (n = 26) with OCP pre-treatment starting on day 2 or day 3 of previous cycle.Buserelin acetate 500 micrograms started on day 21 until pituitary down-regulation.Reduced to 250 micrograms per day when follicle > 10 mm diameter, E2 > 50 pg/ml until the day of hCG injection ovarian stimulation with Gonal F 150 IU commenced on day 3.When follicular diameter \u2265 14 mm cetrorelix 0.25 mg/day SC given for three days.HMG given after seventh day of stimulation.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"3\">Haydardedeoglu 2012 (Continued) Haydardedeoglu 2012 (Continued) Heijnen 2007 (Continued) Hershko Klement 2015 (Continued) Hohmann 2003 (Continued) Hoseini 2014 (Continued) Hosseini 2010 (Continued) Hsieh 2008 (Continued) Huirne 2006 Huirne 2006 (Continued)</td></tr><tr><td>Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Notes Outcomes Interventions Methods Participants Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias Notes Outcomes Methods</td><td/><td colspan=\"2\">Baseline characteristics: age (years) 27.57 \u00b1 3.54 vs. 27.70 \u00b1 3.59, BMI (kg/m 2 ) 25.74 \u00b1 4.37 vs. 24.97 \u00b1 4.36, duration of infertility (years) 6.24 \u00b1 3.64 vs. 5.85 \u00b1 3.42, FSH (IU/ml) 4.77 \u00b1 1.80 vs. 5.03 \u00b1 1.36, LH (IU/ml) 5.94 \u00b1 4.17 vs. 5.60 \u00b1 3.49, E2 (pg/ml) 42.82 \u00b1 33.62 vs. 38.83 \u00b1 25.02, IVF/ICSI indications: PCOS + Low risk \"\u2026assigned using consecutively numbered opaque, sealed envelopes on the day of initiation of OCP.\" Unclear risk Not reported but unlikely to affect measurement of outcome Low risk Number randomised = 300, number analysed = 300 Unclear risk All outcomes reported in the pre-specified manner, except that clinical preg-nancy listed as outcome measure at protocol but not reported in study. Live High risk Not blind Low risk No missing outcome data Low risk The study protocol was not available, but it is clear that the published reports included most expected outcomes Low risk The study appears to be free of other source of bias Unclear risk 60 women were randomised and nine did not complete treatment (15%). Three chose another fertility unit, three decided to stop fertility treatment, two were screened out during routine laboratory testing and one had a spon-taneous extrauterine pregnancy that required surgical intervention and then postponed fertility treatment. The groups that these women were allocated to was not specified 27/31 women in the antagonist group were analysed and 24/29 in the agonist group Unclear risk Clinical pregnancy rate was the only prespecified outcome although there are more outcomes reported in the results section. OHSS was not reported E2 (n mol/litre) P (n mol/litre) Number of follicles (10 mm) day hCG Number of follicles (15 mm) day hCG Number of oocytes retrieved Number of embryos Fertilisation rate per subject (%) Number of pregnancies (%) Number of ongoing pregnancies (%) Number of twin pregnancies (%) Ovarian stimulation started on day 3 using rFSH 150 to 225 IU hCG 5000 IU given IM when at least three follicles had a mean diameter of 17 mm Ooycte retrieval 34 to 36 hours after hCG injection Gene expression. No pregnancy outcomes reported for inclusion in a meta-analysis Down-regulation Group 1 (n = 86): cetrorelix 0.25 mg/day, cetrorelix was administered from menstrual day 8 until the day of hCG administration. (Fixed) RCT, multi-centre (eight European IVF centres), phase IIIb study 182 infertile women undergoing IVF/ICSI Low risk No missing outcome data Antagonist (n = 57) Agonist (n = 55) buserelin 0.5 mg SC started on day 21 of previous cycle. Ovarian stimulation with Go-nal F 150 IU commenced on day 3 of next cycle and replaced with HMG after the seventh day of stimula-Inclusion criteria: participants needed to have a regular IVF/ICSI indication, a male partner with viable Low risk The study protocol was not available, but it is clear that the published reports Group 2 (n = 28): cetrorelix 0.2 mg/day sperm in the ejaculate (testicular biopsy or epididymal sperm was not allowed), aged between 18 and included most expected outcomes tion 39 years Group 3 (n = 30): cetrorelix 0.15 mg/day Oocycte maturation triggered when at least two follicles \u2265 17 mm and hCG 10,000 IU given IM Oocyte retrieval 36 to 38 hours after hCG. Low risk The study appears to be free from other sources of bias Exclusion criteria: people with any previous assisted reproduction treatment cycles with less than Group 4 (n = 58): leuprolide acetate 0.5 mg/day, administered on days 21-23 of the previous menstrual three oocytes or three or more consecutive ART cycles without a clinical pregnancy or with any con-cycle traindication to ART, gonadotrophins or OC pills. People with a significant systemic disease Number of participants at randomisation: 169 (cetrorelix: NA/ triptoreline: NA) Number of participants at stimulation: 142 (cetrorelix: 45/ triptoreline: 97) Number of participants at OPU: 104 (cetrorelix: 38/ triptoreline: 66) Sample size calculation -no ITT analysis -no Luteal phase support -progesterone suppository cyclogest 800 mg daily Clinical pregnancy, chemical pregnancy, number of oocytes retrieved, number and days of go-Group 5 (n = 49): leuprolide acetate depot 1.88 mg. Single dose leuprolide acetate depot subcuta-Baseline characteristics: age (years) 32.8 \u00b1 3.8 vs 32.2 \u00b1 4.2. BMI (kg/m 2 ) 23.7 \u00b1 4.0 vs 22.6 \u00b1 3.5. FSH (IU/ neous l) on cycle day 2 or 3 7.2 \u00b1 2.2 vs 7.4 \u00b1 3.3 0. Estradiol (pmol/l) on cycle day 2 or 3 138 \u00b1 55, 148 \u00b1 103 birth rate not reported nadotrophins, miscarriage, multiple pregnancy, OHSS and severe OHSS COH: 150 -225 IU/day rFSH (Gonal-F) in women &lt; 34 years old, 225 -300 IU rFSH in women &gt; 34 years RCT, single-centre Part II trial</td></tr><tr><td>Other bias Methods Hershko Klement 2015 Other bias Risk of bias Bias Risk of bias Notes Interventions Participants</td><td/><td colspan=\"2\">male factor (%) 40.7 (61/150) vs. 38.7 (58/150), PCOS only (%) 54.7 (82/150) vs. 53.3 (80/150), PCOS tubal factor (%) 4.7 (7/150) vs. 8 (12/150). Low risk None identified Pilot randomised controlled trial, single centre Low risk Groups were balanced at baseline day of r-hCG administration. (Fixed) ITT analysis -yes Authors' judgement Support for judgement Funding -Deputy Ministry for Research, Tehran Sample size calculation -no GnRH antagonist (n = 91 ): daily OCPs (30 \u03bcg ethinyl E2 and 150 \u03bcg levonorgestrel) for 21 -28 days Final oocyte maturation triggering: 5000 IU hCG were given when at least three mature \u2265 18 mm folli-cetrorelix 0.25 mg subcutaneously started on stimulation day 6 and continued up to and including the cles were obtained + r-hFSH 150 -225 IU (Gonal-F) according to the study centre's standard practice (adjusted)+ daily 60 PCOS infertile women undergoing IVF/ICSI</td></tr><tr><td colspan=\"2\">Participants Hohmann 2003 Random sequence genera-Bias tion (selection bias) Heijnen 2007 Allocation concealment Random sequence genera-tion (selection bias) Risk of bias</td><td colspan=\"2\">60 women Low risk Authors' judgement Support for judgement Computer-generated randomisation Funding -none stated Low risk Schedule assigned via numbered sealed envelopes Unclear risk Randomised no details</td></tr><tr><td>(selection bias) Allocation concealment Bias</td><td/><td colspan=\"2\">Unclear risk Authors' judgement Support for judgement No details</td></tr><tr><td colspan=\"2\">Blinding (performance All outcomes Blinding (performance tion (selection bias) bias and detection bias) (selection bias) Random sequence genera-</td><td>Unclear risk High risk Unclear risk</td><td>No details for participants or outcome assessors Not blind 'Randomized'</td></tr><tr><td>Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) bias and detection bias) All outcomes Incomplete outcome data All outcomes All outcomes bias and detection bias) Risk of bias (attrition bias) Blinding (performance Allocation concealment (selection bias) Notes</td><td/><td colspan=\"2\">Low risk Low risk Unclear risk Unclear risk Unclear risk Baseline characteristics: age (years) 31.4 \u00b1 3.5 vs 31.7 \u00b1 3.7. Duration of infertility (years) 4.4 \u00b1 1.9 vs No missing outcome data, however LBR not addressed by the study The study protocol was not available, but it is clear that the published reports included most expected outcomes outcomes. Blinding of outcome assessors was not reported No details. Unlikely to have been blinded but blinding unlikely to affect fertility Insufficient details were reported to make a conclusive judgement 'Sequential' no details 4.4 \u00b1 1.6. BMI (kg/m 2 ) 23.2 \u00b1 2.8 vs 23.4 \u00b1 2.9. Baseline FSH 5.8 \u00b1 1.2 vs 5.4 \u00b1 1.7</td></tr><tr><td colspan=\"2\">Other bias Selective reporting (re-porting bias) Bias Incomplete outcome data Other bias (attrition bias) tion (selection bias) All outcomes Random sequence genera-</td><td colspan=\"2\">Mean number of embryos transferred: antagonist: 1.4 \u00b1 0.7 vs agonist 1.2 \u00b1 0.6 Number of ampoules used: antagonist 24.9 \u00b1 8.1 vs agonist 25.5 \u00b1 13.3 Controlled ovarian hyperstimulation initiated with rFSH alone or in combination with hMG. Adjust-Low risk The study appears to be free from other sources of bias High risk Authors' judgement Support for judgement No pregnancy outcomes reported. Unable to include any data in a meta-analy-Low risk Women randomised were analysed. No losses reported sis Low risk Groups appear balanced at baseline Unclear risk Reported as a randomised trial without any further details</td></tr><tr><td>Hoseini 2014 Selective reporting (re-porting bias) (selection bias) Allocation concealment</td><td/><td colspan=\"2\">ments made dependant on individual response Unclear risk All outcomes reported. However, did not report on live birth or ongoing preg-nancy as an outcome Unclear risk Not reported</td></tr><tr><td colspan=\"2\">Notes Risk of bias Bias Random sequence genera-tion (selection bias) Risk of bias Bias Outcomes Notes Risk of bias Bias Methods Hosseini 2010 Other bias Notes Blinding (performance Participants Methods bias and detection bias) Risk of bias All outcomes Outcomes Participants Bias Methods Incomplete outcome data Hsieh 2008 (attrition bias) Random sequence genera-All outcomes tion (selection bias) Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance Participants Selective reporting (re-porting bias) Allocation concealment (selection bias) Interventions Interventions All outcomes bias and detection bias) Other bias Blinding (performance</td><td colspan=\"2\">fertilisation rate, grade 1 embryo number, grade 2 embryo number, total transferred embryos, positive hCG rate, biochemical pregnancy rate, implantation rate, cryopreservation rate, multiple pregnancy rate Authors' judgement Support for judgement Low risk \"The 300 eligible patients were randomized into two groups by an allocation sequence generated from a random numbers table and assigned using con-secutively numbered opaque, sealed envelopes on the day of initiation of OCP. Clinical pregnancy is the only prespecified outcome. Also reported on fertilisation rate, embryo quality, number of embryos transferred, amount of FSH, follicular size Authors' judgement Support for judgement Randomised controlled trial High risk Women in the agonist group were slightly older at baseline Unclear risk Not reported Maximum number of embryos transferred: 2 embryos were transferred at 3 -5 days 50 infertile couples undergoing IVF/ICSI Randomised controlled trial. Single centre Luteal support: intravaginal progesterone (P; Progestan, Organon; 200 mg, three times daily) was giv-en from the day of oocyte retrieval until a urine pregnancy test was performed 17 days later Included patients (n = 142) Age (yr) Inclusion criteria: male factor, tubal factor or unexplained subfertility, no ovulatory dysfunction, age 40 years or less, normal basal FSH and LH (&lt; 10 mIU/ml) Exclusion criteria: no details Authors' judgement Support for judgement 112 infertile women with PCOS (Rotterdam criteria) Inclusion criteria: PCOS, &lt; 35 years, normal BMI (&lt; 27 kg/m 2 ), normal prolactin, normal thyroid levels, normal semen analysis for male partner RCT phase III, open-label, single-centre study Low risk No missing outcome data, however LBR not addressed by the study Low risk Computer-generated concealed randomisation list. Randomisation was per-formed by centre Authors' judgement Support for judgement Low risk Computer-generated random blocks of size four and six were stratified by cen-tre Low risk Numbered sealed envelopes and made available at each centre; envelopes were sequentially allocated to consecutive participants and opened by treat-ing physicians at IVF planning consultations Unclear risk Randomised but no other details Low risk Allocation using sealed envelopes handled by an administrator not involved in the study Unclear risk Open label study but blinding unlikely to effect fertility outcomes Body mass index (kg/m2) FSH day 2/3 (IU/litre) Inhibin Bday 2/3 (ng/litre) Baseline characteristics: age -antagonist 33.8 \u00b1 5.6 years versus agonist 30.4 \u00b1 5.5 years Setting and timing: infertility centre, Iran June 2012 to November 2013 Setting and Timing: Department of Infertility, Tehran, Iran. During 2006 Baseline characteristics: age-antagonist 27.8 \u00b1 3.4 years versus agonist 29.3 \u00b1 4.2 years 251 infertile women undergoing IVF/ICSI Low risk The study protocol was not available, but it is clear that the published reports Unclear risk Not reported included most expected outcomes Inclusion criteria: age at least 18 years but not older than 39 years; and body weight of 40 -70 kg Participants undergoing oocyte retrieval (n 104) n (% per started cycle) Cycle day start cetrorelix Day hCG FSH (IU/litre) Antagonist Fixed multi-dose protocol (n = 24) cetrorelix acetate 0.25 mg/day on day 6 until day of hCG injection All participants had folic acid 1 mg/day before the induction cycle, low-dose OCP on day 3 of previous cycle and doxycycline 100 mg twice daily for the first 10 days of the previous cycle vs 3.9 \u00b1 1.3 vs 3.8 \u00b1 1.4 vs 3.6 \u00b1 1.8 m 2 ) 20.6 \u00b1 1.4 vs 19.0 \u00b1 1.0 vs 19.5 \u00b1 1.1 vs 20.7 \u00b1 2.1 vs 21.1 \u00b1 1.8; Baseline FSH (IU/L) 4.0 \u00b1 1.8 vs 3.7 \u00b1 1.6 Baseline characteristics: age (yr) 33.9 \u00b1 4.4 vs 32.3 \u00b1 2.1 vs 31.6 \u00b1 2.4 vs 30.9 \u00b1 2.5 vs 32.1 \u00b1 2.7; BMI (kg/ Unclear risk No source of other bias identified Unclear risk Not reported</td></tr><tr><td>bias and detection bias)</td><td/><td>LH (IU/litre)</td></tr></table>",
                "type_str": "table"
            },
            "TABREF23": {
                "text": "GnRH agonist/gonadotrophin) six participants were excluded, 13 participants did not come back, and follow up in three participants lost.In study group (CC/gonadotrophin/antagonist) two participants were excluded, 12 participants did not come back, and follow up in seven participants lost Secondary -total amount and days of rFSH, number of fertilised oocytes and grade I and II embryos, implantation rate, clinical pregnancy rate per cycle and live birth rate per cycle, miscarriage rate infertile women with PCOS (PCOS diagnosis was based on the revised PCOS diagnostic criteria of the 2003 Rotterdam consensus).Good health with normal cardiac, hepatic and renal functions, and had experienced spontaneous onset of puberty and normal sexual development",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Hwang 2004 (Continued) Inza 2004 (Continued) Karimzadeh 2010 (Continued) Khalaf 2010 (Continued) Kim 2011 (Continued)</td><td/></tr><tr><td colspan=\"4\">Notes Risk of bias Bias Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) Notes Risk of bias Bias Outcomes In control group (Risk of bias Authors' judgement Support for judgement Low risk Computer-generated block randomisation numbers with a block size of 10 Unclear risk Not reported Unclear risk No reported Funding -Prgramme Hospitalier Recherche Clinique Authors' judgement Support for judgement Primary -number of mature oocytes retrieved Notes Power calculation -yes All outcomes Incomplete outcome data Unclear risk No missing outcome data, however LBR not addressed by the study Bias Random sequence genera-Unclear risk 'randomly assigned' 'ballot'; no further details reported Authors' judgement Support for judgement tion (selection bias) ITT analysis -yes</td></tr><tr><td colspan=\"2\">Allocation concealment (selection bias) (attrition bias) All outcomes Random sequence genera-Allocation concealment tion (selection bias) (selection bias)</td><td colspan=\"2\">Low risk Low risk Unclear risk Funding -not reported Earlier publications were Kim 2005 and Kim 2009 Sealed envelopes Computer-generated randomisation schedule No details</td></tr><tr><td>Hwang 2004 Blinding (performance Selective reporting (re-porting bias) Allocation concealment (selection bias) Blinding (performance Risk of bias bias and detection bias) bias and detection bias) All outcomes Other bias Blinding (performance All outcomes Bias</td><td/><td colspan=\"2\">Low risk Low risk Low risk Unclear risk Low risk Unclear risk Authors' judgement Support for judgement The laboratory sta were blinded to the stimulation protocol The study protocol was not available, but it is clear that the published reports included most expected outcomes Numbered sealed envelopes 'without blinding'. Lack of blinding is unlikely to affect fertility outcomes The study appears to be free from other sources of bias Not reported</td></tr><tr><td colspan=\"2\">Incomplete outcome data (attrition bias) All outcomes bias and detection bias) All outcomes Incomplete outcome data Incomplete outcome data All outcomes tion (selection bias) (attrition bias) Random sequence genera-</td><td>Low risk Unclear risk Low risk Low risk</td><td>No missing outcome data, however LBR not addressed by the study No missing outcome data, however the study did not address live birth rate All women randomised were analysed 'computer-generated lists'</td></tr><tr><td>Selective reporting (re-porting bias) Methods (attrition bias) All outcomes Selective reporting (re-porting bias) Allocation concealment (selection bias)</td><td/><td>Low risk RCT, single-centre trial High risk Unclear risk</td><td>The study protocol was not available, but it is clear that the published reports included most expected outcomes 'The sequence of allocation to the three groups was provided to the investigat-There were no pregnancy outcomes pre-specified ing physicians...'</td></tr><tr><td>Other bias Participants Selective reporting (re-porting bias) Other bias bias and detection bias) Blinding (performance</td><td/><td colspan=\"2\">Low risk 243 women who were candidates for ART The study appears to be free from other sources of bias. Low risk The study protocol was not available, but it is clear that the published reports included most expected outcomes Low risk Groups appear balanced at baseline Unclear risk Trial not blinded but unlikely to affect outcome of pregnancy</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>The study appears to be free from other sources of bias</td></tr><tr><td>Incomplete outcome data</td><td/><td>Low risk</td><td>In groups 1 and 3 there were no losses, withdrawals or cancellations. In group</td></tr><tr><td>Inza 2004 All outcomes Kim 2004 (attrition bias)</td><td/><td/><td>2, one cycle was cancelled before embryo transfer</td></tr><tr><td>Methods Methods Khalaf 2010 Selective reporting (re-</td><td/><td colspan=\"2\">RCT, single-centre, parallel design RCT, single-centre, parallel design Low risk All outcomes listed were reported: although multiple pregnancy is reported it</td></tr><tr><td>Participants Methods Participants porting bias)</td><td/><td colspan=\"2\">Patients &lt; 40, with FSH levels on day 3 &lt; 12 IU/ml Randomised controlled trial. Single centre 41 women undergoing IVF/ICSI is not listed a priori</td></tr><tr><td>Interventions Participants Other bias</td><td/><td colspan=\"2\">GnRH agonist long protocol versus GnRH antagonist protocol (type of antagonist protocol: N/A) (un-50 women Inclusion/exclusion criteria: not stated Low risk Groups were balanced at baseline</td></tr><tr><td>Outcomes Interventions</td><td/><td colspan=\"2\">known) Number and quality of retrieved oocytes GnRH antagonist: OCP+ cetrorelix 0.125 mg/day, was administered on days 1 and 2 of COH with rFSH, Inclusion criteria: \u2264 35 years, regular menstrual cycles, normal basal FSH (\u2264 10 IU/L), LH (\u2264 10 IU/L) and and cetrorelix 0.25 mg/day was restarted when the leading follicle reached a mean diameter of 13 mm estradiol \u2264 50 pg/ml), BMI 18 to 24 kg/m 2 and continued to the day of hCG injection. (Flexible)</td></tr><tr><td/><td/><td colspan=\"2\">Amount of gonadotrophins used Days of stimulation Exclusion criteria: clinical evidence of endometriosis, PCOS or OHSS during stimulation GnRH agonist: no details were available for the agonist group, except that they were down-regulated</td></tr><tr><td>Methods</td><td/><td colspan=\"2\">Final estradiol levels Fertilisation rate Setting and timing: Assisted Reproduction Unit, Caen, France. Timing not specified with triptorelin (triptorelin 0.1 mg/day) RCT, single centre trial</td></tr><tr><td>Outcomes Participants Interventions</td><td/><td colspan=\"2\">Number and quality of embryos transferred Pregnancy rate Implantation rate Baseline characteristics: age -antagonist 31 \u00b1 0.7 years versus agonist 31 \u00b1 0.8 years Number of retrieved oocytes 211 infertile women with PCOS undergoing IVF Oocyte retrieval: 34 to 36 hrs after hCG and IVF or ICSI was performed cle \u2265 14 mm and continued up to day of hCG administration Fertilisation rate ET: on day 2 or 3, under ultrasound guidance Antagonist -(n = 22) cetrorelix 0.25 mg daily (multiple dose protocol) starting day when dominant folli-Number of MII oocytes Number of embryos transferred Inclusion criteria:</td></tr><tr><td>Notes Notes</td><td/><td colspan=\"2\">Number of participants at randomisation: 45 (antagonist: 23/agonist: 22) Number of participants at stimulation: 45 (antagonist: 23/ agonist: 22) Number of participants at OPU: 45 (antagonist: 23/ agonist: 22) Ongoing pregnancy rate Luteal support: progesterone in oil 100 mg daily IM was started on the day of oocyte retrieval and con-Agonist -(n = 28) triptorelin 0.1 mg/day from first day of menstrual cycle up to day of hCG administra-tinued until the documentation of fetal heart activity on ultrasound Follow up: pregnancy was confirmed by measuring serum \u00df-hCG levels 12 days after ET. Clinical preg-tion Number of participants at randomisation: 41 (cetrorelix: 21/ triptorelin: 20)</td></tr><tr><td>Risk of bias</td><td/><td colspan=\"2\">nancy was considered as the presence of gestational sac with fetal heart activity by TVS that was per-formed three weeks after positive \u00df-hCG Number of participants at stimulation: 41 (cetrorelix: 21/ triptorelin: 20) rFSH 225 IU/day on second day of menstrual cycle Number of participants at OPU: 41 (cetrorelix: 21/ triptorelin: 20)</td></tr><tr><td>Bias Outcomes Risk of bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement Primary outcome measures: clinical pregnancy rate per cycle and ongoing pregnancy; later were de-hCG (5000 IU) when at least three follicles 18 mm diameter</td></tr><tr><td colspan=\"2\">Random sequence genera-Outcomes Bias</td><td colspan=\"2\">Unclear risk fined as pregnancy proceeding beyond the 12th gestational week Reported as a randomised trial without any further details Aromatase activity in granulosa lutein cells Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">tion (selection bias) Notes Random sequence genera-</td><td colspan=\"2\">Sample size calculation -no Unclear risk Reported as a randomised trial without any further details</td></tr><tr><td>tion (selection bias)</td><td/><td>ITT analysis -yes</td></tr></table>",
                "type_str": "table"
            },
            "TABREF24": {
                "text": "10,000 IU hCG or SC injection of 250 \u03bcg hCG when the dominant follicle reached \u2265 18 mm with the following two \u2265 16 mm and estradiol level between 1000 and 4000 pg/mL Oocyte retrieval: 36 hours later, followed by ICSI GnRH agonist long protocol, GnRH antagonist protocol, and GnRH antagonist with hCG 200 IU protocol following contraceptive pills for two to three weeks as pretreatment.(Unknown)OutcomesTotalamount of FSH dosage, Blood E2 level at hCG injection, the number of oocytes, small follicle (< 10 mm) counts at OPU, day 3 embryo high quality rate, clinical pregnancy rate, and severe OHSS rate OCP + 150 IU rFSH (adjusted) + long GnRH agonist, 0.1 mg triptorelin three days before discontinuation of the OCP, once down-regulation was achieved, the dose of GnRH agonist was decreased on that day to 0.05 mg/day (low-dose GnRH",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Kim 2012 (Continued) Kurzawa 2008 Kurzawa 2008 (Continued)</td><td/><td/></tr><tr><td>Methods Blinding (performance</td><td/><td>RCT, single-centre trial High risk</td><td>Not blinded</td></tr><tr><td>bias and detection bias) Methods</td><td/><td>RCT, single-centre</td></tr><tr><td>Participants All outcomes</td><td/><td colspan=\"2\">74 PCOS meeting Rotterdam criteria undergoing ICSI</td></tr><tr><td>Incomplete outcome data Participants</td><td/><td colspan=\"2\">Low risk Inclusion criteria: male factor subfertility, several unsuccessful intrauterine inseminations, previous No missing outcome data 78 infertile women with PCOS undergoing IVF/ICSI</td></tr><tr><td>(attrition bias)</td><td/><td colspan=\"2\">ineffective IVF (none or &lt; 30% of fertilisations), age \u2264 35 years, BMI &lt; 26 kg/m 2 , basal FSH &lt; 12 mIU/ml, Inclusion criteria: PCOS (presence of oligo-ovulation/anovulation and polycystic ovaries), age 18 -39</td></tr><tr><td>All outcomes</td><td/><td colspan=\"2\">negative HBV and HCV virus infection and HIV years, less than three previous IVF/ICSI attempts, no endometriotic cyst present as assessed by trans-</td></tr><tr><td/><td/><td colspan=\"2\">Exclusion criteria: \u2265 2 miscarriages, \u2265 3 unsuccessful IVF/ICSI cycles, anatomical abnormalities of the vaginal, ultrasound examination, and basal hormonal levels of FSH in the early follicular phase of 10 IU</td></tr><tr><td>Selective reporting (re-porting bias) Interventions Other bias</td><td/><td colspan=\"2\">uterus on laparoscopy or hysteroscopy and existence of ovarian cysts Low risk l21 The study protocol was not available, but it is clear that the published reports Exclusion criteria: women with known previous poor ovarian response included most expected outcomes Baseline characteristics:age (years) 31.33 \u00b1 3.91 vs 30.36 \u00b1 3.40, BMI (kg/m 2 ) 23.1 \u00b1 1.3 vs 22.3 \u00b1 1.6 GnRH antagonist (n = 37): OCP (Cilest) + 150 IU rFSH on 2nd day of the cycle (adjusted) + 0.25 mg SC Low risk Baseline characteristics: age (years) 32.0 (14) vs 30.5 (16), BMI (kg m 2 ) 23.2 (20.9) vs 23.6 (18.9), FSH (IU The study appears to be free from other sources of bias l21) 6.3 (1.7) vs 5.8 (2.6)</td></tr><tr><td/><td/><td colspan=\"2\">of cetrorelix acetate (Cetrotide) administered when follicles reached a diameter of 14 mm (flexible</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">protocol) GnRH antagonist (n = 26): OCP + 150 IU rFSH on 2nd day of the cycle (adjusted) + 0.25 mg SC of</td></tr><tr><td/><td/><td colspan=\"2\">ganirelix (Orgalutran) administered on day 2 of menses/day 1 of stimulation (flexible protocol)</td></tr><tr><td>Kyono 2005</td><td/><td colspan=\"2\">GnRH agonist (n = 37): OCP (Cilest) + 150 IU rFSH (adjusted) + long GnRH agonist triptorelin (Diphere-line SR 3.75 ) (DepotGnRH agonist protocol) GnRH agonist (n = 52):</td></tr><tr><td colspan=\"4\">Methods Participants Oocyte maturation triggering: Maximum Outcomes RCT, open-label, parallel design, single-centre Women under the age of 40 yrs with previous cycles &lt; 3 times, and BMI &lt; 27 kg/m 2 underwent COH for ART Primary endpoints Embryological: Matured oocyte (M2) rate, defined as proportion of metaphase II to total number of retrieved oocytes Interventions Participants were treated with Notes Number of participants at randomisation: 192 (cetrorelix: 126/ buserelin: 66)</td></tr><tr><td/><td/><td colspan=\"2\">Fertilisation rate, defined as proportion of two pronuclei oocytes to number of injected oocytes Number of participants at stimulation: N/A</td></tr><tr><td/><td/><td colspan=\"2\">Quality of zygotes on the first day of culture Number of participants at OPU: N/A</td></tr><tr><td/><td/><td colspan=\"2\">Quality of embryos on the third day of culture</td></tr><tr><td/><td/><td colspan=\"2\">Secondary endpoints Clinical:</td></tr><tr><td/><td/><td colspan=\"2\">Delivery per attempt, defined as a live birth after 32 weeks of gestation</td></tr><tr><td/><td/><td colspan=\"2\">Clinical pregnancy per attempt, defined as an ongoing pregnancy at 12 weeks of gestation</td></tr><tr><td/><td/><td colspan=\"2\">Implantation rate; defined as gestational sacs per number of transferred embryos</td></tr><tr><td colspan=\"2\">tion (selection bias) Random sequence genera-</td><td colspan=\"2\">Multiple pregnancy per viable pregnancy weeks of gestation Miscarriage per intrauterine pregnancy, defined as a miscarriage of an ongoing pregnancy after 12 Unclear risk Reported as a randomised trial without any further details.</td></tr><tr><td>(selection bias) Allocation concealment</td><td/><td colspan=\"2\">Occurrence of severe OHSS Gonadotrophin consumption Number of days of gonadotrophin treatment Unclear risk Not reported</td></tr><tr><td>Blinding (performance</td><td/><td colspan=\"2\">Correlation between serum LH level and IVF outcome High risk Not blind</td></tr><tr><td>Notes bias and detection bias) All outcomes</td><td/><td colspan=\"2\">Financial support-grant number KBN 2 P05E 034 28 from State Committee for Scientific Research</td></tr><tr><td>Risk of bias Incomplete outcome data</td><td/><td>Unclear risk</td><td>No missing outcome data, however LBR not addressed by the study</td></tr><tr><td>Bias (attrition bias) All outcomes</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Other bias Random sequence genera-tion (selection bias) Selective reporting (re-porting bias)</td><td>Low risk Low risk Low risk Low risk</td><td>All outcomes reported as it is in the pre-specified manner None detected Computer-generated random letters (A for GnRH antagonists protocol or B for The study protocol was not available, but it is clear that the published reports GnRH agonists protocol) included most expected outcomes</td></tr><tr><td>Allocation concealment Other bias</td><td/><td>Low risk Low risk</td><td>Opaque sealed envelopes The study appears to be free from other sources of bias</td></tr><tr><td>(selection bias)</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF25": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table/>",
                "type_str": "table"
            },
            "TABREF26": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Lainas 2007 (Continued)</td><td/><td/></tr><tr><td>Lainas 2007 Other bias</td><td/><td>Low risk</td><td>The study appears to be free from other sources of bias</td></tr><tr><td>Methods</td><td/><td>RCT, single-centre</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">220 PCOS women undergoing ICSI</td></tr><tr><td/><td/><td colspan=\"2\">Inclusion criteria: PCOS (presence of oligo-ovulation/anovulation) and polycystic ovaries, age 18 -39</td></tr><tr><td/><td/><td colspan=\"2\">years, no endometriotic cyst present, as assessed by transvaginal ultrasound examination, basal FSH</td></tr><tr><td/><td/><td>10 IU/ml</td></tr><tr><td/><td/><td colspan=\"2\">Exclusion criteria: women with known previous poor ovarian response</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics:age (years) 32 (29 -35) vs 31 (28 -35), BMI (kg/m 2 ) 23.2 (20.9 -25.8) vs 24.6</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Low risk</td><td>Computer-generated randomisation list in a 1:2 ratio</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Allocation concealment</td><td/><td>Low risk</td><td>By a study nurse, the responsible physicians (investigators) were not involved</td></tr><tr><td>(selection bias)</td><td/><td/><td>in the randomisation process</td></tr><tr><td>Blinding (performance</td><td/><td>High risk</td><td>Neither participants nor doctors were blinded to the treatment assigned</td></tr><tr><td>bias and detection bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Incomplete outcome data</td><td/><td>Unclear risk</td><td>No missing outcome data, however LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-</td><td/><td>Low risk</td><td>The study protocol was not available, but it is clear that the published reports</td></tr><tr><td>porting bias)</td><td/><td/><td>included most expected outcomes</td></tr></table>",
                "type_str": "table"
            },
            "TABREF27": {
                "text": "Inclusion criteria: women aged 37 years or less and in their first IVF/ICSI cycle, BMI < 30 kg/m 2 , regular menses and the presence of two normal ovaries",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Lainas 2010 (Continued)</td><td/><td/></tr><tr><td>Incomplete outcome data</td><td/><td>Low risk</td><td>No missing outcome data, however LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-Lainas 2010 porting bias)</td><td/><td>Low risk</td><td>The study protocol was not available, but it is clear that the published reports included most expected outcomes</td></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>The study appears to be free from other sources of bias</td></tr><tr><td>Methods</td><td/><td>Two-arm parallel RCT</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">32 infertile women undergoing ICSI cycle</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics: age (years) antagonist: 32.1 \u00b1 3.1; agonist: 33.7 \u00b1 2.7, P = 0.12; BMI: GnRH an-</td></tr><tr><td/><td/><td colspan=\"2\">tagonist 23.4 \u00b1 2.7, GnRH agonist 23.7 \u00b1 3.1, P = 0.75</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">GnRH antagonist (n = 16</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Low risk</td><td>Computer-generated randomisation list, in a 1:1 ratio</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Allocation concealment</td><td/><td>Unclear risk</td><td>Not reported</td></tr><tr><td>(selection bias)</td><td/><td/></tr><tr><td>Blinding (performance</td><td/><td>High risk</td><td>Neither participants nor doctors were blinded to the treatment assigned</td></tr><tr><td>bias and detection bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF28": {
                "text": "Inclusion criteria: were no more than 39 years of age, a history of regular menstruation cycles (menstrual cycle length 26 -33 days), BMI 18 -29 kg/m 2 , no history of poor ovarian response or reserve (less than three oocytes in a previous IVF cycle), baseline FSH levels < 11 IU/L, normal results for serum liver and renal function testing, presence of two ovaries, and no pill or hormone pretreatment within three months prior to stimulation cycle Exclusion criteria: ovarian-factor or uterine-factor infertility, or those suffering ovarian cysts, as determined by the use of ultrasound at the commencement of a stimulation cycle",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Lavorato 2012 (Continued) Lee 2005 (Continued) Lin 2006 (Continued) Loutradis 2004 (Continued)</td><td/><td/></tr><tr><td colspan=\"2\">Blinding (performance Allocation concealment Random sequence genera-Random sequence genera-</td><td>Unclear risk Unclear risk Low risk Low risk</td><td>No information was reported on blinding of participants and personnel, in-Not reported clearly Blocked randomisation Computer-generated randomisation table, randomisation: 1:1 (cetrorelix:trip-</td></tr><tr><td>bias and detection bias) (selection bias) tion (selection bias) tion (selection bias)</td><td/><td/><td>cluding outcome assessors. However, none of the reported outcomes were rel-toreline) ratio</td></tr><tr><td>All outcomes</td><td/><td/><td>evant to the review</td></tr><tr><td>Blinding (performance Allocation concealment Allocation concealment</td><td/><td>Unclear risk Low risk Unclear risk</td><td>Not reported clearly Sealed in envelopes and the physicians were not aware of the allocation Not reported</td></tr><tr><td>Incomplete outcome data bias and detection bias) (selection bias) (selection bias)</td><td/><td>Unclear risk</td><td>None of the reported outcomes were relevant to the review</td></tr><tr><td>(attrition bias) All outcomes</td><td/><td/></tr><tr><td>All outcomes Blinding (performance Blinding (performance</td><td/><td>Unclear risk High risk</td><td>Not reported Not blind</td></tr><tr><td>Incomplete outcome data bias and detection bias) bias and detection bias)</td><td/><td>Unclear risk</td><td>No missing outcomes data, however LBR not addressed by the study</td></tr><tr><td>Selective reporting (re-(attrition bias) All outcomes All outcomes</td><td/><td>Unclear risk</td><td>None of the reported outcomes were relevant to the review</td></tr><tr><td>porting bias) All outcomes</td><td/><td/></tr><tr><td>Incomplete outcome data Incomplete outcome data</td><td/><td>Low risk Unclear risk</td><td>No missing outcomes data No missing outcome data, however LBR not addressed by the study</td></tr><tr><td>Other bias Selective reporting (re-(attrition bias) (attrition bias) Lavorato 2012 porting bias) All outcomes All outcomes</td><td/><td>Low risk Low risk</td><td>Groups were balanced at baseline The study protocol was not available, but it is clear that the published reports included most expected outcomes</td></tr><tr><td>Other bias Selective reporting (re-Selective reporting (re-</td><td/><td>Low risk Low risk Low risk</td><td>University grant; the study appears to be free from other sources of bias The study protocol was not available, but it is clear that the published reports The study protocol was not available, but it is clear that the published reports</td></tr><tr><td>Lee 2005 porting bias) porting bias)</td><td/><td/><td>included most expected outcomes included most expected outcomes</td></tr><tr><td>Methods Other bias Other bias</td><td/><td colspan=\"2\">RCT, single-centre, university hospital, tertiary medical centre, parallel design Low risk The study appears to be free from other sources of bias Low risk The study appears to be free from other sources of bias</td></tr><tr><td>Participants Lin 2006</td><td/><td colspan=\"2\">61 infertile women undergoing IVF/ICSI</td></tr><tr><td>Methods</td><td/><td>RCT, single-centre trial</td></tr><tr><td>Participants Loutradis 2004</td><td/><td colspan=\"2\">120 infertile women undergoing ICSI</td></tr><tr><td>Methods</td><td/><td colspan=\"2\">RCT, single-centre, open-label, parallel design</td></tr><tr><td/><td/><td colspan=\"2\">Baseline characteristics: age (years) 31.3 \u00b1 4.4 vs 30.7 \u00b1 4.4, weight (kg) 53.5 \u00b1 8.2 vs 55.2 \u00b1 8.2, day 3</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) ad-FSH level (mIU/ml) 5.12 \u00b1 1.76 vs 5.28 \u00b1 1.44, Day 3 LH level (mIU/ml) 4.75 \u00b1 2.19 vs 4.31 \u00b1 2.39</td></tr><tr><td/><td/><td colspan=\"2\">ministration (Flexible), or with a long protocol (LP) for GnRH agonist (buserelin) administration, fol-</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">lowed by oocyte retrieval, IVF/ICSI, and embryo transfer GnRH antagonist (n = 60): 100 mg/day CC cd 3 to 7 + 2 -4 ampoules hMG was given on days 4, 6, 8 and</td></tr><tr><td/><td/><td colspan=\"2\">9 + 2.5 mg cetrorelix acetate (Cetrotide 1) when the leading follicle had reached 14 mm (Flexible)</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Amount of hMG administered (ampoules) GnRH agonist (n = 60): 0.5 mg/day buserelin GnRH agonist long protocol + 2 -4 ampoules of hMG Period of hMG stimulation (days) Serum E2 level on day of hCG administration (pg/mL) (Pergonal) or FSH (Metrodin) Oocyte maturation triggering: when the leading follicle had reached a diameter of 18 mm in group Numbers of follicles (size 10 mm) on day of hCG administration Oocyte maturation triggering: 10,000 IU hCG (Pregnyl 1), when at least two follicles had reached 18 A and 20 mm in group B and at least two follicles had reached 15 mm or more, rFSH was discontinued Thickness of endometrium (mm) on day of hCG administration Number of oocytes retrieved mm and a single 10,000 IU hCG dose (Pregnyl) was administered</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Fertilisation rate (%) Oocyte retrieval: 34 -36 hrs, followed by ICSI Peak E2 (pg/mL) Number of zygotes Number of transferred embryos Total dosage of gonadotrophins (IU) Maximum embryo transfer: not stated Duration of gonadotrophin administration (in days) Number of frozen embryos Implantation rated Pregnancy rated Number of oocytes retrieved Luteal phase support: 600 mg/day vaginally of micronised progesterone (Utrogestan) starting from Total number of good-quality embryos the day after oocyte retrieval Number of ETs</td></tr><tr><td>Notes Outcomes</td><td/><td colspan=\"2\">Follow up: up to live birth Clinical pregnancy rates Number of participants at randomisation: 61 (cetrorelix: 41/ buserelin: 20) Implantation rates Number of participants at stimulation: 60 (cetrorelix: 40/ buserelin: 20) Number of participants at OPU: 60 (cetrorelix: 40/ buserelin: 20) Primary outcome measure: amount of gonadotrophin used Number of cryopreserved embryos</td></tr><tr><td>Notes Risk of bias</td><td/><td colspan=\"2\">Secondary outcome measures: endometrial thickness, number of oocytes and MII oocytes recovered, Number of participants at randomisation: 116 (cetrorelix: 58/ triptoreline: 58) as well as rates of fertilisation and pregnancy Number of participants at stimulation: 116 (cetrorelix: 58/ triptoreline: 58)</td></tr><tr><td/><td/><td colspan=\"2\">Number of participants at OPU: 116 (cetrorelix: 58/ triptoreline: 58)</td></tr><tr><td colspan=\"2\">Random sequence genera-Bias Notes</td><td colspan=\"2\">Low risk Authors' judgement Support for judgement Computer-generated random sequence</td></tr><tr><td colspan=\"2\">Risk of bias tion (selection bias) Allocation concealment Random sequence genera-Risk of bias tion (selection bias) Bias</td><td colspan=\"2\">Unclear risk Unclear risk Authors' judgement Support for judgement The method used in allocation concealment was not reported Reported as a randomised trial without any further details</td></tr><tr><td>(selection bias) Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr></table>",
                "type_str": "table"
            },
            "TABREF29": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.Luteal phase support: intravaginal progesterone gel (Crinone 8%) and was started no later than the day of ET until a urine pregnancy test was performed 12 days later Follow up: An ultrasound scan was carried out five to six weeks after oocyte retrieval to determine the viability of the pregnancy.A second ultrasound was performed at 12 weeks' gestation to confirm any ongoing pregnancy (positive heart beat)",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Oocyte retrieval: 36 hrs after hCG administration followed by IVF/ICSI Embryo transfers: were performed 48 hrs after oocyte retrieval Luteal phase: 2 \u00d7 200 mg/day of micronised vaginal progesterone (Prometrium) Follow up: serum hCG concentrations were measured 14 days after embryo transfer. Clinical pregnan-cies were confirmed 28 -35 days after embryo transfer by the presence of a gestational sac under ultra-sound Age (years) Initiated cycles Stopped cycles Cycles with oocyte retrieval Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Stimulation duration (days) Number of ampoules Follicles &gt; 15 mm Oocytes retrieved Oocytes fertilised Cycles with transfers Embryos transferred Endometrial thickness (mm) Clinical pregnancies Number of participants at randomisation: 60 (cetrorelix: 30/ enantone: 30) Number of participants at stimulation: 60 (cetrorelix: 30/ enantone: 30) Number of participants at OPU: 55 (cetrorelix: 29/ enantone: 26) Authors' judgement Support for judgement Random sequence genera-Outcomes Marci 2005 Cochrane Library Notes Risk of bias Bias tion (selection bias) Unclear risk Reported as a randomised trial without any further details Allocation concealment (selection bias) Unclear risk Not reported Blinding (performance bias and detection bias) All outcomes High risk Not blind Incomplete outcome data (attrition bias) All outcomes Low risk No missing outcomes data Selective reporting (re-porting bias) Low risk The study protocol was not available, but it is clear that the published reports included most expected outcomes Other bias Low risk The study appears to be free from other sources of bias Marci 2005 (Continued) Methods RCT, single-centre, donor-recipient cycle Participants 323 Donors: &lt; 35 years, baseline FSH &lt; 10 U, BMI &lt; 30 kg/m 2 , no history of hereditary disease Baseline characteristics: Age (years) 27.2 + 4.7 vs 26.5 + 4.7, BMI (kg/m2) 23.0 + 3.5 vs 23.1 + 3.0, base-line FSH (IU/ml) 7.0 + 2.3 vs 6.5 + 2.1 Setting and timing: private hospital, Spain. January 2005 to November 2006 Martinez 2008 Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Interventions GnRH antagonist: vaginal contraceptive (Nuvaring) + rFSH 150-200 U/day + ganirelix (Orgalutran) 0.25 mg/day, from day 6 of stimulation (Fixed) GnRH agonist: vaginal contraceptive (Nuvaring) + leuprorelin acetate, 3.75 mg + 2 -3 ampoules per day of hMG Oocyte maturation triggering: 10,000 U of hCG when at least three follicles &gt; 20 mm in diameter Oocyte retrieval: 35 -36 hours later, followed by IVF/ ICSI Follow up: 10 -14 days after puncture Outcomes Clinical pregnancy rate (confirmed by the presence of a gestational sac in the ultrasound examination carried out 4 -5 weeks after transfer) The implantation rate was calculated by dividing the number of gestational sacs by the number of em-bryos transferred Other secondary results were the total number of OCCs retrieved, the number of days and total dose of gonadotrophin stimulation, and plasma estradiol levels on the day of hCG administration Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Low risk Computer-generated randomisation table Allocation concealment (selection bias) Low risk Telephone call Blinding (performance bias and detection bias) All outcomes Low risk Researchers Incomplete outcome data (attrition bias) All outcomes Low risk No missing outcome data Selective reporting (re-porting bias) Low risk The study protocol was not available, but it is clear that the published reports included most expected outcomes Other bias Low risk The study appears to be free from other sources of bias Study funding not re-ported Martinez 2008 (Continued) Methods RCT Participants 30 women Inclusion criteria: known to be low responders (developed fewer than six follicles &gt; 12 mm in previous IVF cycles under the standard mid-luteal phase down-regulation protocol) Exclusion criteria: abnormally high FSH &gt; 13 IU/l Setting and timing: centre for assisted conception, UK. timing not specified Mohamed 2006 Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Baseline characteristics: age agonist group 37 (95% CI 35 to 39) vs antagonist group 36 (95% CI 33.5 to 38) Interventions Agonist group -500 micrograms buserelin SC daily starting day 1 of menstrual cycle Antagonist group -cetrorelix 0.25 mg SC daily started on cycle day 8 and continued until day of hCG in-jection Ovarian stimulation started on cycle day 3 with 225 to 375 IU gonadotrophin daily based on highest dose reached in previous IVF cycle Both buserelin and gonadotrophin continued until day of hCG 10,000 IU injection Gonadotrophin increased by 75 IU/day if fewer than three follicles measuring 12 mm or more were found on cycle day 9 Luteal support -progesterone used for luteal support 400 mg twice daily Number of ampoules -agonist 44.5 (95% CI 38.5 to 54) vs antagonist group 35.5 (95% CI 33 to 41) Outcomes Serum LH and E2 levels, cycle cancellation Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Unclear risk \"randomised\" but no other details Allocation concealment (selection bias) Unclear risk Sealed envelopes used but no details as to whether opaque or given out se-quentially Blinding (performance Unclear risk No details but blinding unlikely. The lack of blinding is unlikely to effect the Incomplete outcome data (attrition bias) All outcomes Unclear risk Two women not analysed from 30 women randomised due to cycle cancella-tion. Both were in the antagonist group Selective reporting (re-porting bias) Unclear risk No pregnancy outcomes of relevance were reported. The primary outcomes relate to serum LH and E2 levels Cycle cancellation was reported but was not pre-specified as an outcome Other bias Low risk No other bias identified, groups were balanced at baseline Mohamed 2006 (Continued) Methods RCT, single-centre Participants 93 women undergoing IVF/ICSI between May 2005 and August 2006, Age: 25 -38 years Exclusion criteria: history of previous poor response (&lt; 4 follicles and/or serum estradiol (E2) level &lt; 500 pg/ml on the day of hCG), \u2265 previous IVF cycles, PCOS or azoospermia, were aged over 38 years, had a BMI \u2265 30 kg/m 2 and basal FSH measurement \u2265 10 IU/ml, and those with relevant systemic disease, se-vere endometriosis or uterine and ovarian abnormalities Moraloglu 2008 Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Baseline characteristics: age: 30.91 \u00b1 5.52 vs 30.25 \u00b1 4.94. BMI: 29.36 \u00b1 4.45 vs 26.58 \u00b1 3.32. Basal E2: 6.63 \u00b1 1.33 vs 6.32 \u00b1 1.77. AFC: 5.02 \u00b1 2.56 vs 8.02 \u00b1 2.95 Interventions GnRH antagonist (n = 45): OCP (Desogesteral + 225 IU FSH + 0.25 mg SC of cetrorelix acetate (Cetrotide) administered when follicles reached a diameter of \u2265 14 mm (flexible protocol) GnRH agonist (n = 48): OCP (Desogesteral + 225 IU FSH + long GnRH agonist leuprolide acetate 1 mg/ day SC (Lupron) one week before the expected menses with approximately a five-day overlap with the OCP. The dose of GnRH agonist was then reduced to 0.5 mg/day, (Low-dose GnRH agonist protocol) Oocyte maturation triggering: hCG 5000 IU (Profai) SC &gt; 3 follicles of 18 mm in diameter Oocyte retrieval: 36 hours later, followed by IVF/ ICSI Maximum embryos transferred: 3 Outcomes Antral follicle numbers Total stimulation duration, days Total gonadotrophin consumption, IU/l Serum E2 value on day of hCG Cycles cancelled for premature LH surge (%) Cycles cancelled for fertilisation failure (%) Number of oocytes per retrieval Number of mature oocytes (M2) Number of fertilised oocytes, fertilisation rate (%) Total embryos obtained Number of embryos transferred Clinical pregnancy per cycle initiated (%) Number of cycles with OHSS (%) Clinical pregnancy per transfer Gonadotrophin-releasing Cochrane bias and detection bias) All outcomes fertility outcomes Notes</td></tr></table>",
                "type_str": "table"
            },
            "TABREF30": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Moraloglu 2008 (Continued)</td><td/><td/></tr><tr><td>Moshin 2007</td><td/><td/></tr><tr><td>Methods</td><td/><td>RCT, single-centre trial</td></tr><tr><td>Participants</td><td/><td colspan=\"2\">49 PCOS infertile women undergoing IVF/ICSI</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">GnRH antagonist (n = 25): 225 IU FSH on 2nd day of the cycle (fixed) + 0.25 mg SC of GnRH antagonist</td></tr><tr><td/><td/><td colspan=\"2\">cetrorelix (Cetrotide, Serono International, Switzerland) started on the sixth day of stimulation (fixed</td></tr><tr><td/><td/><td>protocol)</td></tr><tr><td/><td/><td colspan=\"2\">GnRH agonist (n = 24): 225 IU rFSH (fixed) + long GnRH agonist, 3.75 mg of triptorelin (Dipherelin) in</td></tr><tr><td/><td/><td colspan=\"2\">the mild-luteal phase of the preceding cycle(long depot GnRH agonist protocol)</td></tr><tr><td/><td/><td colspan=\"2\">Oocyte maturation triggering: 10,000 IU SC hCG (Pregnyl) when one follicle 18 -20 mm</td></tr><tr><td/><td/><td colspan=\"2\">Oocyte retrieval: 35 hours later, followed by IVF/ ICSI</td></tr><tr><td>Outcomes</td><td/><td colspan=\"2\">Duration of stimulation, number of ampoules of FSH, fertilisation rate, implantation rate, ongoing preg-</td></tr><tr><td/><td/><td colspan=\"2\">nancy rate, OHSS incidence</td></tr><tr><td>Notes</td><td/><td>Abstract</td></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td>Bias</td><td/><td colspan=\"2\">Authors' judgement Support for judgement</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td>Unclear risk</td><td>Reported as a randomised trial without any further details</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Allocation concealment</td><td/><td>Unclear risk</td><td>Not reported</td></tr><tr><td>(selection bias)</td><td/><td/></tr><tr><td>Blinding (performance</td><td/><td>Unclear risk</td><td>Not reported</td></tr><tr><td>bias and detection bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Incomplete outcome data</td><td/><td>Unclear risk</td><td>No missing outcomes data, however LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-</td><td/><td>Low risk</td><td>The study protocol was not available, but it is clear that the published reports</td></tr><tr><td colspan=\"2\">Random sequence genera-porting bias)</td><td>Low risk</td><td>Computer-generated randomisation schedule included most expected outcomes</td></tr><tr><td>tion (selection bias) Other bias</td><td/><td>Unclear risk</td><td>Insufficient information to make a conclusive judgement</td></tr><tr><td>Allocation concealment</td><td/><td>Low risk</td><td>Numbered sealed envelopes</td></tr><tr><td>(selection bias)</td><td/><td/></tr><tr><td>Blinding (performance bias and detection bias) Olivennes 2000</td><td/><td>Unclear risk</td><td>Not reported</td></tr><tr><td>All outcomes Methods</td><td/><td colspan=\"2\">RCT, multi-centre (9 centres ), open-label, parallel design</td></tr><tr><td>Incomplete outcome data Participants</td><td/><td colspan=\"2\">Unclear risk 169 infertile couples undergoing ovarian stimulation for IVF-ET with or without ICSI No missing outcomes data, however LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td colspan=\"2\">Inclusion criteria: with no more than three previous IVF-ET attempts with all causes of infertility (except</td></tr><tr><td/><td/><td colspan=\"2\">polycystic ovary and moderate or severe endometriosis)</td></tr><tr><td>Selective reporting (re-porting bias)</td><td/><td colspan=\"2\">Low risk Baseline characteristics: age cetrorelix 31.4 \u00b1 3.7, decapeptyl 31.8 \u00b1 3.8. Duration of infertility: cetrore-The study protocol was not available, but it is clear that the published reports included most expected outcomes lix 59.3 \u00b1 35, decapeptyl 55.3 \u00b1 38.1. FSH: cetrorelix 6.3 \u00b1 2, decapeptyl 6.3 \u00b11.9. BMI cetrorelix 22.4, de-</td></tr><tr><td>Other bias</td><td/><td>Low risk capeptyl 22.8</td><td>The study appears to be free from other sources of bias. Not reported</td></tr><tr><td>Gonadotrophin-releasing</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF31": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Interventions</td><td colspan=\"2\">A single dose of 3 mg of GnRH antagonist (cetrorelix) (Depot) was administered SC to 115 participants</td></tr><tr><td/><td>On day 7 of hMG</td><td/></tr><tr><td/><td>mid-luteal GnRH analogue (decapeptyl 3.75)</td><td/></tr><tr><td/><td colspan=\"2\">Ovarian suppression was confirmed by E2 &gt; 50 pg/ml / FSH and LH &lt; 10 IU/L, P &lt; 1 \u00b5g/ml</td></tr><tr><td/><td colspan=\"2\">Then hMG (menogon) was started at 2 or 3 ampoules for four days and the dose was adjusted accord-</td></tr><tr><td/><td>ing to response</td><td/></tr><tr><td/><td>Luteal phase support using daily vaginal progesterone</td><td/></tr><tr><td/><td colspan=\"2\">ICSI was done in 12 women in the cetrorelix group and five women in the decapeptyl group.</td></tr><tr><td>Outcomes</td><td colspan=\"2\">Premature LH surge defined as (LH &gt; 10 IU/L) and progesterone level &gt; 1 ng/L</td></tr><tr><td/><td>Stimulation length</td><td/></tr><tr><td/><td>Number of hMG ampoules</td><td/></tr><tr><td/><td>E2 on hCG</td><td/></tr><tr><td/><td>Number of oocytes retrieved</td><td/></tr><tr><td/><td>Number of embryos obtained</td><td/></tr><tr><td/><td>Number of embryos transferred</td><td/></tr><tr><td/><td>Clinical pregnancy/OPU</td><td/></tr><tr><td/><td>Clinical pregnancy/ET</td><td/></tr><tr><td/><td>Miscarriage</td><td/></tr><tr><td/><td>Ectopic</td><td/></tr><tr><td/><td>OHSS</td><td/></tr><tr><td/><td>Moderate or severe OHSS</td><td/></tr><tr><td/><td colspan=\"2\">Clinical pregnancy was defined as fetal heart beat on ultrasonography</td></tr><tr><td/><td colspan=\"2\">Ongoing pregnancy was defined as pregnancy ongoing after 12 weeks of amenorrhoea</td></tr><tr><td>Notes</td><td colspan=\"2\">\u2022 Number of participants at randomisation: 169 (cetrorelix 126/ decapeptyl 43). Number of participants</td></tr><tr><td/><td colspan=\"2\">at stimulation: 154 (cetrorelix 115 / decapeptyl 39). Number of participants at OPU: 149 (cetrorelix</td></tr><tr><td/><td>113 / decapeptyl 36)</td><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF32": {
                "text": "< 39 years, FSH < 12 mIU/mL, could start gonadotrophin at a dose fixed for five days and with a range of 100 to 300 IU, < 3 previous IVF cycles Exclusion criteria: known endocrine disorders, stage III/IV endometriosis, cases where blood was drawn and analysed in another laboratory, ovarian simulation cancellation if progesterone was > 1.5 ng/ml and estradiol was > 80 pg/ml on the day of initiation of gonadotrophins Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.Chinese women, aged \u2265 18 and \u2264 35 years, BMI 18 to 29 kg/m 2 , normal menstrual cycle, access to ejaculatory sperm and for whom COS and IVF/ICSI were indicated Oocyte retrieval: 36 hours after hCG injection, either IVF or ICSI was performed according to the clinical indication.After two days of in vitro culture, embryos transferred mild/minimal stimulation protocol 75 IU/day of rFSH and 0.25 mg per day cetrorelix administered when the lead follicle was 14 mm diameter (n = 148) Agonist: triptorelin 0.1 mg per day SC from mid-luteal phase of the previous cycle for a minimal of 14 days followed by 150 IU FSH and adjusted as necessary based on follicular size and E2 level",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Olivennes 2000 (Continued) Cochrane Library Trusted evidence. Unclear risk Unclear risk High risk Informed decisions. Better health. Incomplete outcome data (attrition bias) All outcomes Unclear risk Selective reporting (re-porting bias) Low risk Other bias Low risk Olivennes 2000 (Continued) Methods RCT, single centre Participants 190 women Inclusion criteria: Setting and Timing: setting unclear, Greece. August 2007 to December 2009 Reported as a randomised trial without any further details Not reported Not blind Cochrane Database of Systematic Reviews No missing outcomes data, however LBR not addressed by the study The study protocol was not available, but it is clear that the published reports included most expected outcomes The study appears to be free from other sources of bias Baseline characteristics: age agonist 32.8 \u00b1 0.3 SE vs antagonist 32.2 \u00b1 0.3 SE Interventions Antagonist -gonadotrophins administered from day 2 of the cycle if the hormone levels were basal and co-treatment with ganirelix 0.25 mg or cetrorelix 0.25 mg started on day 6 of stimulation Agonist -long protocol started on day 21 of preceding cycle with intranasal buserelin (600 mg /day). Gonadotrophins were administered after two to three weeks of down-regulation and once hormonal levels were basal Gonadotrophin dose 150 -300 IU for all participants and remained fixed for five days. After this period the dose could be adjusted and individualised based on follicular growth, and serum estradiol levels Oocycte maturation induced with 250 micrograms of re hCG when at least 3 follicles of 17-18 mm were present Oocycte retrieval 36 hours after hCG Outcomes Live birth, ongoing pregnancy, miscarriage, clinical pregnancy rates. OHSS Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Low risk \"computer generated list\" Allocation concealment (selection bias) Low risk \"allocation to treatment arms was performed by a consulting nurse who had no intervention in the patients' treatment\" Blinding (performance bias and detection bias) Unclear risk Both participants and treating physicians were aware of the exact protocol fol-lowed. Lack of blinding is unlikely to affect the fertility outcomes Papanikolaou 2012 Oocyte retrieval 34 to 36 hrs after hCG Luteal phase support with progesterone 200 mg three times daily Number of embryos transferred: antagonist 1.92 \u00b1 0.8 vs agonist 2.08 \u00b1 0.8 Outcomes Oocyte retrieval rate, fertilisation rate, number of embryos transferred, cancellation rate, implantation rate, clinical pregnancy rate Notes Risk of bias Bias Authors' Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Random sequence genera-tion (selection bias) Unclear risk \"assigned at random\" . 'No further details were reported Allocation concealment (selection bias) Low risk \"using sealed envelopes\" Blinding (performance bias and detection bias) All outcomes Unclear risk Woman was blinded to allocation, no further details were reported on oth-er personnel. However non blinding of outcome assessors not likely to affect some of the outcome measures as they were objectively assessed Incomplete outcome data (attrition bias) All outcomes Unclear risk Antagonist group 168/182 completed. Agonist group 162/182 completed. No reasons given for withdrawals or losses to follow up Selective reporting (re-porting bias) Unclear risk Some outcomes listed were not pre-specified. No live birth or OHSS data were reported in this trial Other bias Low risk No other source of bias identified. Groups balanced at baseline Prapas 2013 (Continued) Methods RCT. Multi-centre (number of sites not specified) Participants 233 women Inclusion criteria: Exclusion criteria: not specified. Setting and timing: reproductive centres, China. July 2007 to December 2008 Baseline characteristics: age -antagonist 29.3 \u00b1 2.8 years vs agonist 29.1 \u00b1 3.0 years Interventions Antagonist -ganirelix 0.25 mg/day administered from stimulation day 6 up to and including the day of hCG 10,000 IU injection when three follicles \u2265 17 mm Agonist -long protocol triptorelin 0.05 mg/day started during the luteal phase (days 21 to 24) up to and including the day of hCG 10,000 IU injection when three follicles \u2265 17 mm Starting dose of rFSH was 150 IU and dose could be adjusted from day 6 onwards depending on the ovarian response Luteal phase support IM progesterone (min. dose 60 mg) Outcomes rFSH required, number of oocytes retrieved, embryo quality, ongoing pregnancy rate, fertilisation rate In addition data reported for cancellation rate, OHSS and multiple pregnancy rate Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Unclear risk Randomly assigned, no other details Qiao 2012 Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Maximum embryos transferred: 2 Luteal phase support: 180 mg/d natural progesterone (Crinone 8) for 15 days from the day of ET Follow-up: pregnancy was assessed by serum hCG assay after 15 days from ET and then confirmed by transvaginal ultrasound after two further weeks Outcomes Ongoing pregnancy rate, miscarriage rate, clinical pregnancy rate, cycle cancellation rate, endometrial thickness at OPU, cycles without retrieved oocytes, MII oocytes/OPU, number of oocytes retrieved, to-tally administered Gn dose, length of the ovarian stimulation, fertilisation rate (FR), implantation rate (IR), number of transferred embryos, hCG positive tests, number of gestational sacs Notes Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Low risk \"Randomization was performed using a computerized algorithm without any restriction\" Allocation concealment (selection bias) Low risk \"Allocation concealment was obtained using sequentially numbered dark en-velopes: until they were opened at the time of allocation\" Blinding (performance bias and detection bias) All outcomes Unclear risk \"\u2026both physicians and patients were blinded to the study\" however blinding of outcome assessment not described but unlikely to influence measurement of outcomes Incomplete outcome data (attrition bias) All outcomes High risk Number randomised = 695, number analysed = 640 (55 Lost to follow-up due to cancelled cycle (OPU not performed)); analysis was not based on ITT Selective reporting (re-porting bias) Unclear risk All outcomes reported in the pre-specified manner. Live birth rate not reported Other bias Low risk None identified Revelli 2014 (Continued) Methods Prospective RCT, two centres Participants 349 women Inclusion criteria: age 27 to 38 years, undergoing IVF, infertility due to tubal factor, moderate en-dometriosis, male factor or idiopathic subfertility. Basal FSH and LH &lt; 12 mIU/mL, E2 &lt; 50 pg/mL, pro-lactin &lt; 30 ng/mL, regular menstrual and ovulatory cycles, normal uterine cavity, BMI 20 to 26 kg/m 2 . Previous cycle cancelled due to high risk of OHSS Exclusion criteria: no details Baseline characteristics: age antagonist 35.2 \u00b1 4.7 years versus agonist 35.1 \u00b1 4.9 years Setting and timing: assisted reproduction centre. January 2008 to December 2012 Rinaldi 2014 Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Interventions Antagonist: Oocyte maturation triggered by 10,000 IU hCG Luteal phase support commenced on day of oocyte retrieval using progesterone 50 mg/ml IM daily Outcomes Live birth, clinical pregnancy, and miscarriage. Also reported on oocytes retrieved, fertilisation rate, embryo cleavage rate, embryos transferred, clinical pregnancy, implantation rate, live birth rate, mis-carriage rate, OHSS Notes Sample size calculation -yes ITT analysis -yes Funding -no details Risk of bias Bias Authors' judgement Support for judgement Random sequence genera-tion (selection bias) Low risk \"randomized\" \"using computer generated random assignment\" Allocation concealment (selection bias) Low risk \"sealed and numbered envelopes\" Blinding (performance bias and detection bias) All outcomes Unclear risk \"open label\" unlikely to influence fertility outcomes. No details as to whether outcome assessors were blinded; however, non-blinding of outcome assessors not likely to affect some of the outcome measures as they were objectively as-sessed Incomplete outcome data (attrition bias) All outcomes High risk The proportion of women who did not undergo embryo transfer differed be-tween the two treatment groups; reasons for not having embryo transfer were not reported and not all participants randomised were included in the final da-ta analysis Selective reporting (re-porting bias) Unclear risk Only prespecified clinical pregnancy as an outcome but reported on other pregnancy outcomes including live birth and miscarriage rate. Data are report-ed per embryo transferred and not per woman randomised. However, num-bers of embryos transferred were same as numbers of women Other bias Low risk Groups balanced at baseline Rinaldi 2014 (Continued) Methods RCT, 10 IVF centres, open-label, parallel design Participants 351 infertile women undergoing IVF/ICSI Inclusion criteria: healthy females of infertile couples, age at time of screening between 18 and 39 years, BMI between 18 and 29 kg/m 2 , body weight &lt; 90 kg, a normal menstrual cycle with a range of 24 -35 days and an intra-individual variation of \u00b1 3 days, and willingness to give written informed consent Rombauts 2006 Gonadotrophin-releasing hormone antagonists for assisted reproductive technology (Review) Cochrane Gonadotrophin-releasing</td></tr></table>",
                "type_str": "table"
            },
            "TABREF33": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.Exclusion criteria: included contraindications for the use of gonadotrophins, endocrine abnormalities (e.g.polycystic ovary syndrome), more than three unsuccessful controlled ovarian stimulation cycles, a history of low or no ovarian response during FSH/HMG treatment, and clinically relevant abnormal laboratory values (including hormones) or medical examination findingsInterventionsGnRH antagonist: treatment with the GnRH antagonist ganirelix (0.25 mg, Orgalutran) was started on day 5/6 of rFSH treatment.If no follicles 14 mm were observed by ultrasonography on that day, the start of ganirelix was delayed.Injections containing 0.25 mg ganirelix per 0.5 ml were administered SC in the thigh, once daily in the morning, until and including the day of hCG administration.(Flexible)GnRHagonist: in the OC-scheduled group, women started taking a combined OC pill (30 \u00b5g ethinyl oestradiol/150 \u00b5g desogestrel) Marvelon\u00ae (NV Organon) on day 1 of the menstrual cycle.They took it daily for between 14 and 28 days, depending on the planned start of rFSH treatment Women in the nafarelin group started pretreatment with the GnRH agonist nafarelin (Synarel\u00ae; Pharmacia, Australia) on day 21 -24 of the preceding cycle.Nafarelin was administered intranasally at a daily dose of 0.8 mg until and including the day of hCG administrationIn all three groups ovarian stimulation was performed with rFSH (follitropin beta, Puregon\u00ae; NV Organon, The Netherlands), which was administered SC once daily in the morning at a fixed dose of 200 IU during the first 5 -6 days.After this period the dosage of rFSH could be adjusted depending on the ovarian response as assessed by ultrasound.Treatment was continued until (and including) the day of hCG administration.In the OC-scheduled ganirelix group, stimulation with rFSH was started two days after discontinuation of the OC (irrespective of whether or not menses had started), in the non-scheduled group on day 2 -3 of the menstrual cycle and in the nafarelin group after 2 -4 weeks of nafarelin treatment [as soon as pituitary down-regulation had been achieved (i.e.serum estradiol 50 pg/ml or 200 pmol/l); if this stage was not achieved after four weeks of nafarelin treatment, the subject discontinued].",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews</td></tr></table>",
                "type_str": "table"
            },
            "TABREF34": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.Centre for Reproductive Medicine, Brazil.July 2002 to August 2005InterventionsAll protocols included an initial r-hFSH (Gonal-F) dose ranging from 150 to 300 IU daily dependant on age, and the participants were grouped as follows:Luteal phase support -daily IM progesterone in oil 25 mg and vaginal administration of one full applicator of 8% Crinone gel at bedtime beginning on the day after oocyte retrieval",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Sauer 2004 (Continued) Sbracia 2009 (Continued) Serafini 2008 (Continued) Sunkara 2014 (Continued)</td><td/><td/></tr><tr><td>Outcomes Notes</td><td/><td colspan=\"2\">Oocyte maturation triggering: 10,000 IU of IM hCG when plasma E2 between 800 and 3500 pg/mL and at least three follicles &gt; 16 mm in mean diameter Oocyte retrieval: 36 hours later, followed by ICSI Maximum number of embryos transferred: 3 Luteal phase support: 50 mg daily of P (Prontogest) IM from the day of replacement Oocytes retrieved, dose of gonadotrophin, cycle cancellation, fertilisation rate, embryo transferred, clinical pregnancy rate, ongoing pregnancy rate Sample size calculation -yes Setting and timing: Group A (antagonist): r-hFSH beginning on day 2 or 3 was continued in the full dose until follicles ITT analysis -yes reached 13 to 14 mm or reached day 6 of stimulation, when the r-hFSH dose was lowered to 75 IU and Follow up: pregnancies were confirmed by a rising titre of serum b-hCG 12 days after ET and ultra-sound demonstration of the gestation sac four weeks after the transfer the participants began with 200 IU hCG along with cetrorelix 0.25 mg (flexible) continued until day of hCG injection 10,000 IU Funding -assisted conception unit</td></tr><tr><td>Outcomes Risk of bias</td><td/><td colspan=\"2\">Primary outcomes: clinical pregnancy rate per cycle started and per transfer Group B (antagonist II): r-hFSH beginning on day 2 or 3 was continued in the full dose until two or</td></tr><tr><td>Bias</td><td/><td colspan=\"2\">Secondary outcomes: days of stimulation, E2 at the day of hCG, amount of FSH administered, number of oocytes yielded, number of embryos transferred, implantation rate, and abortion rate more codominant follicles reached 18 mm diameter. 0.25 mg cetrorelix daily SC began either when two codominant follicles reached 13 to 14 mm diameter or participant reached day 6 of stimulation. Contin-Authors' judgement Support for judgement</td></tr><tr><td/><td/><td colspan=\"2\">ued until day of hCG injection</td></tr><tr><td colspan=\"2\">Notes tion (selection bias) Random sequence genera-</td><td colspan=\"2\">Group C (agonist): Leuprolide 0.5 mg SC daily administered in mid-luteal phase of previous menstrual Drop out: four women in the cetrorelix group and two in the control group Unclear risk \"internet based block randomization\"; no further details were reported</td></tr><tr><td>Bias Risk of bias Bias (selection bias) Allocation concealment</td><td/><td colspan=\"2\">Authors' judgement Support for judgement cycle after which rFSH was administered. Continued until day of hCG injection 10,000 IU Authors' judgement Support for judgement rFSH was adjusted based on number and size of follicles Unclear risk \"allocated by a third party\" \"distant\"; no further details were reported</td></tr><tr><td colspan=\"2\">Random sequence genera-tion (selection bias) Allocation concealment Random sequence genera-tion (selection bias) Blinding (performance bias and detection bias) All outcomes</td><td colspan=\"2\">Low risk Unclear risk Low risk Oocyte retrieval -35 to 36 hours after hCG injection Computer-generated, internet-based system. Randomisation 1:1:1 Not reported Unclear risk \"doctor performing oocyte retrieval and the embryologist involved were blind-Computer-generated randomisation number sequence at the time that their ed to the treatment allocation\"; no information was available on blinding of cycle was scheduled participants</td></tr><tr><td>(selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Allocation concealment Incomplete outcome data (selection bias) Blinding (performance Outcomes (attrition bias) All outcomes bias and detection bias) All outcomes Incomplete outcome data (attrition bias)</td><td/><td colspan=\"2\">High risk Low risk Unclear risk Dose of hFSH -Group A 1674.7 \u00b1 59.4 IU versus Group B 2197.9 \u00b1 83.1 IU versus Group C 21,567 \u00b1 80.8 IU Not blind Not reported Low risk For the long agonist regimen 31/37 women received the allocated intervention Unclear risk Not reported (five decided not to have further IVF treatment and there was one spontaneous Number of mature oocytes retrieved pregnancy). Number of normally fertilised oocytes Number of cycles with high-quality embryos For the antagonist regimen 30/37 women received the allocated intervention Number of embryo transfers (six decided not to have further IVF treatment and there was one spontaneous No missing outcome data Unclear risk Implantation rate pregnancy) No missing outcome data, however, LBR, OPR were not addressed by the study Pregnancy rate Incidence of severe ovarian hyperstimulation syndrome (OHSS) ITT analysis was used and 37 women were analysed in each group</td></tr><tr><td>All outcomes</td><td/><td/></tr><tr><td>Selective reporting (re-Selective reporting (re-</td><td/><td>Low risk Dose of hFSH High risk</td><td>The study protocol was not available, but it is clear that the published reports Clinical pregnancy rate is not given per group and live birth and OHSS are not</td></tr><tr><td>porting bias) Selective reporting (re-porting bias) porting bias)</td><td/><td>Low risk E2</td><td>included most expected outcomes The study protocol was not available, but it is clear that the published reports included most expected outcomes reported at all</td></tr><tr><td>Other bias Other bias Other bias</td><td/><td colspan=\"2\">Low risk Low risk Number and quality of embryos The study appears to be free from other sources of bias Groups balanced at baseline Low risk No other source of bias identified. Groups balanced at baseline</td></tr><tr><td>Notes</td><td/><td colspan=\"2\">Sample size calculation -yes</td></tr><tr><td/><td/><td>ITT analysis -yes</td></tr><tr><td>Methods Serafini 2008 Methods</td><td/><td>RCT, single-centre Funding -no details RCT, single-centre</td></tr><tr><td>Participants Methods Risk of bias Participants</td><td/><td colspan=\"2\">564 low responders, undergoing their first IVF cycle were eligible for the study RCT, single-centre, parallel design 96 poor responders who underwent ICSI-ET cycles</td></tr><tr><td>Participants Bias</td><td/><td colspan=\"2\">Inclusion criteria: age 40 years or older and no previous IVF cycle 323 women of reproductive age Authors' judgement Support for judgement Inclusion criteria: baseline follicle stimulating hormone (FSH) &lt; 13 m IU/ml, estradiol level on the day</td></tr><tr><td colspan=\"2\">Random sequence genera-</td><td colspan=\"2\">Inclusion criteria: indication for IVF/ICSI, age 21 to 39 years, presence of two functional ovaries, nor-of human chorionic gonadotrophin (hCG) injection &lt; 500 pg/ ml and a poor response (failure in obtain-Exclusion criteria: PCOS, FSH &gt; 10 IU/ mL, a previous IVF cycle, and age 45 years or older mal uterus based on hysterosalpingography or hysteroscopic evaluation, fewer than three previous Low risk Computer-generated randomisation ing of at least three follicles &gt; 16 mm in diameter and the number of mature oocytes retrieved less than</td></tr><tr><td>tion (selection bias) Allocation concealment</td><td/><td colspan=\"2\">IVF/ICSI attempts, early follicular phase serum FSH 15 IU/L or less and E2 60 pg/ml or less, no history four) after a previous ovarian stimulation cycle Baseline characteristics: maternal age, years 42.3 1.4 vs 42.1 1.5, BMI 25.1 2.6 vs 24.8 2.4, basal FSH of low response, BMI 25 kg/m 2 or less, no untreated endocrinological disease, no treatment with go-Exclusion criteria were: presence of a clinically significant systemic disease; diabetes mellitus; poly-levels, IU/L 7.0 2.5 vs 6.9 2.4 nadotrophin for three or more months before study, male partner sperm 1% or greater strict morpholo-Unclear risk \"A research nurse handed each patient a unique identification envelope in se-cystic ovaries or any other endocrine disorder; submucosal polyp, myoma or uterine septum which</td></tr><tr><td>Interventions (selection bias) Blinding (performance bias and detection bias) All outcomes</td><td/><td colspan=\"2\">gy were detected on hysteroscopy or hysterosalpingography. Intracytoplasmic sperm injection and assist-quential chronological order\". Unclear if sealed and opaque Group A (n= 285): 300 IU/day r-hFSH (Gonal-F) + 0.25 GnRH antagonist cetrorelix (Cetrotide) when the ed hatching were performed in all cycles. leading follicle \u2243 14 mm or the E2 plasma levels were 600 pg/mL (flexible multiple-dose protocol) Exclusion criteria: not stated Baseline characteristics: age Group A 33.5 \u00b1 0.4 years versus Group B 34.4 \u00b1 0.4 years versus Group C 33.4 \u00b1 0.3 years Unclear risk Blinding unlikely. No details on blinding of outcome assessors Baseline characteristics: Age (years) 38.3 \u00b1 4.23 vs 37.9 \u00b1 74.87. Baseline FSH (IU/mL) 6.31 \u00b1 2.19 vs 6.27 \u00b1 2.82</td></tr></table>",
                "type_str": "table"
            },
            "TABREF35": {
                "text": "Follow up: clinical pregnancy was confirmed 28-35 days after embryo transfer by a gestational sac under ultrasound.Ongoing pregnancy was defined as fetal heart beat at 10-12 weeks of gestation.Early pregnancy loss was defined as the proportion of patients with initially positive hCG in whom pregnancy failed to develop before 12 weeks of gestation.In the control group, if E2 level was > 3000 pg/ml, hMG administration was stopped while Superfact injection was continued.Daily measurement of E2 level was performed and hCG was administered when E2 level fell below 3000 pg/ml (Coasting).In the study group, if E2 > 3000 pg/ml, Superfact 500 mg SQ was administered for final oocyte maturation",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Tazegul 2008 (Continued) Tehraninejad 2010 (Continued) Tehraninejad 2010 (Continued) Toltager 2015 (Continued)</td><td/></tr><tr><td>Selective reporting (re-porting bias)</td><td/><td colspan=\"2\">Exclusion criteria: secondary infertility, previous IVF or ICSI, thyroid dysfunction, hyper prolactinemia, uterine abnormality and solitary ovary Low risk Fixed rFSH dose of 150 IU or 225 IU depending on the age (less than or equal to 36 years or greater than The study protocol was not available, but it is clear that the published reports included most expected outcomes 36 years) with dose adjustment at stimulation day 6</td></tr><tr><td>Other bias Outcomes</td><td/><td colspan=\"2\">Baseline characteristics: age (years) 28.99 \u00b1 6.1 vs 30.43 \u00b1 5/08. Duration of infertility (years) 7.82 \u00b1 4.70 vs 8.6 \u00b1 4.61, BMI (kg/m 2 ) 28.99 \u00b1 6.12 vs 30.43 \u00b1 5/08. Baseline FSH (IU/L) 5.4 \u00b1 1.80 vs 5.3 \u00b1 1.22 Low risk The study appears to be free from other sources of bias Ongoing pregnancy rates</td></tr><tr><td/><td/><td colspan=\"2\">OHSS rates (mild, moderate and severe)</td></tr><tr><td>Interventions</td><td/><td colspan=\"2\">GnRH antagonist (n= 45): OCP for 21 days in the previous cycles + 150 -225 IU hMG (Merional) IM</td></tr><tr><td>Notes</td><td/><td colspan=\"2\">based on the patient's age and BMI + 0.25 GnRH antagonist cetrorelix (Cetrotide) when the leading folli-This is a conference abstract with limited information</td></tr><tr><td colspan=\"2\">Tehraninejad 2011 Risk of bias Methods Bias Participants Random sequence genera-Interventions tion (selection bias)</td><td colspan=\"2\">retrieval: was performed 35-37 hrs later Embryos transfer: day 2-3 luteal phase support: micronized vaginal progesterone, 600 mg/day, until the tenth week of gestation cle \u2243 14 mm (flexible multiple-dose protocol) GnRH agonist (n= 47): OCP (30 g ethinyl estradiol plus 0.3 mg levonorgestrel) for 21 days + 500 \u00b5g Two-arm parallel trial buserelin per day (Superfact) SC, commenced on day 19 -20 of OCP cycle. Once the down-regulation Authors' judgement Support for judgement was achieved, the dose of buserelin was reduced to 250 \u00b5g daily + 150 -225 IU hMG (Merional) IM once 300 normo-responder women undergoing IVF in infertility clinic daily depending on patient's age and BMI (GnRH agonist protocol) Unclear risk Insufficient information was provided on sequence generation; it was only in cases where a pregnancy was achieved Oocyte maturation triggering: when at least two leading follicles were 18 mm in diameter, serum E2 GnRH antagonist: no details reported stated that randomisation was done in ratio 1:1</td></tr><tr><td>Allocation concealment</td><td/><td colspan=\"2\">levels were measured. If E2 level was measured to be less than 3000 pg/ml, participants in both groups would receive 10,000 IU hCG (Profasi) IM. GnRH agonist: no further details reported Unclear risk No information was given on allocation concealment</td></tr><tr><td>Outcomes (selection bias)</td><td/><td colspan=\"2\">Ongoing pregnancy rate and clinical pregnancy rate</td></tr><tr><td colspan=\"4\">Outcomes Blinding (performance Notes bias and detection bias) All outcomes Notes Risk of bias Bias Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Risk of bias Bias Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Other bias Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias Methods Oocyte Random sequence genera-Unclear risk Clinical and ongoing pregnancy per randomised patient, the duration of stimulation, consumption of No information was provided on blinding of participants and/or personnel, including outcome assessors; however, non-blinding of outcome assessors not likely to affect some of the outcome measures as they were objectively as-gonadotrophins, cycle cancellation rate, the number of oocytes retrieved and embryos transferred The hormone levels throughout the cycle Authors' judgement Support for judgement Low risk Computer-based program. Unclear risk No details were reported to make a conclusive judgement High risk Not blind Unclear risk No missing outcomes data, however LBR did not addressed by the study Unclear risk The study protocol was not available, but it is clear that the published reports included most expected outcomes Low risk Computer-generated randomised schedules Authors' judgement Support for judgement Low risk \"Patients were allocated to two groups according to a sequence of computer generated random numbers (0 or 1).\" Unclear risk Method of allocation concealment not reported Unclear risk Blinding not reported but unlikely to influence measurement of outcomes Low risk Number randomised = 300, number analysed = 300 Unclear risk Insufficient details to make a conclusive judgement sessed Unclear risk No information was reported on attrition, withdrawals or exclusions and num-ber of women analysed in each treatment group at the end of study was not re-ported Low risk All outcome measures were pre-specified Unclear risk It was unclear if the numbers of participants were balanced at randomisation as the numbers of participants in the treatment groups were not reported RCT, single-centre, open-label design Selective reporting (re-porting bias) Unclear risk Methods section not detailed enough to make conclusive judgement on re-porting bias Participants 131 infertile women undergoing IVF/ICSI</td></tr><tr><td>tion (selection bias)</td><td/><td/></tr><tr><td>Other bias</td><td/><td>Low risk</td><td>The study appears to be free from other sources of bias</td></tr><tr><td>Allocation concealment</td><td/><td>Low risk</td><td>Sealed in envelopes</td></tr><tr><td>(selection bias) Methods</td><td/><td>Two-arm parallel RCT</td></tr><tr><td>Blinding (performance Participants</td><td/><td colspan=\"2\">Unclear risk 1099 women undergoing first IVF/ICSI cycles, less than 40 years of age including both low and high re-Not reported clearly</td></tr><tr><td>bias and detection bias)</td><td/><td>sponders</td></tr><tr><td>Methods All outcomes Interventions</td><td/><td colspan=\"2\">RCT, single-centre trial GnRH-antagonist (550 women, mean age 32.1, BMI 23.1); no further details were given about treat-</td></tr><tr><td>Incomplete outcome data</td><td/><td>Unclear risk ment</td><td>No missing outcome data, however LBR not addressed by the study</td></tr><tr><td>(attrition bias)</td><td/><td/></tr><tr><td>All outcomes</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF36": {
                "text": "were considered eligible if they were scheduled for controlled ovarian stimulation and IVF with or without ICSI.Women older than 40 years or with day 3 FSH = 10 IU/ L, or with more than three previous IVF/ICSI cycles were excluded from the studyInterventionsGnRH antagonist protocol: rFSH treatment was begun on day 3 of the menstrual cycle.The starting dose for the first five days varied between 150 and 450 IU, depending on age and previous experience and was administered daily by SC injection.Thereafter, the dose was adjusted on the basis of ultrasonographic and analytic findings.On day 6 of rFSH treatment, cetrorelix was started if the ovarian response was adequate (at least one follicle = 13 mm or serum estradiol levels = 400 pg/mL).If the ovarian response was not adequate, cetrorelix administration was postponed until ultrasonographic or analytic criteria were achieved (Flexible).250microgram was administered daily by SC injection.When at least three follicles = 17 mm were observed, rFSH and cetrorelix administration was interrupted and hCG (10,000 IU IM) was administered for the timed oocyte retrieval 35 h later.Vaginal micronised progesterone was started 24 h after oocyte retrieval for luteal support in a standard dose of 600 mg daily for 14 days.Serum hCG was to be measured approximately two weeks after embryo transfer.Any pregnancy was confirmed by vaginal ultrasound scan at six weeks' gestation GnRH agonist protocol: on cycle days 21 -23, 0.6 mg of buserelin acetate was started, by daily SC injection until menses had begun and adequate suppression was achieved (serum estradiol level = 50 pg/ mL), at which time treatment with rFSH was started.The starting dose for the first five days varied between 150 and 450 IU, depending on age and previous experience of the participant and was administered daily by SC injection.Thereafter, the dose was adjusted on the basis of ultrasonographic and analytic findings and the cycle management was the same in both groupsOutcomesThe main outcome measures for assessing efficacy and safety of both protocols were: the clinical pregnancy rate per cycle and per transfer (gestational sac visualised on ultrasound at six weeks' gestation), number of oocytes collected, number of days of stimulation, number of days of analogue administration and the number of detected cases of moderate and severe OHSS.Other variables assessed were the total amount of rFSH used, serum estradiol level on the day of hCG administration, number of follicles = 15 mm on the day of the oocyte retrieval, endometrial thickness on the day of the oocyte retrieval, fertilisation rate, quality of the embryos transferred and the number of cancelled cycles.ICSI cycles were included, age 25 to 35 years old, BMI 18 -25 kg/m 2 ; the number of previous IVF cycles < 3, and no previous poor response to ovarian stimulation (poor ovarian response was characterised by cancellation of the cycle due to either poor follicular development or \u2264 4 cumulus oocytecomplexes collected at oocyte retrieval); normal ovulatory cycles (25 to 35 days), both ovaries present and normal uterus; no hormone therapy within the past three months; and no current or past diseases affecting ovaries, gonadotrophin, sex steroid secretion, clearance or excretion Cochrane Database of Systematic Reviews Baseline characteristics: age (range) 30.3 \u00b1 2.8 (24 -35) vs 30.2 \u00b1 2.8 (25 -35), BMI (range) 20.7 \u00b1 1.9 (16.9 -24.9) vs 21.0 \u00b1 1.8 (17.7 -25), Basal FSH (IU/L) 6.2 \u00b1 1.6 vs 6.5 \u00b1 1.3 Interventions Study group: E2 pre-treatment oral estradiol valerate 4 mg preceding the IVF cycle from day 21 until day 2 of next cycle + 225 IU of rFSH (Gonal-F, Serono) from day 3 + 0.25 GnRH antagonist cetrorelix (Cetrotide) was injected daily when the leading follicles reached 12 -14 mm in diameter (flexible) Control group: triptorelin (Decapeptyl) 0.1 mg SC preceding the IVF cycle from day 21, when pituitary down-regulation was achieved, the triptorelin dose was reduced to 0.05 mg/d + 225 IU of rFSH (Gonal-F) Final oocyte maturation triggering: 10,000 IU hCG (Profasi) were given when at least three mature \u2265 18 mm follicles were obtained Oocytes retrievals: 36 hrs later Embryo transfer: 2 to 3 embryos were transferred at 72 hrs after IVF/ ICSI injection Luteal phase support: IM progesterone 80 mg/day starting on the day of oocyte retrieval until the day of pregnancy test.If a pregnancy occurred, progesterone administration was extended up to 10 to 12 weeks of pregnancy Outcomes Number of oocytes collected, MII oocytes, fertilisation, implantation, live birth and early pregnancy rate, and hormone profiles (LH, P, E2) Notes The early pregnancy loss was defined as spontaneous abortion before 12 weeks Cochrane Database of Systematic Reviews Characteristics of excluded studies [ordered by study ID] trials, were randomly assigned to all women on the basis of the day of the week of their first appointment Davar 2012 Microdose GnRH agonist protocol used and number of women in each group not specified randomised on the day of hCG to receive, evaluate the effect of using vaginal micronised E2 administration, in addition to progesterone supplementation as luteal support, on clinical pregnancy rates in patients undergoing their first cycle of IVF/intracytoplasmic sperm injection (ICSI) treatment Evangelio 2011 Irrelevant interventions.Study objective was \"to determine whether the addition of recombinant LH in women with low response predictors, improved response to ovarian stimulation and clinical outcome in cycles of IVF/ICSI with a GnRH antagonist protocol.\"Study did not compare with long GnRH agonist protocol arm Fabregues 2012 Administration of GnRH analogues in the luteal phase of ART index cycle.Type GnRH agonist protocol not reported.No data/numbers provided to extract although the outcome reported fulfils the outcomes of interest",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library Cochrane Library Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>Xavier 2005 (Continued) Ye 2009 (Continued) Study</td><td>Reason for exclusion</td><td/></tr><tr><td>Zikopoulos 2005</td><td>IUI treatment cycles instead of IVF/ICSI</td><td/></tr><tr><td>Study</td><td>Reason for exclusion</td><td/></tr><tr><td colspan=\"2\">Ashrafi 2004 Characteristics of studies awaiting assessment [ordered by study ID] No available data for inclusion</td><td/></tr><tr><td>Bonduelle 2010</td><td>Retrospective analysis</td><td/></tr><tr><td>Cattani 2000</td><td>No available data for inclusion</td><td/></tr><tr><td>Causio 2004</td><td>Quasi-randomised study</td><td/></tr><tr><td>Crosignani 2007</td><td colspan=\"2\">The quality of embryos used for transfer were classified using the following grading system: (A) no frag-RCT in IUI cycles</td></tr><tr><td/><td colspan=\"2\">mentation; (B) 1% -20% fragmentation; (C) 21% -50% fragmentation; (D) = 51% fragmentation. The</td></tr><tr><td colspan=\"3\">OHS classification utilised in this study was the one proposed by Golan 1989 Number of participants at randomisation: 131 (cetrorelix: 66/buserelin: 65) Number of participants at stimulation: 112 (cetrorelix: 53/buserelin: 59) Number of participants at OPU: 112 (cetrorelix: 53/buserelin: 59) Quasi-randomised De Klerk 2007 Notes D'Amato 2004 Overlap with Eijkemans 2006; Heijnen 2007; Polinder 2008</td></tr><tr><td>Risk of bias</td><td/><td/></tr><tr><td>Dudley 2010</td><td colspan=\"2\">Cross-over study. Data not provided separately before and after cross-over</td></tr><tr><td>Bias Risk of bias Eijkemans 2006</td><td>Authors' judgement Support for judgement Overlap with Heijnen 2007</td><td/></tr><tr><td colspan=\"3\">Xavier 2005 Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Other bias Bias Random sequence genera-tion (selection bias) Allocation concealment (selection bias) Blinding (performance bias and detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-Engmann 2008b RCT, participant Ficicioglu 2010 Low risk Unclear risk High risk Unclear risk Low risk Low risk Authors' judgement Support for judgement Computer-generated random number table, randomisation: 1:1 (Cetrore-lix:Buserelin) ratio Not reported Not blind No missing outcome data, however LBR not addressed by the study The study protocol was not available, but it is clear that the published reports included most expected outcomes Low risk Computer-generated random numbers Unclear risk Not reported High risk Not blind Low risk No missing outcome data Low risk Retrospective study The study protocol was not available, but it is clear that the published reports The study appears to be free from other sources of bias porting bias) included most expected outcomes Freitas 2004 No available data for inclusion</td></tr><tr><td>Other bias Ghosh 2003</td><td colspan=\"2\">Low risk Marked heterogeneity between the two study groups The study appears to be free from other sources of bias</td></tr><tr><td colspan=\"3\">Methods Participants AFC: Antral Follicle Count AMH: anti-mullerian hormone CC: clomiphene citrate Gordts 2011 Guivarc'h-Lev\u00eaque 2010 220 IVF/Ye 2009 RCT, single-centre Study used a GnRH agonist short protocol for pituitary suppression RCT, quasi-randomised, as odd or even days of the consultation delivery of treatment COS: controlled ovarian stimulation ET: embryo transfer Ibrahim 2011 Study used microdose flare-up GnRH agonist protocol for pituitary suppression</td></tr><tr><td colspan=\"2\">FSH: follicle-stimulating hormone</td><td/></tr><tr><td colspan=\"3\">hCG: human chorionic gonadotrophin Jindal 2013 Numbers of participants randomised at baseline to each treatment group were not reported</td></tr><tr><td>IM: intramuscularly</td><td/><td/></tr><tr><td colspan=\"3\">IVF-ET: in vitro fertilisation embryo transfer Karimzadeh 2011 Study used microdose GnRH agonist flare-up (microdose protocol) for pituitary suppression</td></tr><tr><td>MII = metaphase II</td><td/><td/></tr><tr><td>SC: subcutaneously</td><td/><td/></tr></table>",
                "type_str": "table"
            },
            "TABREF37": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"5\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td>Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td colspan=\"2\">Outcome or subgroup title Study or subgroup</td><td colspan=\"2\">GnRH an-tagonist n/N</td><td/><td colspan=\"2\">No. of studies GnRH agonist n/N</td><td>No. of partici-Odds Ratio pants M-H, Fixed, 95% CI Statistical method Weight</td><td>Odds Ratio Effect size M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"5\">5 Ovarian hyperstimulation per woman randomised -moderate or se-Heijnen 2007 70/205 Huirne 2006 17/91 Kim 2011 20/80 vere Kim 2012 36/106</td><td>20</td><td>78/199 17/91 11/40 36/105</td><td>5141</td><td>Odds Ratio (M-H, Fixed, 95% 23.45% 6.22% CI) 4.95% 10.75%</td><td>0.8[0.54,1.21] 0.53 [0.40, 0.69] 1[0.47,2.11] 0.88[0.37,2.07] 0.99[0.56,1.74]</td></tr><tr><td colspan=\"5\">6 Ongoing pregnancy rate per woman Kurzawa 2008 14/37</td><td>37</td><td>18/37</td><td>8311</td><td>Odds Ratio (M-H, Fixed, 95% 5.03%</td><td>0.92 [0.83, 1.01] 0.64[0.25,1.62]</td></tr><tr><td>randomised -all women Lin 2006</td><td/><td/><td colspan=\"2\">22/60</td><td/><td>21/60</td><td>CI)</td><td>5.98%</td><td>1.08[0.51,2.27]</td></tr><tr><td>Marci 2005</td><td/><td/><td colspan=\"2\">4/30</td><td/><td>0/30</td><td>0.19%</td><td>10.36[0.53,201.45]</td></tr><tr><td colspan=\"5\">7 Ongoing pregnancy rate per woman Papanikolaou 2012 27/96</td><td>7</td><td>23/94</td><td>1456</td><td>Odds Ratio (M-H, Fixed, 95% 7.52%</td><td>0.94 [0.75, 1.18] 1.21[0.63,2.31]</td></tr><tr><td colspan=\"3\">randomised -minimal stimulation Rinaldi 2014</td><td colspan=\"2\">47/148</td><td/><td>36/201</td><td>CI)</td><td>9.37%</td><td>2.13[1.29,3.52]</td></tr><tr><td>Ye 2009</td><td/><td/><td colspan=\"2\">35/109</td><td/><td>39/111</td><td>11.8%</td><td>0.87[0.5,1.53]</td></tr><tr><td colspan=\"4\">8 Ongoing pregnancy rate per women</td><td/><td>37</td><td/><td>Odds Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"3\">randomised -grouped by trigger Total (95% CI)</td><td colspan=\"2\">1200</td><td/><td>1103</td><td>CI)</td><td>100%</td><td>1.02[0.85,1.23]</td></tr><tr><td colspan=\"6\">Total events: 339 (GnRH antagonist), 315 (GnRH agonist)</td><td/></tr><tr><td colspan=\"7\">8.1 hCG trigger Heterogeneity: Tau =0; Chi =15.06, df=11(P=0.18); I =26.95% 29 Test for overall effect: Z=0.25(P=0.8)</td><td>5170</td><td>Odds Ratio (M-H, Fixed, 95% CI)</td><td>0.95 [0.84, 1.08]</td></tr><tr><td colspan=\"4\">8.2 Mixed trigger (hCG/GnRH agonist)</td><td colspan=\"3\">1 Favours GnRH agonist</td><td>66 0.05</td><td>0.2</td><td>1</td><td>Odds Ratio (M-H, Fixed, 95% 20 5 Favours GnRH antagonist 0.61 [0.23, 1.61]</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>8.3 Unknown trigger</td><td/><td/><td/><td/><td>7</td><td/><td>3075</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>0.87 [0.74, 1.03]</td></tr><tr><td colspan=\"3\">Analysis 1.2.</td><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">9 Clinical pregnancy rate per woman</td><td/><td/><td>54</td><td/><td>9959</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>0.91 [0.83, 1.00]</td></tr><tr><td>randomised -all women</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"4\">10 Clinical pregnancy rate per woman</td><td/><td>6</td><td/><td>1102</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>1.50 [1.15, 1.96]</td></tr><tr><td colspan=\"3\">randomised -minimal stimulation</td><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">11 Miscarriage rate per woman ran-</td><td/><td/><td>34</td><td/><td>7082</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>1.03 [0.82, 1.29]</td></tr><tr><td>domised</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">12 Miscarriage rate per clinical preg-</td><td/><td/><td>34</td><td/><td>2308</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>1.08 [0.84, 1.37]</td></tr><tr><td colspan=\"2\">Outcome or subgroup title nancy</td><td/><td/><td/><td colspan=\"2\">No. of studies</td><td>No. of partici-</td><td>Statistical method CI)</td><td>Effect size</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>pants</td></tr><tr><td colspan=\"4\">13 Cycle cancellation rate per woman</td><td/><td>34</td><td/><td>Odds Ratio (M-H, Fixed, 95%</td><td>Subtotals only</td></tr><tr><td colspan=\"3\">1 Live birth rate per woman ran-randomised</td><td/><td/><td>12</td><td/><td>2303</td><td>Odds Ratio (M-H, Fixed, 95% CI)</td><td>1.02 [0.85, 1.23]</td></tr><tr><td>domised</td><td/><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"3\">13.1 Cancellation due to high risk of</td><td/><td/><td>19</td><td/><td>4256</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>0.47 [0.32, 0.69]</td></tr><tr><td colspan=\"3\">2 Live birth rate per woman ran-OHSS</td><td/><td/><td>2</td><td/><td>524</td><td>Odds Ratio (M-H, Fixed, 95% CI)</td><td>0.89 [0.62, 1.26]</td></tr><tr><td colspan=\"2\">domised -minimal stimulation</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td colspan=\"4\">13.2 Cancellation due to poor ovarian</td><td/><td>25</td><td/><td>5230</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>1.32 [1.06, 1.65]</td></tr><tr><td colspan=\"3\">3 Live birth rate per woman ran-response</td><td/><td/><td>12</td><td/><td>2303</td><td>Odds Ratio (M-H, Fixed, 95% CI)</td><td>1.02 [0.85, 1.23]</td></tr><tr><td colspan=\"2\">domised -grouped by trigger</td><td/><td/><td/><td/><td/><td>CI)</td></tr><tr><td>3.1 hCG trigger</td><td/><td/><td/><td/><td>11</td><td/><td>1899</td><td>Odds Ratio (M-H, Fixed, 95%</td><td>1.09 [0.89, 1.34]</td></tr><tr><td colspan=\"6\">3.2 Unknown trigger Analysis 1.1. Study or subgroup 1 GnRH an-</td><td>GnRH agonist</td><td>404</td><td>Odds Ratio</td><td>CI) Odds Ratio (M-H, Fixed, 95% CI) Weight</td><td>0.80 [0.54, 1.21] Odds Ratio</td></tr><tr><td/><td/><td colspan=\"2\">tagonist</td><td/><td/><td/></tr><tr><td colspan=\"2\">4 Ovarian hyperstimulation per</td><td colspan=\"2\">n/N</td><td/><td>36</td><td>n/N</td><td>7944</td><td>Odds Ratio (M-H, Fixed, 95% M-H, Fixed, 95% CI</td><td>0.61 [0.51, 0.72] M-H, Fixed, 95% CI</td></tr><tr><td colspan=\"3\">woman randomised -all women Albano 2000</td><td colspan=\"2\">34/198</td><td/><td>19/95</td><td>CI)</td><td>9.57%</td><td>0.83[0.44,1.55]</td></tr><tr><td>Barmat 2005</td><td/><td/><td colspan=\"2\">13/40</td><td/><td>17/40</td><td>5.16%</td><td>0.65[0.26,1.62]</td></tr><tr><td/><td/><td/><td/><td colspan=\"3\">Favours GnRH agonist</td><td>0.05</td><td>0.2</td><td>1</td><td>5</td><td>20</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF38": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Heijnen 2007</td><td>75/205</td><td>81/199</td><td/><td/><td/><td/><td>79.67%</td><td>0.84[0.56,1.25]</td></tr><tr><td>Lin 2006</td><td>22/60</td><td>21/60</td><td/><td/><td/><td/><td>20.33%</td><td>1.08[0.51,2.27]</td></tr><tr><td>Total (95% CI)</td><td>265</td><td>259</td><td/><td/><td/><td/><td>100%</td><td>0.89[0.62,1.26]</td></tr><tr><td colspan=\"2\">Total events: 97 (GnRH antagonist), 102 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =0.32, df=1(P=0.57); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.66(P=0.51)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF39": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Marci 2005</td><td>4/30</td><td>0/30</td><td/><td/><td/><td/><td>0.19%</td><td>10.36[0.53,201.45]</td></tr><tr><td>Papanikolaou 2012</td><td>27/96</td><td>23/94</td><td/><td/><td/><td/><td>7.52%</td><td>1.21[0.63,2.31]</td></tr><tr><td>Rinaldi 2014</td><td>47/148</td><td>36/201</td><td/><td/><td/><td/><td>9.37%</td><td>2.13[1.29,3.52]</td></tr><tr><td>Ye 2009</td><td>35/109</td><td>39/111</td><td/><td/><td/><td/><td>11.8%</td><td>0.87[0.5,1.53]</td></tr><tr><td>Subtotal (95% CI)</td><td>995</td><td>904</td><td/><td/><td/><td/><td>76.55%</td><td>1.09[0.89,1.34]</td></tr><tr><td colspan=\"2\">Total events: 269 (GnRH antagonist), 237 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =13.47, df=10(P=0.2); I =25.77%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.82(P=0.41)</td><td/><td/><td/><td/><td/></tr><tr><td>1.3.2 Unknown trigger</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Heijnen 2007</td><td>70/205</td><td>78/199</td><td/><td/><td/><td/><td>23.45%</td><td>0.8[0.54,1.21]</td></tr><tr><td>Subtotal (95% CI)</td><td>205</td><td>199</td><td/><td/><td/><td/><td>23.45%</td><td>0.8[0.54,1.21]</td></tr><tr><td colspan=\"2\">Total events: 70 (GnRH antagonist), 78 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td>Heterogeneity: Not applicable</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.05(P=0.29)</td><td/><td/><td/><td/><td/></tr><tr><td>Total (95% CI)</td><td>1200</td><td>1103</td><td/><td/><td/><td/><td>100%</td><td>1.02[0.85,1.23]</td></tr><tr><td colspan=\"2\">Total events: 339 (GnRH antagonist), 315 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Tau =0; Chi =15.06, df=11(P=0.18); I =26.95%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=0.25(P=0.8)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Test for subgroup differences: Chi =1.72, df=1 (P=0.19), I =41.74%</td><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH antagonist</td></tr><tr><td colspan=\"2\">Analysis 1.4.</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>1.3.1 hCG trigger</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Albano 2000</td><td>34/198</td><td>19/95</td><td/><td/><td/><td/><td>9.57%</td><td>0.83[0.44,1.55]</td></tr><tr><td>Barmat 2005</td><td>13/40</td><td>17/40</td><td/><td/><td/><td/><td>5.16%</td><td>0.65[0.26,1.62]</td></tr><tr><td>Huirne 2006</td><td>17/91</td><td>17/91</td><td/><td/><td/><td/><td>6.22%</td><td>1[0.47,2.11]</td></tr><tr><td>Kim 2011</td><td>20/80</td><td>11/40</td><td/><td/><td/><td/><td>4.95%</td><td>0.88[0.37,2.07]</td></tr><tr><td>Kim 2012</td><td>36/106</td><td>36/105</td><td/><td/><td/><td/><td>10.75%</td><td>0.99[0.56,1.74]</td></tr><tr><td>Kurzawa 2008</td><td>14/37</td><td>18/37</td><td/><td/><td/><td/><td>5.03%</td><td>0.64[0.25,1.62]</td></tr><tr><td>Lin 2006</td><td>22/60</td><td>21/60</td><td/><td/><td/><td/><td>5.98%</td><td>1.08[0.51,2.27]</td></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF40": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Lainas 2007</td><td>3/26</td><td>20/52</td><td/><td/><td/><td/><td>3.44%</td><td>0.21[0.06,0.79]</td></tr><tr><td>Lainas 2010</td><td>5/110</td><td>6/110</td><td/><td/><td/><td/><td>1.67%</td><td>0.83[0.24,2.79]</td></tr><tr><td>Lee 2005</td><td>3/40</td><td>2/20</td><td/><td/><td/><td/><td>0.72%</td><td>0.73[0.11,4.76]</td></tr><tr><td>Lin 2006</td><td>1/60</td><td>3/60</td><td/><td/><td/><td/><td>0.86%</td><td>0.32[0.03,3.19]</td></tr><tr><td>Moraloglu 2008</td><td>2/45</td><td>4/48</td><td/><td/><td/><td/><td>1.08%</td><td>0.51[0.09,2.94]</td></tr><tr><td>Moshin 2007</td><td>0/25</td><td>1/24</td><td/><td/><td/><td/><td>0.44%</td><td>0.31[0.01,7.92]</td></tr><tr><td>Olivennes 2000</td><td>4/126</td><td>5/43</td><td/><td/><td/><td/><td>2.1%</td><td>0.25[0.06,0.98]</td></tr><tr><td>Papanikolaou 2012</td><td>2/96</td><td>1/94</td><td/><td/><td/><td/><td>0.29%</td><td>1.98[0.18,22.2]</td></tr><tr><td>Qiao 2012</td><td>5/113</td><td>7/120</td><td/><td/><td/><td/><td>1.89%</td><td>0.75[0.23,2.43]</td></tr><tr><td>Rabati 2012</td><td>15/69</td><td>25/67</td><td/><td/><td/><td/><td>5.79%</td><td>0.47[0.22,0.99]</td></tr><tr><td>Rombauts 2006</td><td>5/234</td><td>6/117</td><td/><td/><td/><td/><td>2.28%</td><td>0.4[0.12,1.35]</td></tr><tr><td>Serafini 2008</td><td>7/217</td><td>6/106</td><td/><td/><td/><td/><td>2.27%</td><td>0.56[0.18,1.7]</td></tr><tr><td>Tehraninejad 2010</td><td>0/45</td><td>15/47</td><td/><td/><td/><td/><td>4.37%</td><td>0.02[0,0.4]</td></tr><tr><td>Toltager 2015</td><td>163/550</td><td>177/549</td><td/><td/><td/><td/><td>36.33%</td><td>0.89[0.69,1.14]</td></tr><tr><td>Xavier 2005</td><td>4/66</td><td>1/65</td><td/><td/><td/><td/><td>0.28%</td><td>4.13[0.45,37.98]</td></tr><tr><td>Ye 2009</td><td>3/109</td><td>2/111</td><td/><td/><td/><td/><td>0.56%</td><td>1.54[0.25,9.42]</td></tr><tr><td>Total (95% CI)</td><td>4474</td><td>3470</td><td/><td/><td/><td/><td>100%</td><td>0.61[0.51,0.72]</td></tr><tr><td colspan=\"2\">Total events: 290 (GnRH antagonist), 396 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"3\">Heterogeneity: Tau =0; Chi =49.44, df=34(P=0.04); I =31.23%</td><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=5.74(P&lt;0.0001)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH antagonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH agonist</td></tr><tr><td colspan=\"2\">Analysis 1.5</td><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Albano 2000</td><td>2/198</td><td>5/95</td><td/><td/><td/><td/><td>1.95%</td><td>0.18[0.03,0.96]</td></tr><tr><td>Badrawi 2005</td><td>2/50</td><td>2/50</td><td/><td/><td/><td/><td>0.56%</td><td>1[0.14,7.39]</td></tr><tr><td>Bahceci 2005</td><td>3/73</td><td>5/75</td><td/><td/><td/><td/><td>1.38%</td><td>0.6[0.14,2.61]</td></tr><tr><td>Barmat 2005</td><td>0/40</td><td>0/40</td><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Engmann 2008a</td><td>0/34</td><td>10/32</td><td/><td/><td/><td/><td>3.11%</td><td>0.03[0,0.56]</td></tr><tr><td>Euro Middle East 2001</td><td>4/236</td><td>1/119</td><td/><td/><td/><td/><td>0.38%</td><td>2.03[0.22,18.41]</td></tr><tr><td>Euro Orgalutran 2000</td><td>11/486</td><td>14/244</td><td/><td/><td/><td/><td>5.31%</td><td>0.38[0.17,0.85]</td></tr><tr><td>Firouzabadi 2010</td><td>3/118</td><td>12/117</td><td/><td/><td/><td/><td>3.42%</td><td>0.23[0.06,0.83]</td></tr><tr><td>Fluker 2001</td><td>12/205</td><td>2/108</td><td/><td/><td/><td/><td>0.72%</td><td>3.3[0.72,15]</td></tr><tr><td>Haydardedeoglu 2012</td><td>5/150</td><td>6/150</td><td/><td/><td/><td/><td>1.69%</td><td>0.83[0.25,2.77]</td></tr><tr><td>Heijnen 2007</td><td>6/205</td><td>12/199</td><td/><td/><td/><td/><td>3.45%</td><td>0.47[0.17,1.28]</td></tr><tr><td>Hohmann 2003</td><td>1/97</td><td>0/45</td><td/><td/><td/><td/><td>0.2%</td><td>1.41[0.06,35.4]</td></tr><tr><td>Hosseini 2010</td><td>9/57</td><td>17/55</td><td/><td/><td/><td/><td>4.25%</td><td>0.42[0.17,1.04]</td></tr><tr><td>Hsieh 2008</td><td>3/86</td><td>2/58</td><td/><td/><td/><td/><td>0.67%</td><td>1.01[0.16,6.25]</td></tr><tr><td>Huirne 2006</td><td>2/91</td><td>3/91</td><td/><td/><td/><td/><td>0.86%</td><td>0.66[0.11,4.04]</td></tr><tr><td>Hwang 2004</td><td>2/27</td><td>2/29</td><td/><td/><td/><td/><td>0.52%</td><td>1.08[0.14,8.26]</td></tr><tr><td>Karimzadeh 2010</td><td>0/121</td><td>6/122</td><td/><td/><td/><td/><td>1.88%</td><td>0.07[0,1.32]</td></tr><tr><td>Kim 2012</td><td>1/106</td><td>8/105</td><td/><td/><td/><td/><td>2.32%</td><td>0.12[0.01,0.94]</td></tr><tr><td>Kurzawa 2008</td><td>0/37</td><td>2/37</td><td/><td/><td/><td/><td>0.72%</td><td>0.19[0.01,4.08]</td></tr><tr><td>Kyono 2005</td><td>2/126</td><td>6/66</td><td/><td/><td/><td/><td>2.26%</td><td>0.16[0.03,0.82]</td></tr><tr><td/><td colspan=\"2\">Favours GnRH antagonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH agonist</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td>123</td></tr></table>",
                "type_str": "table"
            },
            "TABREF41": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td colspan=\"3\">Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Toltager 2015</td><td>131/550</td><td>125/549</td><td/><td/><td/><td/><td/><td/><td>12.28%</td><td>1.06[0.8,1.4]</td></tr><tr><td>Total (95% CI)</td><td>4523</td><td>3788</td><td/><td/><td/><td/><td/><td/><td>100%</td><td>0.92[0.83,1.01]</td></tr><tr><td colspan=\"2\">Total events: 1159 (GnRH antagonist), 1105 (GnRH agonist)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =18.48, df=36(P=0.99); I =0%</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.68(P=0.09)</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.1</td><td>0.2</td><td>0.5</td><td>1</td><td>2</td><td>5</td><td>10</td><td>Favours GnRH antagonist</td></tr><tr><td colspan=\"2\">Analysis 1.7.</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td colspan=\"3\">Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td colspan=\"3\">M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Albano 2000</td><td>2/198</td><td>5/95</td><td/><td/><td/><td/><td/><td/><td>4.53%</td><td>0.18[0.03,0.96]</td></tr><tr><td>Barmat 2005</td><td>0/40</td><td>0/40</td><td/><td/><td/><td/><td/><td/><td>Not estimable</td></tr><tr><td>Engmann 2008a</td><td>0/34</td><td>5/32</td><td/><td/><td/><td/><td/><td/><td>3.78%</td><td>0.07[0,1.37]</td></tr><tr><td>Euro Orgalutran 2000</td><td>2/486</td><td>0/244</td><td/><td/><td/><td/><td/><td/><td>0.45%</td><td>2.52[0.12,52.76]</td></tr><tr><td>Fluker 2001</td><td>3/205</td><td>2/108</td><td/><td/><td/><td/><td/><td/><td>1.75%</td><td>0.79[0.13,4.78]</td></tr><tr><td>Haydardedeoglu 2012</td><td>5/150</td><td>6/150</td><td/><td/><td/><td/><td/><td/><td>3.92%</td><td>0.83[0.25,2.77]</td></tr><tr><td>Hosseini 2010</td><td>9/57</td><td>17/55</td><td/><td/><td/><td/><td/><td/><td>9.86%</td><td>0.42[0.17,1.04]</td></tr><tr><td>Kim 2012</td><td>1/106</td><td>8/105</td><td/><td/><td/><td/><td/><td/><td>5.39%</td><td>0.12[0.01,0.94]</td></tr><tr><td>Kurzawa 2008</td><td>0/37</td><td>2/37</td><td/><td/><td/><td/><td/><td/><td>1.67%</td><td>0.19[0.01,4.08]</td></tr><tr><td>Kyono 2005</td><td>2/126</td><td>6/66</td><td/><td/><td/><td/><td/><td/><td>5.24%</td><td>0.16[0.03,0.82]</td></tr><tr><td>Lainas 2007</td><td>3/26</td><td>20/52</td><td/><td/><td/><td/><td/><td/><td>7.98%</td><td>0.21[0.06,0.79]</td></tr><tr><td>Lainas 2010</td><td>5/110</td><td>6/110</td><td/><td/><td/><td/><td/><td/><td>3.88%</td><td>0.83[0.24,2.79]</td></tr><tr><td>Lee 2005</td><td>3/40</td><td>2/20</td><td/><td/><td/><td/><td/><td/><td>1.67%</td><td>0.73[0.11,4.76]</td></tr><tr><td>Lin 2006</td><td>1/60</td><td>3/60</td><td/><td/><td/><td/><td/><td/><td>2%</td><td>0.32[0.03,3.19]</td></tr><tr><td>Olivennes 2000</td><td>4/126</td><td>5/43</td><td/><td/><td/><td/><td/><td/><td>4.88%</td><td>0.25[0.06,0.98]</td></tr><tr><td>Qiao 2012</td><td>2/113</td><td>5/120</td><td/><td/><td/><td/><td/><td/><td>3.22%</td><td>0.41[0.08,2.18]</td></tr><tr><td>Rabati 2012</td><td>15/69</td><td>25/67</td><td/><td/><td/><td/><td/><td/><td>13.43%</td><td>0.47[0.22,0.99]</td></tr><tr><td>Rombauts 2006</td><td>0/221</td><td>1/111</td><td/><td/><td/><td/><td/><td/><td>1.35%</td><td>0.17[0.01,4.12]</td></tr><tr><td>Serafini 2008</td><td>7/217</td><td>6/106</td><td/><td/><td/><td/><td/><td/><td>5.28%</td><td>0.56[0.18,1.7]</td></tr><tr><td>Toltager 2015</td><td>33/550</td><td>31/549</td><td/><td/><td/><td/><td/><td/><td>19.73%</td><td>1.07[0.64,1.77]</td></tr><tr><td/><td colspan=\"2\">Favours GnRH antagonist</td><td>0.01</td><td>0.1</td><td/><td>1</td><td/><td>10</td><td>100</td><td>Favours GnRH agonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF42": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Baart 2007</td><td>12/67</td><td>7/44</td><td/><td/><td/><td/><td>4.55%</td><td>1.15[0.42,3.2]</td></tr><tr><td>Haydardedeoglu 2012</td><td>47/150</td><td>51/150</td><td/><td/><td/><td/><td>22.97%</td><td>0.89[0.55,1.44]</td></tr><tr><td>Heijnen 2007</td><td>78/205</td><td>93/199</td><td/><td/><td/><td/><td>38.35%</td><td>0.7[0.47,1.04]</td></tr><tr><td>Hohmann 2003</td><td>16/97</td><td>8/45</td><td/><td/><td/><td/><td>5.99%</td><td>0.91[0.36,2.32]</td></tr><tr><td>Karimzadeh 2010</td><td>32/121</td><td>26/122</td><td/><td/><td/><td/><td>12.49%</td><td>1.33[0.73,2.4]</td></tr><tr><td>Lin 2006</td><td>24/60</td><td>21/60</td><td/><td/><td/><td/><td>8.27%</td><td>1.24[0.59,2.6]</td></tr><tr><td>Rabati 2012</td><td>18/69</td><td>15/67</td><td/><td/><td/><td/><td>7.38%</td><td>1.22[0.56,2.69]</td></tr><tr><td>Total (95% CI)</td><td>769</td><td>687</td><td/><td/><td/><td/><td>100%</td><td>0.94[0.75,1.18]</td></tr><tr><td colspan=\"2\">Total events: 227 (GnRH antagonist), 221 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =4.61, df=6(P=0.59); I =0%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=0.55(P=0.58)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF43": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library</td><td>Trusted evidence. Informed decisions. Better health.</td><td/><td/><td/><td/><td/><td>Cochrane Database of Systematic Reviews</td></tr><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td colspan=\"3\">Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"4\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>Serafini 2008</td><td>91/217</td><td>41/106</td><td/><td/><td/><td/><td>3.28%</td><td>1.14[0.71,1.84]</td></tr><tr><td>Tazegul 2008</td><td>10/48</td><td>11/48</td><td/><td/><td/><td/><td>0.89%</td><td>0.89[0.34,2.33]</td></tr><tr><td>Tehraninejad 2010</td><td>18/45</td><td>15/47</td><td/><td/><td/><td/><td>0.9%</td><td>1.42[0.6,3.35]</td></tr><tr><td>Tehraninejad 2011</td><td>51/150</td><td>53/150</td><td/><td/><td/><td/><td>3.58%</td><td>0.94[0.59,1.52]</td></tr><tr><td>Xavier 2005</td><td>8/66</td><td>10/65</td><td/><td/><td/><td/><td>0.91%</td><td>0.76[0.28,2.06]</td></tr><tr><td>Ye 2009</td><td>54/109</td><td>63/111</td><td/><td/><td/><td/><td>3.23%</td><td>0.75[0.44,1.27]</td></tr><tr><td>Total (95% CI)</td><td>5431</td><td>4528</td><td/><td/><td/><td/><td>100%</td><td>0.91[0.83,1]</td></tr><tr><td colspan=\"2\">Total events: 1510 (GnRH antagonist), 1365 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =54.69, df=53(P=0.41); I =3.09%</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Test for overall effect: Z=1.99(P=0.05)</td><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td/><td>0.5</td><td>0.7</td><td>1</td><td>1.5</td><td>2</td><td>Favours GnRH antagonist</td></tr><tr><td colspan=\"2\">Analysis 1.</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td colspan=\"4\">M-H, Fixed, 95% CI</td><td>M-H, Fixed, 95% CI</td></tr><tr><td>1.8.1 hCG trigger</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Albano 2000</td><td>34/198</td><td>19/95</td><td/><td/><td/><td/><td>4.55%</td><td>0.83[0.44,1.55]</td></tr><tr><td>Baart 2007</td><td>12/67</td><td>7/44</td><td/><td/><td/><td/><td>1.48%</td><td>1.15[0.42,3.2]</td></tr><tr><td>Badrawi 2005</td><td>11/50</td><td>13/50</td><td/><td/><td/><td/><td>2.17%</td><td>0.8[0.32,2.02]</td></tr><tr><td>Bahceci 2005</td><td>32/73</td><td>36/75</td><td/><td/><td/><td/><td>4.27%</td><td>0.85[0.44,1.62]</td></tr><tr><td>Barmat 2005</td><td>13/40</td><td>17/40</td><td/><td/><td/><td/><td>2.46%</td><td>0.65[0.26,1.62]</td></tr><tr><td>Cheung 2005</td><td>3/33</td><td>3/33</td><td/><td/><td/><td/><td>0.58%</td><td>1[0.19,5.36]</td></tr><tr><td>Depalo 2009</td><td>16/67</td><td>21/69</td><td/><td/><td/><td/><td>3.37%</td><td>0.72[0.34,1.53]</td></tr><tr><td>Euro Middle East 2001</td><td>70/236</td><td>37/119</td><td/><td/><td/><td/><td>7.4%</td><td>0.93[0.58,1.51]</td></tr><tr><td>Firouzabadi 2010</td><td>34/118</td><td>27/117</td><td/><td/><td/><td/><td>4.13%</td><td>1.35[0.75,2.42]</td></tr><tr><td>Gizzo 2014</td><td>53/90</td><td>114/180</td><td/><td/><td/><td/><td>6.69%</td><td>0.83[0.49,1.39]</td></tr><tr><td>Haydardedeoglu 2012</td><td>47/150</td><td>51/150</td><td/><td/><td/><td/><td>7.49%</td><td>0.89[0.55,1.44]</td></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.005</td><td>0.1</td><td/><td>1</td><td>10</td><td>200</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF44": {
                "text": "",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Study or subgroup</td><td>GnRH an-</td><td>GnRH agonist</td><td/><td/><td>Odds Ratio</td><td/><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td>tagonist</td><td/><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td>n/N</td><td/><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Hohmann 2003</td><td>20/97</td><td>10/45</td><td/><td/><td/><td/><td>12.12%</td><td>0.91[0.39,2.14]</td></tr><tr><td>Hosseini 2010</td><td>23/57</td><td>9/55</td><td/><td/><td/><td/><td>6.11%</td><td>3.46[1.42,8.41]</td></tr><tr><td>Karimzadeh 2010</td><td>37/121</td><td>31/122</td><td/><td/><td/><td/><td>23.95%</td><td>1.29[0.74,2.27]</td></tr><tr><td>Lin 2006</td><td>25/60</td><td>24/60</td><td/><td/><td/><td/><td>15.64%</td><td>1.07[0.52,2.22]</td></tr><tr><td>Rabati 2012</td><td>20/69</td><td>21/67</td><td/><td/><td/><td/><td>16.91%</td><td>0.89[0.43,1.86]</td></tr><tr><td>Rinaldi 2014</td><td>54/148</td><td>42/201</td><td/><td/><td/><td/><td>25.28%</td><td>2.17[1.35,3.5]</td></tr><tr><td>Total (95% CI)</td><td>552</td><td>550</td><td/><td/><td/><td/><td>100%</td><td>1.5[1.15,1.96]</td></tr><tr><td colspan=\"2\">Total events: 179 (GnRH antagonist), 137 (GnRH agonist)</td><td/><td/><td/><td/><td/></tr><tr><td colspan=\"2\">Heterogeneity: Tau =0; Chi =10.03, df=5(P=0.07); I =50.16%</td><td/><td/><td/><td/><td/></tr><tr><td>Test for overall effect: Z=2.99(P=0)</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td colspan=\"2\">Favours GnRH agonist</td><td>0.01</td><td>0.1</td><td>1</td><td>10</td><td>100</td><td>Favours GnRH antagonist</td></tr></table>",
                "type_str": "table"
            },
            "TABREF45": {
                "text": "Copyright \u00a9 2016 The Cochrane Collaboration.Published by John Wiley & Sons, Ltd.Authorship: new author added (Mohamed AFM Youssef) and order of authors changed \u2022 27 new studies were added \u2022 New comparisons: cetrorelix versus ganirelix \u2022 New subgroups: poor responders; PCOS; GnRH antagonist plus OCP; flexible antagonist protocol; fixed antagonist protocol; mild IVF \u2022 A date limited search of Cochrane Menstrual Disorders and Subfertility Group Specialised Register, CENTRAL from April 2010 to April 2011 was run.18 studies have been entered into the Classification pending references section of this update.These studies will be appraised for inclusion or exclusion in the next update of this review, due April 2012.",
                "html": null,
                "num": null,
                "content": "<table><tr><td>Cochrane Library Cochrane Library</td><td colspan=\"2\">Trusted evidence. Informed decisions. Better health. Trusted evidence. Informed decisions. Better health.</td><td/><td/><td colspan=\"3\">Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews</td></tr><tr><td>(Continued) Date</td><td>Event</td><td/><td/><td/><td>Description</td><td/></tr><tr><td>S17</td><td colspan=\"3\">TX (GNRH-a or GNRH a)</td><td/><td/><td/></tr><tr><td>3 February 2016</td><td colspan=\"4\">New citation required and conclusions</td><td colspan=\"3\">The addition of new studies did not change the conclusions of</td></tr><tr><td>S16</td><td colspan=\"3\">TX (decapeptyl or trelstar) have changed</td><td/><td>this review.</td><td/></tr><tr><td>S15 3 February 2016</td><td colspan=\"3\">TX triptorelin or TX Zoladex New search has been performed</td><td/><td colspan=\"3\">This review has been updated, and 28 new studies added.</td></tr><tr><td>S14 7 July 2011</td><td colspan=\"3\">TX (leuprolide or nafarelin) Amended</td><td/><td colspan=\"3\">Minor amendments to new citation version published May 2011</td></tr><tr><td colspan=\"6\">S13 S12 S11 S10 S9 S8 S7 S6 13 April 2011 \u2022 13 April 2011 TX (buserelin or goserelin) TX GnRH agonist* TX gonadotrophin releasing hormone agonist* TX gonadotropin releasing hormone agonist* S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 TX Degarelix TX Antagon TX (Abarelix or Plenaxis) New search has been performed New citation required and conclusions The conclusion has changed</td><td/></tr><tr><td/><td colspan=\"2\">have changed</td><td/><td/><td/><td/></tr><tr><td>S5</td><td colspan=\"2\">TX Ganirelix</td><td/><td/><td/><td/></tr><tr><td>13 June 2008</td><td>Amended</td><td/><td/><td/><td>Converted to new review format.</td><td/></tr><tr><td>S4</td><td colspan=\"3\">TX (Cetrorelix or Cetrotide)</td><td/><td/><td/></tr><tr><td>19 May 2006</td><td colspan=\"4\">New citation required and conclusions</td><td>Substantive amendment</td><td/></tr><tr><td>S3</td><td colspan=\"3\">TX GnRH antagonist* have changed</td><td/><td/><td/></tr><tr><td>S2</td><td colspan=\"5\">TX gonadotrophin releasing hormone antagonist*</td><td/></tr><tr><td>S1</td><td colspan=\"5\">TX gonadotropin releasing hormone antagonist*</td><td/></tr><tr><td>W H A T ' S N E W</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Date</td><td>Event</td><td/><td/><td/><td>Description</td><td/></tr><tr><td>31 August 2016</td><td colspan=\"3\">Review declared as stable</td><td/><td colspan=\"3\">Further evidence is unlikely to change the conclusions of this re-</td></tr><tr><td/><td/><td/><td/><td/><td>view.</td><td/></tr><tr><td>Study or subgroup</td><td colspan=\"2\">GnRH an-</td><td>GnRH agonist</td><td/><td>Odds Ratio</td><td>Weight</td><td>Odds Ratio</td></tr><tr><td/><td colspan=\"2\">tagonist</td><td/><td/><td/><td/></tr><tr><td/><td>n/N</td><td/><td>n/N</td><td/><td>M-H, Fixed, 95% CI</td><td/><td>M-H, Fixed, 95% CI</td></tr><tr><td>Albano 2000 H I S T O R Y</td><td/><td>7/198</td><td>2/95</td><td/><td/><td>1.76%</td><td>1.7[0.35,8.36]</td></tr><tr><td colspan=\"2\">Badrawi 2005 Bahceci 2005 Protocol first published: Issue 3, 1999 Barmat 2005 Review first published: Issue 4, 2001</td><td>1/50 2/73 3/40</td><td>2/50 5/75 1/40</td><td/><td/><td>1.32% 3.24% 0.62%</td><td>0.49[0.04,5.58] 0.39[0.07,2.1] 3.16[0.31,31.78]</td></tr><tr><td>Check 2004</td><td/><td>0/30</td><td>1/30</td><td/><td/><td>1%</td><td>0.32[0.01,8.24]</td></tr><tr><td>Cheung 2005 Depalo 2009 Date</td><td>Event</td><td>2/33 3/67</td><td>1/33 4/69</td><td/><td>Description</td><td>0.63% 2.54%</td><td>2.06[0.18,23.94] 0.76[0.16,3.54]</td></tr><tr><td>Engmann 2008a 9 May 2016</td><td>Amended</td><td colspan=\"2\">1/34 Favours GnRH antagonist 1/32</td><td>0.002</td><td colspan=\"3\">0.68% Favours GnRH agonist Correction to reinstate data removed in error (Marci 2005) 0.94[0.06,15.68] 500 10 0.1 1</td></tr></table>",
                "type_str": "table"
            }
        }
    }
}